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Co-infection with HIV in patients with chronic HCV infection is a common 
occurrence, which accelerates disease progression and the rate of liver fibrosis. 
Current literature report conflicting results on the effect of HIV co-infection on HCV 
at the genetic level. This thesis sets out to further explore the genetic variation of 
HCV in this group of patients, and use new techniques which may impact upon the 
diagnosis and management of HCV. 
 
In resource-limited settings such as sub-Saharan Africa, there is a paucity of data 
concerning rates of active HCV infection in patients with HIV infection. The limited 
infrastructure and financial restrictions are contributing factors in this. Consequently, 
cheaper and novel diagnostic procedures are required to promote testing in these 
important cohorts. A real-time PCR assay for use with pooled plasma and dried 
plasma spot specimens was developed to screen a large cohort of HIV-infected 
individuals from Ghana and assess its suitability for screening in such a setting. The 
prevalence of active HCV infection in this cohort was similar to previous estimates 
from blood donors but was much lower than estimates from serological tests, 
highlighting the potential risks in relying on these tests alone in this region. The 
diversity of strains found within this population agreed well with previous studies. 
 
As the yield of HCV infections was low in Ghana, further studies were completed 
with the UK and European cohort. A deep sequencing approach was utilised to two 
effects. The first focussed on a specific notable polymorphism – Q80K in the NS3 
gene – to determine whether deep sequencing would benefit the clinic in the 
detection of this polymorphism at low frequencies, which are below the threshold of 
detection by traditional population sequencing. The second use of deep sequencing 
aimed to determine the impact of HIV co-infection on the presence of resistance 
associated mutations occurring at baseline, studying the largest cohort to date. 
 
The Q80K polymorphism was not observed in any sample as a minority variant, 
suggesting that the current clinical procedures for pre-treatment screening are 
suitable and provide sufficient sensitivity. Overall, resistance mutations were 
relatively common among patients and it was observed that, generally, there were no 
differences in the prevalences of resistance mutations between HCV mono-infected 
and HIV/HCV co-infected patients. This finding is in agreement with previous 
small-scale studies. 
 
This work has direct clinical implications on the use of deep sequencing for 
screening patients for the presence of resistance mutations. Furthermore, it suggests 
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1. General Introduction 
1.1. HCV 
During the 1970s, it was observed that a non-A, non-B (NANB) hepatitis agent in 
contaminated blood supplies was responsible for cases of post-transfusion hepatitis 
(PTH), which continued to occur even after screening tests for hepatitis B surface 
antigen (HBsAg) became available (Feinstone et al., 1975). A NANB hepatitis agent 
was deemed to be responsible for such PTH cases after the exclusion of other 
infectious agents including hepatitis A virus, hepatitis B virus (HBV), Epstein-Barr 
virus and cytomegalovirus. 
In 1989, the NANB hepatitis agent was successfully cloned and defined as hepatitis 
C virus (HCV) (Choo et al., 1989). HCV is a positive-sense, single stranded RNA 
virus belonging to the Flaviviridae family. Transmission routes include contact with 
infected blood or blood products, such as transfusion with contaminated blood and 
the sharing of needles among injecting drug users (IDUs). Current estimates place 
the number of HCV infections at approximately 130-150 million people worldwide, 
with an estimated 500,000 HCV-related mortalities annually (World Health 
Organisation, 2015). 
 
1.2. HCV structure 
Despite the recent advances in the development of a replicon system to culture HCV 
in vitro, the structure of the virion has not yet been fully elucidated. Virus particles 
are approximately 40-100nm in diameter (Catanese et al., 2013). The single-stranded 
RNA genome interacts with the core protein to form a nucleocapsid, which is 
surrounded by the lipid membrane into which the envelope glycoproteins are 
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anchored (Lindenbach, 2013). Two models have been proposed regarding the 
interaction of lipoproteins with the virus particles; the hybrid particle model and the 
two particle model. The hybrid model suggests that the particle comprises both a 
lipoprotein and a viral moiety (Andre et al., 2002). Alternatively, the two particle 
model proposes serum lipoproteins attach to virus particles through interactions with 




Figure 1.1. Taken from (Bartenschlager et al., 2011) Structure of the HCV 
genome and functions of the viral proteins. Proteases involved in the processing 
of the polyprotein are shown at the top and cleavage sites are indicated by the 
arrows. 
 
1.3. HCV Genome 
Through use of overlapping cDNA clones, the HCV genome was determined to 
consist of one continuous open reading frame (ORF) encoding a polyprotein 3011 
amino acids in length (Choo et al., 1991). The single stranded RNA genome encodes 
a 5’ non-coding region, the ORF encoding structural and non-structural proteins and 
a 3’ non-coding region (Moradpour et al., 2007). The ORF is enzymatically cleaved 
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post-translationally to produce 10 proteins comprised of the structural (core, E1 and 
E2) and non-structural (p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B) proteins 
(Figure 1.1). 
The core protein, encoded at the amino-terminal end of the polyprotein, encodes two 
domains responsible for promoting the formation of the nucleocapsid and interacting 
with lipid droplets (Boulant et al., 2005, Boulant et al., 2006). The core protein not 
only plays a structural role, but also interacts with cellular proteins to influence 
processes such as lipid metabolism and apoptosis (McLauchlan, 2000). 
The E1 and E2 genes encode the envelope glycoproteins of the virion. The two 
proteins are expressed on the surface of the virus and are essential for binding to 
various receptors on the surface of the host cell, facilitating cell entry. The E2 gene 
encodes both hypervariable region (HVR) 1 and HVR 2; two of the most variable 
regions of the entire genome (Hijikata et al., 1991a). HVR1 is a target of neutralising 
antibodies and the heterogeneity found in this region allows the virus to evade the 
response of the immune system (Kato et al., 1993, van Doorn et al., 1995). 
The seven remaining non-structural proteins are all involved in the replication of the 
genome and assembly of new virions, either through enzymatic activity or other 
roles. 
P7 forms a transmembrane protein which plays a role in ion transfer and is also 
considered to be a viroporin; a protein involved in virus particle assembly and 
release from the host cell (Griffin et al., 2003).  
The NS2 transmembrane protein inserts into the membrane of the ER. The C-
terminal of the protein contains a cytosolic domain with cysteine protease activity 
which cleaves the NS2/3 junction (Grakoui et al., 1993b). In vitro, the NS2 protein 
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has also been shown to inhibit cell proliferation and arrest the cell cycle during S-
phase in HeLa and Vero cells (Yang et al., 2006). 
The NS3 protein is a multifunctional protein, encoding both a serine protease at the 
N-terminal and NTPase/RNA helicase at the C-terminal (Han et al., 1995, Kim et al., 
1995). The RNA helicase of the C-terminus is involved in unwinding double 
stranded RNA in short sections at regular spacing, enabling the replication of the 
genome (Serebrov and Pyle, 2004). NS4A is a cofactor of the serine protease, which 
is responsible for the cleavage of the junctions between NS3/4A, 4A/4B, 4B/5A and 
5A/5B (Bartenschlager et al., 1994). The NS3-4A serine protease has also been 
shown to cleave Toll-IL-1 receptor domain-containing adaptor inducing IFN-β 
(TRIF), thereby inhibiting the activation of NF-κB and IRF-3 and promoting the 
evasion of the innate immune system by the virus (Li et al., 2005). Three residues 
form the catalytic triad responsible for the protease activity; His-1083, Asp-1107 and 
Ser-1165 (Grakoui et al., 1993a). The interaction of NS3 with NS4A enables the 
activation of the active site of the protease and enhances the efficiency of cleavage 
(Kim et al., 1996). 
The N-terminus of NS4A is involved in targeting NS3 to the membrane of the ER 
and also contains a transmembrane helix responsible for anchoring the complex to 
the ER (Wolk et al., 2000). In addition to its interactions with NS3, NS4A interacts 
with a region in the centre of NS5A to aid in the phosphorylation of NS5A (Kaneko 
et al., 1994). 
NS4B is an integral membrane protein, which co-localises with the other non-
structural proteins in the ER membrane (Hugle et al., 2001). It generates a 
membranous web by inducing changes in the ER, which serves the vital purpose of a 
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scaffold for the HCV replication complex as well as RNA binding activity important 
for the replication of the virus (Egger et al., 2002). 
The NS5A protein comprises three domains and, although no enzymatic activity of 
the protein has been observed, it is vital for the replication of the virus. It is involved 
in the binding of RNA for replication (Huang et al., 2005) and is capable of down-
regulating the translation of viral RNA, through interactions between amino acids 
and RNA (Hoffman et al., 2015a, Hoffman et al., 2015b). The protein is also 
responsible for binding to host Cyclophilin A (CypA), which is involved in the 
subcellular distribution of NS5A (Dujardin et al., 2015). Domain III of the protein is 
necessary for the assembly of virions (Appel et al., 2008). Alongside roles in 
replication and assembly, the protein also contains the interferon-ɑ sensitivity-
determining region (ISDR). This region of NS5A binds to the double-stranded RNA-
activated protein kinase (PKR), the product of an interferon-ɑ stimulated gene (ISG). 
PKR is an important cellular antiviral protein which inhibits the synthesis of proteins 
by activating eukaryotic initiation factor-2ɑ (Gale et al., 1997, Gale et al., 1998). 
Through binding to PKR, ISDR inhibits its antiviral activity (Gale et al., 1997, Gale 
et al., 1998). 
The NS5B protein encodes the RNA-dependent RNA polymerase (RdRP), essential 
for replication of the genome. The RdRP has a typical ‘right hand’ polymerase 
structure with thumb and finger domains enclosing the active site of the palm 
domain (Lesburg et al., 1999) and creating a channel for binding to a single stranded 
RNA template for translation (Penin et al., 2004). 
Proteins which are vital to the replication of the virus make attractive therapeutic 
targets and the knowledge about the HCV genome has aided the development of 
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specifically targeted antiviral therapy for HCV (STAT-C) drugs, including protease 
and polymerase inhibitors (Manns et al., 2007).  
 
1.4. Replication cycle of HCV 
1.4.1. Cell entry 
The entry of the virion into the host cell is a complex multistep process involving 
interactions between the viral envelope glycoproteins, E1 and E2, and numerous 
receptors on the surface of the target cell. Entry of the HCV virion is dependent on at 
least four cellular proteins, including CD81 (Pileri et al., 1998), scavenger receptor 
class B type I (SRB1) (Scarselli et al., 2002), claudin-1 (CLDN1) (Evans et al., 
2007) and occludin (OCLN) (Ploss et al., 2009). SRB1 interacts with the E2 
glycoprotein and lipoproteins mediating a post-binding event through increased 
exposure of the CD81 binding site on E2 (Scarselli et al., 2002, Dao Thi et al., 
2012). Interaction of CD81 with E2 may prime the envelope glycoproteins for 
activation by the low pH experienced during entry (Sharma et al., 2011). This 
interaction also activates RHO GTPases allowing the lateral movement of HCV-
CD81 complexes to cell-cell junctions and interaction of CD81 with CLDN1 
(Brazzoli et al., 2008). The precise role of OCLN, a tight junction protein, in the 
process is currently unknown although it has been shown to be necessary in the late 
stages of virus entry (Benedicto et al., 2009, Sourisseau et al., 2013). 
Endocytosis of the HCV particle into the host cell is mediated through a clathrin-
dependent process (Blanchard et al., 2006) and fusion of the endocytosed virus takes 
place in early endosomes (Meertens et al., 2006, Coller et al., 2009). The 
multifactorial entry of HCV in the host cell is also influenced by the presence of host 
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restriction factors that protect cells from infection with virions. The restriction factor 
EW1-2wint blocks the vital interaction between CD81 and the envelope 
glycoproteins of HCV and may also block essential signalling pathways (Potel et al., 
2013). 
1.4.2. RNA translation and replication 
Upon internalisation into the cytoplasm, the positive sense RNA genome is 
translated. To initiate this process, the internal ribosome entry site (IRES) of the 5’ 
non-coding region binds to the 40S ribosomal subunit and eukaryotic initiation factor 
3 (eIF3) (Lindenbach and Rice, 2005). This ternary complex then associates with 
eIF2, GTP and initiator tRNA to produce a 48S complex before an 80S complex can 
be formed and translation begins to produce the viral polyprotein (Lindenbach and 
Rice, 2005). Proteases, both cellular and viral, are involved in processing the 
polyprotein into the ten proteins encoded by the genome. The core/E1, E1/E2 and 
E2/p7 junctions are cleaved by ER signal peptidases (Hijikata et al., 1991b). NS4A 
is then cleaved from its position by NS3 before forming a protease complex by 
associating with the N-terminus of NS3. This protease is responsible for the cleavage 
of junctions between NS4B/5A and NS5A/5B whilst the junction between NS2 and 
NS3 is cleaved by the NS2 cysteine protease (Bartenschlager et al., 1993, Grakoui et 
al., 1993b). 
Prior to replication, HCV first induces rearrangements in the intracellular 
membranes to produce a membranous web, with which non-structural proteins can 
associate (Egger et al., 2002, Gosert et al., 2003). The translated proteins associate 
with the membranous web forming the replication machinery necessary for 
replicating the viral genome via a negative sense intermediate (Dubuisson and 
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Cosset, 2014). The positive sense viral genomes produced during replication serve 
three purposes: to produce new proteins, act as templates for RNA replication and 
are used in the production of infectious virions (Dubuisson and Cosset, 2014). 
This process is dependent on the liver-specific microRNA 122, which stabilises the 
5’ end of the genome by recruiting Argonaute 2 (Shimakami et al., 2012). 
Subsequent degradation by the cellular exonuclease Xrn1 is reduced (Li et al., 2013). 
1.4.3. Assembly and release 
The exact mechanism through which virus particles are assembled is not yet clear 
but some of the roles played by the viral proteins have been determined (Figure 1.2). 
The core protein associates around lipid droplets (LDs) in the cytoplasm, rearranging 
their intracellular distribution and leading to their accumulation in the perinuclear 
region (Barba et al., 1997, Boulant et al., 2008). The NS5A protein is also recruited 
to LDs, interacting with the associated core protein through its C-terminal domain 
(Appel et al., 2008, Masaki et al., 2008). The NS2 protein is vital for the recruitment 
of the E1-E2 heterodimer from the ER and its interaction with the NS3/4A protease 
complex (Phan et al., 2009, Jirasko et al., 2010). This latter interaction is necessary 
for the recruitment of the core protein from LDs to the site of virion assembly 
(Counihan et al., 2011). The HCV RNA may also be packaged by the NS3/4A 
complex during assembly of virus particles (Counihan et al., 2011). The p7 protein 
forms ion channels capable of equilibriating the pH gradient within the secretory 
pathway of the cell (Wozniak et al., 2010), thereby protecting the virion from 
exposure to the low pH during the release of the particles from the infected cell 
(Wozniak et al., 2010). The production of infectious virions is closely linked to the 
VLDL assembly pathway (Gastaminza et al., 2008). In vitro, it was observed that the 
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intracellular virus particles had a higher density than that of the extracellular 
particles, leading to the assumption that the particles seem to acquire the lower 
density in a post-ER compartment during transit through the secretory pathway 
(Gastaminza et al., 2006). 
 
 
Figure 1.2. Taken from (Paul et al., 2014). Models of HCV virion production. 
The left side shows a hypothetical model of virion assembly. NS3 and NS5A aid 
in the transport of viral RNA to cytosolic lipid droplets. The re-recruitment of 
core protein to the ER is thought to trigger the formation of the nucleocapsid 
and budding into the ER lumen. Virions incorporate cellular lipoproteins, 
which either occurs during budding (hybrid particle model) or during egress 
via interaction between the virion and VLDL particles (two particle model). ER 
endoplasmic reticulum, E1/E2 envelope glycoprotein 1/2, NS non-structural, 
DGAT 1/2 Diglyceride acyltransferase 1/2, ApoE apolipoprotein E, MTP 
microsomal triglyceride transfer protein. 
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1.5. Immune responses against HCV 
Both the innate and adaptive immune responses play a role in the outcome of HCV 
infection; either viral clearance or the evolution of the virus. 
The innate immune response provides the initial defence against a viral infection 
such as HCV. The virus is recognised by various receptors including retinoic acid 
inducible gene-I (RIG-I) and toll-like receptors (TLRs), leading to the activation of 
transcription factors NF-κB and interferon regulatory factor 3 and 7, which bind to 
promoter regions of interferon genes (reviewed in Heim and Thimme, 2014). 
Interferons regulate the transcription of interferon stimulated genes (ISGs), the 
products of which are the main antiviral effectors, facilitating in the clearance of 
infected cells and the recruitment of immune cells to promote an adaptive response 
(reviewed in Yang and Zhu, 2015). 
Natural killer (NK) cells play an important role in the innate immune response and 
can generally be divided into two subsets; i) CD56bright cells providing non-cytolytic 
responses, such as the release of IFN-γ and tumour necrosis factor-α (TNF-α), and 
the priming of T helper cell type I cells and ii) CD56dim cells capable of direct 
cytotoxicity (Ahlenstiel, 2013). The significance of the role that NK cells play in 
acute HCV infection is not currently known (reviewed in Rehermann, 2015). In 
chronic HCV infection, NK cells remain activated but their functions are skewed 
towards a reduction in cytokine levels and an increase in cytotoxic capacity, which 
may contribute to viral persistence and disease progression (Oliviero et al., 2009, 
Ahlenstiel et al., 2010). 
HCV has evolved a range of mechanisms to evade the innate immune system and the 
selective pressures exerted by it. The NS3/4A protease is responsible for the 
cleavage of MAVS from intracellular membranes, thereby preventing the RIG-I 
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signalling pathway and the activation of interferons (Loo et al., 2006). Lower levels 
of IFN induction have been observed in the livers of patients with chronic HCV 
infection, confirming the role of MAVS cleavage in vivo (Bellecave et al., 2010). 
Other viral proteins, such as the core, are also involved in the regulation of the innate 
immune system. The core protein can prevent the nuclear accumulation of STAT1 to 
prevent the activation of ISGs as well as promoting expression of suppressor of 
cytokine signalling-3 (SOCS3), which is a negative regulator of the Jak/Stat pathway 
(Bode et al., 2003, Melen et al., 2004). 
The impairment of NK cells by HCV is not well understood. In vitro, HCV virions 
have been shown to downregulate the production of IFN-γ by NK cells through the 
interaction of the HCV E2 protein with CD81 resulting in an environment with a 
cytokine profile more permissive to HCV infectivity (Crotta et al., 2010). The 
stabilisation of HLA-E through binding to a specific HCV core-derived epitope 
results in the inhibition of NK cell cytotoxicity (Nattermann et al., 2005). 
The adaptive immune response comprises the humoral and cellular immune 
responses. The humoral immune response involves neutralising antibodies, the 
majority of which have been mapped against the E1 and E2 glycoproteins (reviewed 
in Edwards et al., 2012). These targets play a role in cell binding so neutralising 
antibodies may be able prevent the spread of virus to other cells. In vitro, several 
anti-E2 antibodies prevent infection at a post-attachment stage (Sabo et al., 2011). 
The cellular immune response comprises the response by CD4 and CD8 T cells. The 
CD4 response is an important factor in determining whether a patient will 
spontaneously clear the virus or develop a chronic infection (Urbani et al., 2006). In 
cases of self-limited infection, CD4 cells produce Th1 cytokines which aid in 
sustaining cytotoxic T lymphocyte function as well as generating CD8 memory cells 
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(Urbani et al., 2006). However, virus-specific CD4 cell responses are rarely detected 
in chronic infection (Lucas et al., 2007). 
The CD8 cells are the main effector cells involved in the clearance of the virus. 
HCV-specific CD8 cells appear in the blood approximately 6-8 weeks after infection 
and this is linked with a sharp decline in the viral load (Thimme et al., 2001). A 
study in chimpanzees demonstrated that after the antibody-mediated depletion of 
CD8 cells, the viral load remained high for a prolonged period, only declining upon 
the re-emergence of HCV-specific CD8 cells (Shoukry et al., 2003). CD8 T cells can 
act through both cytotoxic and non-cytolytic mechanisms in order to inhibit HCV 
replication although IFN-γ-mediated non-cytolytic mechanism is the primary 
effector for inhibition (Jo et al., 2009). 
Previous studies have shown that the immune system provides a selective pressure 
for HCV and may be a driving force in its evolution in the host. One of the main 
factors in the persistence of an HCV infection is the appearance of viral escape 
mutations, which are not recognised by the immune system. Such mutations have 
been observed in multiple epitopes which are targets of neutralising antibodies (von 
Hahn et al., 2007). Some mutations in the target epitopes of neutralising antibodies 
act through an altered use of host-cell entry factors (Fofana et al., 2012). 
There are three possible mutation sites within epitopes which may affect the CD8 T 
cell response; i) Mutations within the binding anchors of the epitope prevent 
presentation of the antigen to T cell, ii) Mutations within the contact residues of the 
T cell receptor region which impair recognition by epitope-specific CD8 T cells 
(Soderholm et al., 2006) and iii) Mutations in flanking regions of an epitope which 
can inhibit antigen presentation through the disruption of antigen processing by the 
proteasome (Seifert et al., 2004, Kimura et al., 2005). Amino acid mutations have 
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been observed in Class I-restricted epitopes from multiple HCV proteins, including 
NS3 and NS5B, in a longitudinal study examining the evolution of 
transmitted/founder viruses (Bull et al., 2015). The Q80K polymorphism lies within 
a Class I-restricted epitope (Ward et al., 2002), which may have played a role in the 
origins of this mutation. 
Mutations in Class II-restricted epitopes can also aid in viral escape. An in vitro 
study of a specific NS3358-375 Class II-restricted epitope found that mutations within 
this region reduced the T cell and IFN-γ responses compared to the original epitope 
(Cusick et al., 2011). Variants of a HVR1 epitope have also been shown to inhibit 
cytokine production (Frasca et al., 1999). 
 
1.6. Genetic variability and resistance 
HCV is currently classified into seven genotypes (shown by a number 1-7) and each 
genotype is subdivided into many different subtypes (represented by a lower case 
letter). There are considered to be over 80 different subtypes, demonstrating the vast 
diversity of HCV due to its rapid evolution (Argentini et al., 2009). At the nucleotide 
level, genotypes have a 31-33% difference whereas subtypes differ by 20-25% 
(Simmonds et al., 2005). Presently, the classification system of genotypes and 
subtypes is based on both sequence data and phylogenetic analysis of the NS5B 
region of the genome (Argentini et al., 2009). 
There is also a large degree of heterogeneity at the intra-patient level of the virus. 
The term quasispecies describes a group of genetically linked variants that contains a 
dominant sequence alongside a range of other variants (Martell et al., 1992). HCV 
has several key features which contribute to its existence as a quasispecies. Firstly, it 
has a high rate of replication, with approximately 1012 virions produced daily, at a 
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rate of 50 infectious particles per hepatocyte per day (Neumann et al., 1998, Zeuzem 
et al., 1998).  
Secondly, whereas the DNA polymerases of DNA-based viruses have a proofreading 
ability to minimise the risk of misincorporations, the RNA polymerase of HCV lacks 
such a mechanism. This results in an increased error rate, estimated at approximately 
1.2x10-4 to 2.5x10-5 mutations per nucleotide per genome replication in vivo (Cuevas 
et al., 2009, Ribeiro et al., 2012). However, this mutation rate is likely to vary 
between regions of the genome. Through the use of statistical models, it has been 
demonstrated the majority of the non-structural genes, which are vital to the 
replication of the virus, mutated at a rate of 1x10-3 substitutions/site/year whereas the 
genome regions containing E1/E2 envelope proteins showed a higher mutation rate 
up to 6.9x10-3 substitutions/site/year (Gray et al., 2011). 
The combination of these two factors plays a pivotal role in the diversity and 
evolution of the virus. 
The incorporation of incorrect nucleotides during transcription leads to mutations in 
the virions produced. An estimated 8.7 x 1010 and 4.2 x 109 virions produced each 
day contain a single or double nucleotide substitution respectively (Rong et al., 
2010). There are 2.9 × 104 and 4.1 × 108 possible single and double mutants, 
respectively, and due to the large volume of virions produced in a host, each mutant 
is expected to be produced multiple times each day (Rong et al., 2010). 
Mutations conferring resistance to antiviral drugs will be spontaneously generated 
during replication, without the need for the selective pressure of antiviral therapy. 
Mutations in proteins that are essential for the virus’ replication generally confer a 
reduced fitness, especially if they lie within an active site. The A156V mutation of 
the NS3 gene increases the resistance of the virus to the NS3 protease inhibitor 
16 
 
simeprevir by 177-fold but also reduces the viral fitness by approximately 5-fold, 
impairing its ability to produce infectious virions (Lenz et al., 2010). If the 
replicative fitness of a mutant is negatively affected, then the mutant will remain at a 
low, background frequency until a selection pressure is applied which positively 
selects for the mutant i.e. antiviral therapy. A previous study determined that in vitro 
incubation with non-nucleoside inhibitors (NNIs) resulted in NNI-resistant variants 
present at a background level becoming predominant in the HCV quasispecies 
population (Le Pogam et al., 2008). In vitro, the emergence of resistant variants is 
also dependent on the concentration of drug administered (Verbinnen et al., 2010). 
One study observed the emergence of low-level resistance mutations upon exposure 
to a low concentration of the NS3 inhibitor TMC380765, which were replaced by 
variants harbouring a high-level resistance mutation when exposure to the drug was 
increased (Verbinnen et al., 2010). 
The genetic barrier to resistance is an important factor in the emergence of resistant 
variants. The genetic barrier is the number of mutations required to negate the 
antiviral activity of a drug and the difficulty in generating these specific mutations 
(Gotte, 2012). A resistant variant requiring a single transition has a lower barrier to 
resistance than those requiring a transversion or more than one transition (Powdrill et 
al., 2011). The differences between genotypes can impact upon the barrier to 
resistance. One prominent example of this is the substitution of arginine to lysine at 
position 155 of NS3. Subtype 1a requires a single transition (AGG to AAG) whilst 
both a transition and transversion (CGG to AAG) is necessary for the same amino 
acid substitution in subtype 1b (Powdrill et al., 2011). 
DAAs with a low barrier to resistance can still be used to effectively treat infection 
when used with other drugs in a combination therapy regimen. Alternatively, 
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increasing the level of the antiviral to that of the variants’ IC90 value can also 
overcome a low genetic barrier (Lim and Gallay, 2014). The opposite also applies in 
cases where antiviral drugs with high barriers to resistance are used in low 
concentrations allowing resistance to emerge (Lim and Gallay, 2014). 
In vivo, the impact of low frequency resistant variants has not been fully elucidated 
although small scale studies have begun to make progress into this area (Akuta et al., 
2013, Akuta et al., 2014b, Kosaka et al., 2015). From these studies, variants present 
at baseline at a frequency ≤1% do not appear to have an impact on treatment 
responses. Instead, they remain at background levels and treatment failure in patients 
seems to be a consequence of de novo mutations absent at baseline which emerge in 
response to the antiviral treatment. In a very limited number of patients (n=4) 
undergoing treatment with simeprevir plus sofosbuvir, the presence of minority 
variants, at frequencies ranging from 1.3%-13.0%, did not impact upon the treatment 
response (Fevery et al., 2015). 
Cessation of antiviral therapy leads to resistant mutants reverting to a low frequency 
as the wild-type strain with a higher replicative fitness outgrows them (Sarrazin et 
al., 2007). This process has been observed to begin as soon as 7 days after the end of 
therapy and takes place over several months (Sarrazin et al., 2007). Resistant 
variants have been observed persisting at varying degrees, according to the gene in 
which they exist and their replicative capacity. One study observed protease inhibitor 
resistant variants persisting at frequencies up to 9% for a period of up to 4 years after 
the discontinuation of treatment (Susser et al., 2011). Another found differences in 
persistence between RAMs; the R155K variant was found in 25% of patients at week 
48 post-treatment in contrast to only 2% of patients harbouring D168V at the same 
time point (Krishnan et al., 2015b). Regarding NS5A variants, persistence of RAMs 
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at high and low frequencies have both been reported. In a proportion of patients at 6 
months post-treatment, resistant variants still dominated in the population at 
frequencies up to 100% (Wang et al., 2013). Another study found that 94.4% of 
patients still harboured a RAM in NS5A, detectable by deep sequencing, 96 weeks 
post-treatment, although the frequencies had declined over this period (dvory-Sobol 
et al., 2015). Upon the continuation of replication, a dominant variant can continue 
to accumulate mutations which may compensate for the reduction in viral fitness or 
increase resistance to other antiviral drugs. This is one of the factors likely to 
influence the rate at which resistant variants are outgrown by the wild-type virus. 
 
1.7. Natural history 
The acute stage of HCV infection presents with mild non-specific clinical symptoms 
such as lethargy in only a small proportion of patients, with many infections 
remaining asymptomatic in the acute stage (Orland et al., 2001). The acute illness 
refers to the first 6 months of infection, characterised by the detection of virus in the 
blood, rise in the levels of alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) and development of anti-HCV antibodies (Hajarizadeh et 
al., 2013). 
In approximately 25% of acute infections, the virus is spontaneously cleared 
although this is dependent on several host and viral factors. Infection with genotype 
(Gt) 1 increases the likelihood of spontaneous clearance (Harris et al., 2007) as does 
low quasispecies diversity (Ray et al., 1999). Polymorphisms at the IL28B site of the 
host genome have a strong influence on viral clearance; patients with a CC allele 
have an increased likelihood of naturally clearing the infection compared to those 
with a CT or TT allele (Tillmann et al., 2010). 
19 
 
Patients who do not spontaneously clear HCV during the acute stage of infection go 
on to develop chronic HCV infection. This is often asymptomatic and remains 
undiagnosed until later complications of the infection arise. Generally, the infection 
progresses slowly to cause cirrhosis in 16% of patients over a period of up to 20 
years (Thein et al., 2008a). In some patients, cirrhosis eventually leads to 
hepatocellular carcinoma (HCC) and death. 
The increased risk of fibrosis progression during chronic HCV infection is 
influenced by numerous host and behavioural factors. Age is a significant factor, 
with a positive correlation between the rate of fibrosis progression and the age at 
which a patient is infected (Minola et al., 2002). 
 
1.8. Epidemiology 
The global estimate of HCV infection is approximately 130-150 million people, 
accounting for ~2% of the total world population (World Health Organisation, 
2015). The prevalence between countries varies widely, with rates >10% reported in 
few countries, including Egypt (Guerra et al., 2012). Despite relatively low 
prevalence rates in many Asian countries, the large populations contribute to the 
high number of infections found in these countries, which comprise approximately 
50% of the global infections (Lavanchy, 2011). However, the estimates in 
developing regions vary widely, in part due to limited surveillance and differences in 
testing strategies employed by studies. 
Alongside the varying prevalence between different countries, the primary 
transmission routes also tend to differ. In northern European countries such as the 
UK and Norway, injecting drug users (IDUs) account for approximately 90% and 
67% of infections, respectively (Cornberg et al., 2011). In contrast to this, iatrogenic 
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exposure is considered to be the main risk factor in developing countries such as 
Egypt (Paez Jimenez et al., 2010). 
The distribution of HCV genotypes and subtypes varies throughout the world (Figure 
1.3). Genotypes 1, 2 and 3 are prevalent throughout the world with 1 and 3 making 
up the majority of cases in Europe and the USA. Endemic strains are typically 
classified as those subtypes which are geographically restricted, displaying a high 
degree of heterogeneity and long-term persistence in the region (Pybus et al., 2007). 
Genotypes 2 and 6 are endemic in West Africa and Southeast Asia, respectively, 
each displaying a large degree of local genetic variation (Markov et al., 2009, Pybus 
et al., 2009). The high divergence of strains found in these regions may indicate a 
long-term presence of HCV infections, allowing the virus time to evolve into a range 
of different subtypes (Pybus et al., 2001). 
 
 
Figure 1.3. Taken from (Hajarizadeh et al., 2013) Estimated prevalence and 




Both the prevalence and genotype distribution show temporal changes in pattern. 
Global movement and immigration of people has been determined as a significant 
factor in the distribution of specific genotypes (Savvas et al., 2005, Markov et al., 
2012). One of the largest historical occurrences to influence this distribution is the 
movement of millions of people from Africa to the Americas during the trans-
Atlantic slave trade (Markov et al., 2009). Movements of Gt2 lineages from West 
Africa to Suriname have been estimated to have occurred at the time of these major 
trans-Atlantic slave movements (Markov et al., 2012). In Greece, 15% of infections 
are Gt4, which is one of the dominant genotypes of North and Central Africa 
(Savvas et al., 2005). This distribution is likely to be caused by the return of 
communities from these regions into Greece, bringing with them this genotype, 
where it has subsequently remained amongst the population (Savvas et al., 2005).  
 
1.9. Co-infection with HIV 
It is estimated there are approximately 35 million HIV infections globally (UNAIDS, 
2014a) and the shared transmission routes between viruses mean that persons at high 
risk of HIV are also likely to be at risk of infection with HCV (Sulkowski, 2008). In 
high risk groups such as IDUs, prevalence rates of HCV co-infection have been 
observed at >90% in HIV-infected individuals (Garten et al., 2004). Consequently, 
the CDC recommends routine HCV testing for HIV-infected patients (Centers for 
Disease Control and Prevention, 2013). 
An almost synergistic effect exists between the two viruses in the context of 
transmission. The risk of HCV infection through vertical and perinatal transmission 
is doubled in HIV-infected mothers (Thomas et al., 1998, Mast et al., 2005) as well 
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as a higher risk of HCV transmission from a co-infected individual following 
percutaneous exposure (De Carli et al., 2003). 
Co-infection with HIV has several notable effects on the natural history of HCV 
infection including a marked increase in HCV RNA load which has been 
demonstrated in several different cohorts, including IDUs and haemophiliac patients 
who have received transfusions (Eyster et al., 1994, Beld et al., 1998). Co-infected 
patients are less likely to spontaneous clear the acute HCV infection (Thomas et al., 
2000), probably due to the diminished T-cell responses, which play an important role 
in the prevention of a chronic infection (Claassen et al., 2013). 
Infection with HIV has a profound effect on both the innate and adaptive immune 
systems and the combined influence of both viruses during co-infection is complex. 
Untreated HIV infection can alter the subset distribution of NK cells, skewing the 
population towards a high proportion of CD56-/CD16+ cells which show a reduction 
in both cytolytic activity and the production of cytokines required for the modulation 
of other immune effectors (Mavilio et al., 2003, Mavilio et al., 2005). This change 
may decrease the pressure placed on HCV by the innate immune system, and 
therefore increase the risk of the infection becoming persistent. 
HIV also leads to the impairment and death of CD4 cells, which may affect the 
adaptive immune response against HCV. A previous study observed a decrease in 
levels of antibodies specific to non-structural proteins after HIV infection, with this 
decrease more evident in patients with a low CD4 count (Netski et al., 2007). 
Another study observed a similar trend in anti-HCV antibodies specific to E1 and E2 
glycoproteins (Bailey et al., 2015). This trend may affect the evolution of HCV, with 
less pressure from the immune system leading to a decline in the quasispecies 
variation. The CD4 count of HIV/HCV co-infected patients has also been shown to 
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affect the HCV-specific CD8 response, with such responses only present in 30% of 
subjects with a CD4 count of <500 cells/mm3 (Kim et al., 2005). 
The advent of highly active antiretroviral therapy (HAART) has dramatically 
decreased HIV-related mortality in recent years. However, this has had the knock-on 
effect of HCV co-infection now emerging as a leading cause of disease and death 
among HIV-positive patients (Rotman and Liang, 2009). The effects of HCV are 
exacerbated by HIV co-infection, markedly accelerating the progression of liver 
fibrosis and increasing the likelihood of HCV-related morbidity and mortality 
(Rotman and Liang, 2009). Co-infected patients are at an increased risk of cirrhosis 
(Thein et al., 2008b), at an earlier stage compared to mono-infected patients 
(Benhamou et al., 1999). The effects of HIV on HCV quasispecies and drug 
resistance have been poorly studied, with no consensus determined between the 
studies (Sherman et al., 1996, Shuhart et al., 2006, Lopez-Labrador et al., 2007, 
Tanaka et al., 2007, Netski et al., 2008). 
 
1.10. Diagnosis 
Diagnosis of an active HCV infection is completed through the use of multiple tests. 
The CDC recommends a testing algorithm of a serological assay for the detection of 
anti-HCV antibodies or HCV antigens, followed by a nucleic acid amplification test 
(NAT) to confirm the presence of a current infection (Centers for Disease Control 
and Prevention, 2013). Upon a negative result by NAT, an immunoblot assay can be 
used as a tertiary test to confirm a resolved past infection. 
During the initial acute phase of HCV infection, there is a period of approximately 7-
8 weeks before the development of anti-HCV antibodies by the immune system of 
the host (Bowen and Walker, 2005). Prior to this seroconversion, infection can be 
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diagnosed by assays that directly target the virus, typically nucleic acid amplification 
technology (NAT) for the detection of HCV RNA (Centers for Disease Control and 
Prevention, 2013). Real-time PCR is the most common NAT employed to detect 
HCV RNA in routine diagnostic settings. In addition, quantitative real-time PCR 
measures the HCV RNA load and plays an important role in the clinic by guiding 
antiviral therapy and measuring its efficacy. Commercial real-time PCR assays are 
available in kit format from several manufacturers, although these are often 
expensive to use. On the other hand, serological assays represent a relatively cheap 
diagnostic test, requiring little infrastructure to complete. These features make 
serological assays a prime candidate for initial tests, especially in developing 
regions. However, some reports from studies in African populations have found 
these tests to have a high rate of false-positive results (Chasela et al., 2012, Mullis et 
al., 2013, King et al., 2015). 
 
1.11. Treatment: Drug classes, mechanism of action and resistance 
pathways 
1.11.1. Treatment outcomes 
Unlike HIV and HBV, HCV does not integrate into the genome of the host or have a 
DNA intermediate. Consequently, infection with HCV can be cleared with the use of 
antiviral therapy. The aim of treatment is the eradication of the virus from the 
patient, which then prevents further complications of chronic infection including 
cirrhosis, hepatocellular carcinoma and death (European Association for the Study of 
the Liver, 2015). There are several possible outcomes of therapy at timepoints during 
and after treatment. During therapy, a rapid virological response (RVR) is the 
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decrease in HCV RNA to undetectable levels at week 4 of treatment (Wedemeyer et 
al., 2012). The achievement of an RVR has been observed as a strong predictor of 
the patient achieving sustained virological response (SVR) in trials of treatment with 
a protease inhibitor (PI) plus pegylated interferon and ribavirin (P/R) (Jacobson et 
al., 2011). Despite suppression of the virus during early therapy, some patients 
experience a re-emergence of HCV RNA in a phenomenon known as virologic 
breakthrough. Patients may also fail to suppress the levels of HCV RNA by ≥2 log10 
during the first 12 weeks of therapy. This is known as a null-response. 
An SVR is defined as undetectable HCV RNA at either 12 or 24 weeks after the 
cessation of treatment (Wedemeyer et al., 2012). The alternative outcome to an SVR 
is a virologic relapse, in which the levels of HCV RNA return to pre-treatment level 




Table 1.1. Currently licensed and discontinued direct-acting antivirals for the 
treatment of HCV 
Class Target DAAs 
Peptidomimetic linear 
ketoamide inhibitor 
NS3 protease Boceprevir 
Telaprevir 
Paritaprevir 
Macrocyclic inhibitor NS3 protease Simeprevir 
NS5A inhibitor NS5A Daclatasvir 
Ledipasvir 
Ombitasvir 
Nucleotide inhibitor NS5B polymerase Sofosbuvir 
Non-nucleoside inhibitor NS5B polymerase Dasabuvir 




1.11.2. Pegylated-interferon and ribavirin 
Up until 2011 and the introduction of direct acting antivirals (DAAs) (Table 1.1), the 
gold standard treatment for HCV infection was a combination of pegylated-
interferon (peg-IFN) and ribavirin (RBV). This treatment had a low response rate of 
approximately 50% (Manns et al., 2001) although both host and viral factors affected 
the efficacy of this regimen. Host factors such as African-American ethnicity 
reduced the efficacy of this treatment (Jeffers et al., 2004) although one of the 
greatest influences was polymorphisms at the IL28B locus (Ge et al., 2009, Suppiah 
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et al., 2009). The genotype of HCV also affected the outcome of treatment; Gt1 
being more difficult to treat than other genotypes (McHutchison et al., 1998). 
Peg-IFN and RBV decrease the viral load of HCV through a variety of different 
mechanisms, although they are not virus specific. RBV is a guanosine nucleoside 
analogue that inhibits the replication of HCV. One of the derivatives from the 
phosphorylation of RBV is its triphosphate form, RTP. In vitro, high concentrations 
of RBV results in the blocking of RNA elongation through the misincorporation of 
this molecule opposite cytosine or uridine in the viral RNA chain (Maag et al., 
2001). For clinical use, RBV is used at much lower concentrations so it is likely that 
this mechanism only has a small effect on the replication of HCV (Feld and 
Hoofnagle, 2005). Another proposed mechanism of RBV is that it acts as a viral 
mutagen and this pushes the virus towards the ‘error catastrophe’; the virus carries so 
many mutations that its replicative capacity is completely diminished (Crotty et al., 
2000, Crotty et al., 2001). 
Interferon-alpha acts by binding to IFN cell-surface-receptors, which subsequently 
activate the Janus-activated kinase 1 (Jak1) and tyrosine kinase 2 (Tyk2) (Beadling 
et al., 1994). These kinases phosphorylate the signal transducer and activator of 
transcription proteins 1 and 2 (STAT1 and STAT2), leading to the formation of IFN-
stimulated gene factor 3 (ISGF-3) which binds to the promoter regions IFN-
stimulated genes (ISGs) and activates their transcription (Kessler et al., 1988, Levy 
et al., 1988, Beadling et al., 1994, reviewed in Sen, 2001). Functions of ISGs include 
apoptosis and the degradation of proteins (de Veer et al., 2001). 
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1.11.3. NS3 protease inhibitors 
Four PIs – boceprevir, telaprevir, simeprevir and paritaprevir – have been licensed 
for the clinical treatment of chronic HCV infection. PIs can be divided into two 
classes; linear and macrocyclic inhibitors. The introduction of boceprevir and 
telaprevir to the clinic increased SVR rates to 70% in treatment-naïve cohorts 
(Jacobson et al., 2011, Poordad et al., 2011). However, an increase in side effects 
was also reported alongside the higher response rates. These included skin rashes 
and anaemia in telaprevir and boceprevir, respectively, leading to the discontinuation 
of treatment in 7-11% of patients (Jacobson et al., 2011, Poordad et al., 2011). The 
risk of virological failure was high when these first-generation PIs were used as a 
monotherapy or in dual combination with peg-IFN only (Hezode et al., 2009). For 
this reason, combination therapy with P/R or another class of DAA was 
recommended. A lead-in phase of P/R before the initiation of boceprevir was shown 
to reduce the subsequent risk of treatment failure and resistance (Kwo et al., 2010). 
These two first-generation PIs are soon to be discontinued, with simeprevir and 
paritaprevir acting as their replacements in the treatment of HCV. Simeprevir is used 
with P/R or in combination with sofosbuvir while paritaprevir (boosted with 
ritonavir) is used in combination with ombitasvir ± dasabuvir (European Association 
for the Study of the Liver, 2015). These treatments show improved SVR rates 
(>80%) compared to first-generation PIs, with lower treatment discontinuation rates, 
typically <3% (Feld et al., 2014, Jacobson et al., 2014, Manns et al., 2014). 
Protease inhibitors compete with the substrate of the NS3 protease, inhibiting the 
post-translational cleavage of the polyprotein and thereby terminating replication 
(Raney et al., 2010). 
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Resistance mutations to PIs have been well established, with many of the mutations 
identified conferring resistance to both linear and macrocyclic inhibitors. Sites of 
resistance lie within the inhibitor envelope (the van der Waals surface boundary of 
the inhibitor) and can directly interact with it (Raney et al., 2010). A non-
synonymous mutation at such a site would negatively affect the binding of the 
inhibitor, decreasing the virus’ susceptibility to the drug. The position of these 
resistance sites lie outside the substrate envelope and catalytic site of the protease 
maintaining the enzymatic activity of the protease without completely eliminating 
the replicative fitness of the virus (Raney et al., 2010). 
1.11.4. NS5A inhibitors 
Three NS5A inhibitors have been licensed for the treatment of HCV infection; 
daclatasvir (in combination with sofosbuvir), ledipasvir (in combination with 
sofosbuvir) and ombitasvir (in combination with paritaprevir and dasabuvir). 
Treatment with daclatasvir plus P/R resulted in relatively low SVR rates of ~60% in 
treatment-naïve Gt1 patients (Hezode et al., 2015). In comparison, the addition of 
sofosbuvir to daclatasvir therapy resulted in SVR rates of >90% (Sulkowski et al., 
2014). Ledipasvir in combination with sofosbuvir also lead to SVR rates of >90% in 
Gt1 infected patients who were treatment-naïve or previously treated with a DAA 
and/or P/R (Afdhal et al., 2014a, Afdhal et al., 2014b). 
NS5A has no known enzymatic activity, which makes it difficult to understand its 
mechanism of action. Upon administration of daclatasvir, the rapid early decline of 
the virus observed in vivo can be attributed to the drug having mechanisms which 
block both the synthesis of viral RNA and the assembly or secretion of infectious 
virions (Guedj et al., 2013). The phosphorylation state of NS5A affects its 
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interaction with other proteins, regulating its function (Evans et al., 2004), and 
daclatasvir has been shown to block hyperphosphorylation of NS5A (Qiu et al., 
2011). Ledipasvir and daclatasvir have been shown to directly bind to the NS5A 
protein (Ascher et al., 2014, Kwon et al., 2015). Several other hypotheses have been 
proposed to explain the mechanism of action, including altering the localisation of 
NS5A to the surface of lipid droplets (Qiu et al., 2011, Targett-Adams et al., 2011). 
While NS5A inhibitors display extremely high potency against HCV, they also have 
a low barrier to resistance and the resistant variants have a high replicative capacity 
(Fridell et al., 2011b). Consequently, NS5A inhibitors are all used as part of 
combination therapy with other DAAs rather than alone with P/R (European 
Association for the Study of the Liver, 2015). The known sites of resistance 
mutations are located in domain I of the protein. The Y93H mutation significantly 
reduces the binding affinity of the NS5A molecule to ledipasvir, reducing its efficacy 
(Kwon et al., 2015). As is the case with NS3 RAMs, NS5A mutations are 
responsible for cross-resistance to more than one inhibitor. 
1.11.5. NS5B polymerase inhibitors 
The polymerase inhibitors sofosbuvir and dasabuvir have been licensed for clinical 
use; sofosbuvir in combination with the ledipasvir (NS5A inhibitor) and dasabuvir in 
combination with paritaprevir (PI), ombitasvir (NS5A inhibitor). 
In clinical trials of combination therapies of the aforementioned drugs, SVR rates 
were over 94% in both treatment-naïve and previously treated patients with Gt1 
infections (Afdhal et al., 2014a, Afdhal et al., 2014b, Feld et al., 2014, Zeuzem et al., 
2014). When sofosbuvir was used in conjunction with P/R, 90% of Gt1, treatment-
naïve patients achieved SVR12 (Lawitz et al., 2013). 
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NS5B inhibitors can be classified into two classes; nucleoside inhibitors (NIs) and 
non-nucleoside inhibitors (NNIs). NIs act as a substrate of the viral polymerase and, 
after phosphorylation to their triphosphate derivative, are incorporated into the 
elongating chain of RNA causing premature termination (Migliaccio et al., 2003). 
NIs target the conserved active site of the polymerase, displaying pangenotypic 
activity both in vitro (Lam et al., 2012) and in vivo (Lawitz et al., 2013, Pockros et 
al., 2013). 
The viral polymerase contains four sites to which allosteric site NNIs can bind 
including the palm domain near the active site (palm I) and the outer surface of the 
thumb domain (thumb II) (Najera, 2013). Through this binding, the conformational 
changes to polymerase which are necessary for replication are blocked, thereby 
inhibiting the synthesis of RNA (Biswal et al., 2005). 
The S282T mutation lies close to the active site of the polymerase, conferring 
resistance to both sofosbuvir and mericitabine. S282T results in a reduced affinity of 
the polymerase for the antiviral and an ability to extend the RNA chain which has 
been terminated by the NI (Migliaccio et al., 2003). This mutation is rarely seen at 
baseline in patients, reflecting the negative influence it has on the replicative 
capacity of the virus (Franco et al., 2013, Paolucci et al., 2013). 
The site to which the allosteric NNI binds determines the mutations which confer 
resistance to it. An NNI which binds to the thumb domain is not affected by those 
mutations which confer resistance to an NNI that binds to the palm domain and vice 
versa. 
No cross-resistance between NIs and allosteric NNIs is known to exist (Lam et al., 
2012). The distinct region that each inhibitor binds to allows two polymerase 
inhibitors to be used in combination, without the risk of cross-resistance. 
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1.11.6. Combination therapy 
Although the SVR rates have increased dramatically with the advent and licensing of 
new DAAs, it is clear that these drugs still have a limited effect when used as 
monotherapy or in combination with P/R. 
The highest rates of SVR have been observed in clinical trials of a combination of 
two or more DAAs. Combination therapy for the treatment of HCV combines two or 
more DAAs from different classes i.e. an NS5A inhibitor such as ledipasvir with an 
NS5B polymerase inhibitor such as sofosbuvir. Such treatment options also offer a 
viable treatment option to every class of patient including those patients who are 
ineligible or intolerant to P/R therapy (Suzuki et al., 2013). The combination of 
multiple drugs of the same class, such as PIs, is limited because of the extensive 
cross-resistance observed. 
The genetic barrier to resistance is increased when multiple DAAs with different 
targets are used, decreasing the risk of virological escape and treatment failure. This 
approach is used in HAART for the treatment of HIV to increase the likelihood of 
suppressing the virus. Through the use of multiple drugs, a wide range of the 
existing variants will be eliminated before drug resistant mutants can emerge. 
Synergistic interactions between DAAs have been observed in vitro, enhancing the 
antiviral activity of each drug (Grunberger et al., 2008, Wyles et al., 2008). Despite 
the increased genetic barrier, treatment failure and virological breakthrough have 
still been observed in combination therapies with two DAAs. Variants harbouring 
NS3 and NS5A RAMs were observed in patients experiencing virologic 
breakthrough when treated with daclatasvir and asunaprevir (Karino et al., 2013). 
These breakthroughs occurred in patients whose trough exposures to the drugs were 




1.12. Detection of minor variants 
Before the initiation of therapy, genotypic testing for resistance mutations may be 
performed. This is completed by traditional Sanger sequencing which will detect 
mutants present at a frequency of ≥10-20%. The frequency at which drug resistant 
variants are present before treatment initiation is likely to fall below this threshold 
meaning that more sensitive methods such as allele-specific PCR, cloning or deep 
sequencing are required. 
Allele specific PCR employs the use of primers specific to drug resistance sites in 
the viral genome, enabling the identification of variants present at less than 1%. The 
main disadvantage to this approach is the a priori selection of variants, eliminating 
the possibility of identifying novel mutations (Halfon and Locarnini, 2011). 
Clonal analysis represents another option. Although this method enables the 
identification of mutations at all sites of the examined region, the sensitivity of the 
assay is directly correlated to the number of clones required (Halfon and Locarnini, 
2011). This labour intensive approach is clearly unsuitable for a high-throughput 
clinical environment. 
Next generation sequencing (NGS) represents a viable alternative to traditional 
sequencing methods for the detection of low-frequency variants. Currently, there are 
multiple platforms available, each offering different advantages and the associated 
shortcomings (Quail et al., 2012). Although the initial outlay for the equipment is 
high, NGS is a cost-effective method per amount of data generated, with a cost as 






1. Develop and/or optimise assays for i) screening pools of plasma and dried 
plasma spot specimens for the presence of HCV RNA and ii) genotyping HCV 
RNA positive specimens using two regions of the genome (detailed in chapter 
three). 
2. Determine the prevalence of active HCV infection in an HIV-positive cohort 
from Kumasi, Ghana and perform phylogenetic analyses to assess the diversity of 
the strains found in this region (detailed in chapter four). 
3. Investigate the prevalence of the Q80K polymorphism in a UK population and 
determine whether traditional Sanger sequencing is sufficient for the routine 
screening of samples for Q80K (detailed in chapter five). 
4. Perform deep sequencing on samples from HCV mono-infected and HIV/HCV 
co-infected samples naïve to all anti-HCV therapy, in order to assess the impact 
of HIV co-infection on the prevalence of resistance associated mutations 












2. Materials and Methods 
2.1. Patient cohorts 
2.1.1. Kumasi HIV-positive cohort 
Plasma samples were collected from HIV-infected patients attending the HIV clinic 
at the Komfo Anokye Teaching Hospital in Kumasi, Ghana between 2010 and 2012. 
The study was approved by the Committee on Human Research Publications and 
Ethics at the Kwame Nkrumah University of Science and Technology of Kumasi, 
Ghana (reference CHRPE/143/10). A copy of the approval letter can be found in the 
Appendix. 
2.1.2. European cohort 
Plasma samples from HCV mono-infected and HIV/HCV co-infected patients stored 
at sites throughout the UK (Royal Liverpool Hospital in Liverpool, Chelsea & 
Westminster Hospital in London, King’s College Hospital in London, and Charing 
Cross Hospital in London) and Europe (Hospital Carlos III in Madrid, Spain and 
University Hospital in Siena, Italy) were collected. The study was approved by the 
South Berkshire Regional Ethics Committee (reference 12/SC/0346). Surplus 
samples obtained from hospitals did not require patient consent as, detailed by 
section 1(9) of the Human Tissue Act 2004, there is no legal requirement for consent 
to store or use the tissue for research. All patient identifiable information was 
removed before the samples were made available to the study. Each sample was 





2.2. Sample storage 
Plasma samples were stored in 1ml aliquots at -80oC until needed.  
 
2.3. Dried plasma spot preparation 
Dried plasma spots (DPS) were prepared by spotting 50μl plasma onto each of five 
12mm discs on a Protein saver 903 card (Whatman, Maidstone, UK). DPS were 
dried at room temperature for a minimum and maximum of 12 hours and 18 hours, 
respectively, before being placed into individual sealable plastic bags with silica 
desiccant sachets. DPS were stored at -80oC until needed. Upon being taken out of 
the freezer, DPS were left at room temperature for 30 minutes before being removed 
from bags to prevent the formation of condensation. 
 
2.4. Extraction using easyMAG automated extraction platform prior to 
real-time PCR 
Frozen plasma samples were thawed at room temperature and vortexed to ensure 
homogenisation. Prior to extraction, Phocine Distemper Virus (PDV) was added to 
1ml of plasma as an internal control (IC). Samples were then incubated at 56oC for 
30 minutes and 100oC for 30 minutes (allowing a ramping time of 10 minutes 
between temperatures) with 2ml Nuclisens lysis buffer (bioMérieux, Boxtel, 
Netherlands) containing 40μl Proteinase K (Qiagen) before being transferred to the 
EasyMAG® automated extractor (bioMérieux). Extraction was completed using the 
Specific B protocol 2.0.1 with the elution volume set at 60μl, following 
manufacturer’s instructions. A negative control of water was included on each 
extraction run. For DPS specimens, two 6mm punches were eluted in 3ml Nuclisens 
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lysis buffer containing 40μl Proteinase K (Qiagen) and PDV for 2 hours with gentle 
agitation on a roller-mixer before being extracted as detailed above. 
 
Table 2.1. Primers used for the detection of HCV by real-time PCR 
Primer/Probe 
Name 
Target Primer/Probe Sequence Position 
HCV Fwd 5’-UTR of HCV 5’-GTC TAG CCA TGG CGT TAG 
TA-3’ 
77-96a 
HCV Rev 5’-UTR of HCV 5’-GTA CTC ACC GGT TCC GC-3’ 150-166a 
HCV Probe 5’-UTR of HCV FAM-CCC TCC CGG GAG AGC CAT 
AGT G-TAMRA 
124-145a 
PDV Fwd Haemagglutinin 
of PDV 
5’-CGG GTG CCT TTT ACA AGA 
AC-3’ 
43-62b 
PDV Rev Haemagglutinin 
of PDV 
5’-TTC TTT CCT CAA CCT CGT CC-
3’ 
101-120b 
PDV Probe Haemagglutinin 
of PDV 
JOE-ATG CAA GGG CCA ATT CTT 
CCA AGT T-BHQ1 
64-88b 
a Numbered according to H77 genome (accession number NC_004102) 
b Numbered according to PDV accession number Z36979 
2.5. Real-time PCR assay 
HCV RNA was detected by a real-time PCR assay targeting a conserved 90bp 
sequence of the HCV 5’-UTR region (Daniel et al., 2008). The IC reaction targeted a 
79bp region of the PDV haemagglutinin gene (van Doornum et al., 2007). 
Amplification was performed by the ABI Prism 7500 (Applied Biosystems, Foster 
City, CA, USA) using 20μl of extract in a 50μl final reaction volume containing 25μl 
2X reaction mix, 1μl SuperScript® III/Platinum® Taq mix enzyme, and 200nM of 
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forward and reverse HCV and PDV primers and 100nM probes. Primer and probe 
sequences are listed in Table 2.1. The thermal cycling conditions were 50oC for 15 
min, 95oC for 2 min, followed by 45 cycles of 95oC for 15 s and 60oC for 32 s. 
 
2.6. Genotyping 
2.6.1. Extraction using Qiagen Viral RNA Mini kit 
Plasma samples were extracted following manufacturer’s instructions. DPS 
specimens were extracted following the manufacturer’s instructions, with an 
increased primary incubation step of 30 minutes in buffer AL instead of 10 minutes. 
2.6.2. Amplification of the core region 
A 403bp fragment of the core region of the HCV genome was amplified using 
previously described primers (Mellor et al., 1995). Reverse transcription (RT)-PCR 
was carried out on 15µl of extracted RNA (total reaction volume, 50µl) using the 
one-step RT-PCR kit (Qiagen). Other constituents were 4U of RNasin ribonuclease 
inhibitor (Promega, Madison, WI, USA) and 400nM of each primer (f288 and r751). 
The thermal cycling conditions of the RT-PCR were: reverse transcription at 50oC 
for 30 min, denaturation at 95oC for 15 min, then 35 cycles at 94oC for 30 s, 50oC for 
30 s, 72oC for 1 min, and a final elongation step at 72oC for 10 min. The nested PCR 
was performed on 5µl of PCR product (total reaction volume, 50µl) using 
HotStarTaq DNA polymerase kit (Qiagen), with 400nM of each primer (f321 and 
r724). The following conditions were used: 95oC for 15 min, then 35 cycles of 94oC 
for 30 s, 50oC for 30 s, 72oC for 1 min, and a final stage at 72oC for 10 min. Primer 
sequences are listed in Table 2.2. 
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2.6.3. Amplification of the NS5B region 
A 380bp region of the NS5B gene was amplified using a modified version of a 
previously described method (Sandres-Sauné et al., 2003). 
An RT-PCR was carried out on 10μl of extracted RNA (final reaction volume, 50μl) 
using the one-step RT-PCR kit (Qiagen), 400nM of each primer (Pr3 and Pr4) and 
4U of RNasin ribonuclease inhibitor (Promega). The cycling conditions were: 
reverse transcription at 50oC for 30 min, initial denaturation at 95oC for 15 min 
followed by 5 cycles of 93oC for 30 s, 60oC for 45 s and 72oC for 1 min, then 35 
cycles of 93oC for 30 s, 60oC (0.3oC drop per cycle) for 45 s and 72oC for 1 min with 
a final elongation step of 72oC for 5 min. 
The hemi-nested PCR was carried out on 5µl first round PCR product in a final 
volume of 100µl using the Qiagen HotStarTaq DNA Polymerase kit (Qiagen). 
200nM of Pr3 and Pr5 were used with the following cycling conditions: initial 
denaturation at 95oC for 15 min followed by 35 cycles of 94oC for 30 s, 55oC for 30 





Table 2.2. Primers used for the genotyping of samples 
Primer/Probe 
Name 
Target Orientation Primer/Probe Sequence Position 
Pr3 NS5B Sense 5’-TAT GAY ACC CGC TGY 
TTT GAC TC-3’ 
8256-
8278a 
Pr4 NS5B Sense 5’-GCN GAR TAY CTV GTC 
ATA GCC TC-3’ 
8622-
8644a 




f288 Core Sense 5’-ACT GCC TGA TAG GGT 
GCT TGC GAG-3’ 
288-311a 
r751 Core Antisense 5’-ATG TAC CCC ATG AGG 
TCG GC-3’ 
732-751a 
f321 Core Sense 5’-AGG TCT CGT AGA CCG 
TGC ATC ATG-3’ 
321-344a 
r724 Core Antisense 5’-CAY GTR AGG GTA TCG 
ATG AC-3’ 
705-724a 
a Numbered according to H77 genome (accession number NC_004102) 
 
2.7. NS3 amplification prior to Sanger sequencing 
2.7.1. Extraction using easyMAG automated extractor 
Plasma samples were removed from the -80oC freezer and allowed to thaw at room 
temperature before being vortexed vigorously to ensure homogenisation. 100µl of 
sample was used as input into the EasyMAG® automated extractor (bioMérieux). 
Samples were extracted using the onboard lysis step of 10 minutes and generic 
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protocol v2.0.1 and the nucleic acid eluted into 60µl. The eluate was used in the 
subsequent RT-PCR immediately. 
2.7.2. Amplification of NS3 prior to Sanger sequencing 
cDNA synthesis was performed with the Qiagen OneStep RT-PCR Kit (Qiagen) 
with 400nM of each primer (f3278 and r4032) under the following cycling 
conditions: 50oC for 30 min, 95oC for 15 min, 5 cycles at 93oC for 30s, 60oC for 45s, 
72oC for 1 min, 35 cycles at 93oC for 30s, 60oC for 45s (0.3oC drop each cycle), 
72oC for 1 min, and a final step at 72oC for 5 min. The first round product was 
subjected to nested PCR using the Qiagen HotStarTaq Master Mix Kit (Qiagen) with 
200nM of each primer (f3307 and r4014) under the following cycling conditions: 
95oC for 15 min, 35 cycles at 94oC for 30s, 55oC for 30s, 72oC for 1 min and a final 
stage at 72oC for 10 min. Primers are listed in Table 2.3. 
 
2.8. Agarose gel electrophoresis 
Agarose gels were made at a final concentration of 1% (w/v) using 1.5g of agarose 
(Bioline, London, UK) in 150ml of 1x TBE. SYBRSafe gel stain (Invitrogen) was 
added to the solution, at a ratio of 1μl to 10ml agarose solution. Gels were run in an 
electrophoresis tank containing 0.5x TBE running buffer for 45 minutes at 120V 




Table 2.3. Primers used for the amplification of NS3 and NS5A genes prior to 
sequencing for the detection of resistance associated mutations 
Primer/Probe 
Name 
Target Orientation Primer/Probe Sequence Position 
f3278 NS3 Sense 5’-GGA GAC CAA GMT CAT 
CAC STG G-3’ 
3278-
3299a 




f3307 NS3 Sense 5’-ACA CCG CSG CGT GYG 
GKG ACA T-3’ 
3307-
3328a 












Antisense 5’-GTC CAG GWR TAR GAC 











Antisense 5’-GAC CAR GAC CCG TCR 





















a Numbered according to H77 genome (accession number NC_004102) 
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2.9. Purification using Qiagen QIAquick PCR purification kit 
Prior to cycle sequencing, second round PCR products were purified using the 
QIAquick PCR purification kit (Qiagen), following manufacturer’s instructions. The 
kit uses spin columns and several wash steps and the purified amplicons were eluted 
in 50µl elution buffer. 
 
2.10. Cycle sequencing 
The forward and reverse primers from the nested PCR round alongside gene-specific 
primers were used for sequencing of amplicons (Table 2.4). A mix containing 
BigDye ready reaction mix, nuclease-free water and one primer was prepared. 8µl of 
amplicon was pipette mixed to the cycle sequencing mastermix. Cycle sequencing 
was performed with the following cycling conditions: 25 cycles of 96oC for 10s, 
50oC for 5s and 60oC for 4 min. 
 
2.11. Purification of cycle sequencing products 
Products were purified immediately after the cycle sequencing reaction finished. 
Sodium acetate (2μl per well) and molecular biology grade 100% ethanol (50μl per 
well) were mixed, added to each well and pipette mixed 3-5 times. The plate was 
sealed and centrifuged at 2000xg for 20 minutes at room temperature before the 
supernatant was drained by inverting the plate and centrifuging at 150xg for 1 
minute at room temperature. 150μl of freshly made 70% ethanol was added to the 
wells and the plate centrifuged at 2000xg for 5 minutes before draining the 
supernatant by inverting the plate and centrifuging at 150xg for 2 minutes. An 
incubation time of 30 minutes at room temperature was used to ensure residual 
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ethanol had evaporated. The resulting DNA pellets were resuspended in 10μl of Hi-
Di formamide and analysed on an ABI Prism 3730 Genetic Analyser (Applied 
Biosystems®). 
 
Table 2.4. Cycle sequencing primers prior to Sanger population sequencing 
Primer/Probe 
Name 
Target Orientation Primer/Probe Sequence Position 
f3307 NS3 Sense 5’-ACA CCG CSG CGT GYG 
GKG ACA T-3’ 
3307-
3328a 




















Antisense 5’-GGC GCA CCG GAA TGA-3’ 3757-
3771a 
a Numbered according to H77 genome (accession number NC_004102) 
 
2.12. Sequence analysis 
Sequences were aligned against a reference sequence (accession number: 




2.13. Phylogenetic Analysis 
Sequences were aligned using Clustal W and then checked manually. Phylogenetic 
analyses were performed using the PHYLIP software package v3.69 (Felsenstein, 
1989). Distance matrices were produced by DNADIST (using Kimura-2 parameter 
setting) which were analysed in NEIGHBOR, using neighbor-joining setting. 
Bootstrapping (1000 replicates) was performed by SEQBOOT and CONSENSE. 
Branch lengths on the consensus tree were reconstructed using the original 
sequences and Dnaml, with the consensus tree as the user-defined tree. Bootstrap 
values ≥80% were considered significant. 
The bootstrapping process involves the replacement of n number of nucleotides in 
each sequence, with these new sequences being used to generate a phylogenetic tree 
(Felsenstein, 1985). Each new tree is compared against the original inferred tree and 
a bootstrap value produced which represents the percentage of trees in which the 
examined clade was observed. This bootstrap value is used to assess the confidence 
levels of the clades inferred by a phylogenetic tree, allowing one to make judgements 
about how well supported a phylogenetic relationship is. 
 
2.14. Plasmid control for next generation sequencing 
Two plasmids, each encoding a full length NS3 region in a pCR Topo vector were 
obtained from Andrea Rosi at the University of Siena, Italy. One plasmid was 
classified as a ‘wild-type’ sequence. The other encoded an identical sequence, with 
the exception of 5 single nucleotide polymorphisms at the site of 5 known sites 
associated with drug resistance: V36A, T54S, V55A, R155K and A156S. These 
plasmids served two purposes in the study; i) to determine the levels of error 
incorporated into sequences through a combination of PCR and Illumina MiSeq 
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sequencing errors, and ii) to ensure variants present at a set frequency in the 
population could be observed. 
 
2.15. Extraction using Qiasymphony SP prior to next generation 
sequencing 
Plasma samples were extracted using the Qiasymphony SP automated robot 
(Qiagen). 200μl plasma was added to 450μl 1x PBS and extracted using the DSP 
Virus/Pathogen Midi kit and CellFree_500 protocol v4 into a final elution volume of 
60μl (in AVE buffer). A negative control of 1x PBS was included on each run. 
Extracts were used in the reverse transcription reaction immediately. 
 
2.16. Reverse transcription 
This step was developed in conjunction with Andrea Rosi at University of Siena, 
Italy. 20μl extract of each sample was heated at 70oC for 5 min before being 
immediately placed on ice for a further 5 min to prevent the formation of secondary 
structure in the RNA. The RT reaction mix containing 5X reaction buffer, 10U 
RNasin, MgCl2, dNTPs, 50ng random primers and ImProm-II RT (Promega) was 
added to the extract and pipette mixed 5 times. The following cycling conditions 
were used; 25oC for 10min, 42oC for 60min, 50oC for 30min, 55oC for 30min and a 
final step of 70oC for 15min. 
 
2.17. Amplification of NS3 prior to next generation sequencing 
A partial region (727bp) of the NS3 gene was amplified using nested PCR. First 
round PCR was carried out using 5μl cDNA from the RT in a total volume of 50μl, 
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consisting 10μl reaction buffer, 10μl GC enhancer, 200nM forward and reverse 
primers (f3278 and r4032), 100µM dNTPs, 1U of Q5 polymerase and 21.5μl 
nuclease-free water. Cycling conditions were; initial denaturation at 98oC for 2min, 
followed by 25 cycles of 98oC for 10s, 62oC for 20s, 72oC for 30s and a final 
elongation step of 72oC for 2min. 
Nested PCR was carried out under the same cycling conditions, with an additional 5 
cycles for a total of 30. Primers f3307 and r4014 were used (Table 2.3). 
 
2.18. Amplification of NS5A prior to next generation sequencing 
Near full length NS5A gene (1474bp and 1378bp for Gt1a and Gt1b, respectively) 
was amplified using nested PCR. First round PCR was carried out using 5μl cDNA 
from the RT in a total volume of 50μl, consisting 10μl reaction buffer, 10μl GC 
enhancer, 200nM forward and reverse primers (f6057/f6084 and 
1a_Rev_Out/1b_Rev_Out), 100μM dNTPs, 1U of Q5 polymerase and 21.5μl 
nuclease-free water. Cycling conditions were; initial denaturation at 98oC for 2min, 
followed by 25 cycles of 98oC for 10s, 62oC (61oC for Gt1b) for 30s, 72oC for 1min 
and a final elongation step of 72oC for 2min. 
Nested PCR was carried out under the same conditions, but with an annealing 
temperature of 62oC regardless of subtype and an additional 5 cycles for a total of 
30. The primers f6129 and 1a_Rev_In/1b_Rev_In were used (Table 2.3). The 
primers were adapted from previously published sequences (McCormick et al., 2015, 




2.19. Purification of NS3 and NS5A amplicons using AMPure XP 
PCR products for next generation sequencing were purified using AMPure XP 
magnetic beads, as per manufacturer’s instructions. AMPure XP beads were mixed 
with PCR product at a 1.8x concentration. A 5 minute drying step was incorporated 
after the second ethanol wash, to ensure the evaporation of any residual ethanol. 
Purified products were eluted in 40µl of nuclease-free water. 
 
2.20. Quantification of DNA 
The concentration of DNA was determined using the Quant-iT dsDNA HS assay kit 
(Invitrogen) on a Qubit 2.0 fluorometer, following manufacturer’s instructions.  
 
2.21. Library preparation using Nextera XT 
NS3 and NS5A amplicons from each patient were pooled together in equimolar 
concentrations and diluted to a final concentration of 0.2ng/μl in nuclease-free water. 
These pooled samples were the input into the Nextera XT sample preparation kit 
(Illumina, San Diego, CA, USA). Manufacturer’s instructions were followed 
throughout. Briefly, the protocol involved the ‘tagmentation’ of input DNA to 
produce fragmented regions of the DNA with adapter sequences at each end. The 
tagmented DNA underwent a PCR program of 12 cycles to amplify the DNA with 
dual-indexed primers. AMPure XP beads at a concentration of 0.5x were used to 
purify the products, before the samples were normalised, denatured to single 
stranded DNA and pooled into one library. 
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The pooled amplicon library was sent to the Centre for Genomics Research at the 
University of Liverpool, where sequencing was performed on an Illumina MiSeq 
(Illumina) using v2 reagents. 
 
2.22. Analysis of next generation sequencing data 
Preliminary processing of the sequence files from the Illumina MiSeq runs was 
conducted at the CGR. The raw FASTQ files were trimmed for the presence of 
Illumina adapter sequences using Cutadapt version 1.2.1 with the 3' end of any reads 
which matched the adapter sequence for ≥3bp being trimmed (Martin, 2011). The 
reads were further trimmed using Sickle version 1.200 with a minimum window 
quality score of 20 (Joshi and Fass, 2011). Reads shorter than 10bp after trimming 
were removed. 
The trimmed reads were analysed using the variant detection pipeline VirVarSeq 
(Verbist et al., 2015). The VirVarSeq pipeline utilises several steps to call variants at 
a codon level from reads obtained from Illumina next generation sequencing 
platforms. Briefly, the reads are aligned to a reference genome (H77 for Gt1a and 
HCV-J for Gt1b). Using this alignment, a consensus sequence for the sample is 
determined and the reads are realigned against this to increase the accuracy of 
mapping. Finally, a codon table is constructed, which utilises both the quality of the 
run and quality of individual bases to filter poor quality bases and reduce the number 








Optimisation of techniques for the detection 







Part of the work presented in this chapter has been published in the article: 
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S. F., Chadwick, D., Phillips, R. O. & Geretti, A. M. 2015. Antibody screening tests 
variably overestimate the prevalence of hepatitis C virus infection among HIV-




3. Optimisation of techniques for the detection and genotyping of HCV 
 
Abstract 
Background Testing for HCV RNA is not routinely available in resource-limited 
settings such as sub-Saharan Africa (SSA). Cheaper and novel HCV diagnostic 
approaches are required to improve access to HCV testing in such areas. The aims of 
this chapter were to i) optimise the use of pooled plasma and dried plasma spot 
(DPS) specimens for the detection of HCV RNA ii) Optimise the use of DPS for the 
sequencing of HCV for genotyping purposes. 
Methods The WHO HCV RNA International Standard was used to produce dilution 
series’ of plasma and DPS samples positive for HCV RNA, enabling the 
determination of the sensitivity of the real-time PCR protocol using single and 
pooled specimens. Sequencing protocols targeting the core and NS5B region of 
HCV were tested on extracts from clinical plasma and DPS specimens. 
Results The real-time PCR protocol was found to have a sensitivity of 110 IU/ml 
and 2500 IU/ml for single plasma and DPS specimens, respectively. Sensitivity was 
reduced to 550 IU/ml and 5000 IU/ml when specimens were pooled in groups of 
five. The genotypes and subtypes determined by phylogenetic analyses of the 
sequencing products matched those provided by the clinic and did not differ between 
the two testing matrices. 
Conclusion Pooling plasma and dried plasma spots represents a viable diagnostic 
strategy for resource-limited settings, reducing cost and workload whilst still 






During the initial acute phase of HCV infection, there is a period of approximately 7-
8 weeks before the development of anti-HCV antibodies by the immune system of 
the host (Bowen and Walker, 2005). Prior to seroconversion, infection can be 
diagnosed by assays that directly target the virus, typically nucleic acid amplification 
technology (NAT) for the detection of HCV RNA (Centers for Disease Control and 
Prevention, 2013). In subjects that have already developed anti-HCV antibodies, 
HCV RNA testing is employed to confirm the presence of a current infection 
(Centers for Disease Control and Prevention, 2013). Real-time PCR is the most 
common NAT employed to detect HCV RNA in routine diagnostic settings. In 
addition, quantitative real-time PCR measures the HCV RNA load and plays an 
important role in the clinic by guiding antiviral therapy and measuring its efficacy.  
Commercial real-time PCR assays are available in kit format from several 
manufacturers, although these are often expensive to use. 
 
Estimates of the global distribution of HCV place a large – albeit geographically 
variable – proportion of chronic infections in resource-limited settings in Africa and 
Asia (World Health Organisation, 2015). Testing for HCV RNA is not routinely 
available in sub-Saharan Africa (SSA), reflecting limited infrastructure for molecular 
testing and financial restrictions. Cheaper HCV diagnostic algorithms are required to 
improve HCV ascertainment in these settings. Furthermore, novel diagnostic 
approaches are required to promote access to HCV testing among difficult-to-reach 




Dried blood spots (DBS) and dried plasma spots (DPS) have been used to screen 
populations for a range of infectious diseases, including HIV and HCV (Parker and 
Cubitt, 1999, Waterboer et al., 2012). They offer certain advantages over serum or 
plasma for testing, including nucleic acid stability at room temperature, facilitating 
the shipment of samples to centralised testing facilities (Bennett et al., 2012). 
Pooling samples for testing represents another cost- and labour-saving strategy to 
screen a large number of samples, especially where prevalence of infection is low. 
The pooling strategy has been successfully applied to plasma samples (Smith et al., 
2009). A few studies have employed pooled DBS or DPS for the detection of HIV 
(Lakshmi et al., 2011, Pannus et al., 2013, van Zyl et al., 2011).  
 
The HCV RNA genome is extremely variable (Elena and Sanjuan, 2005). HCV is 
currently divided into seven genotypes, with each of these further categorised into 
subtypes. The HCV genotype guides clinicians to the most appropriate therapy; even 
the subtype influences the efficacy of treatment, as seen in the case of subtypes 1a 
and 1b (European Association for the Study of the Liver, 2015). Sequencing of the 
HCV genome can be used to assign the genotype and subtype, and to identify 
mutations associated with drug resistance. It also provides precious epidemiological 
information, including the identification of transmission networks and novel strains 
(Sandres-Sauné et al., 2003). 
 
Specific regions of the HCV genome are conserved due to their essential role in virus 
infectivity and replication, allowing pan-genotype primers to be designed for the 
purposes of HCV RNA amplification. One of these is the core region, which forms 
the viral nucleocapsid and rearranges the distribution of lipid droplets that are 
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essential for the formation of infectious virions (Boulant et al., 2005, Boulant et al., 
2006). Another conserved region is NS5B, which encodes the RNA-dependent RNA 
polymerase enzyme, responsible for the replication of the HCV genome (Lindenbach 
and Rice, 2005). Although conserved, these two genes also retain sufficient diversity 
to allow the accurate identification of HCV genotypes and subtypes.  
 
The aim of the studies presented in this chapter was to optimise the use of individual 
and pooled plasma and DPS for the detection of HCV RNA by real-time PCR, 
whereby pooling was explored as a strategy to reduce labour and costs, while still 
maintaining accuracy. A further aim was to optimise the recovery of HCV RNA 






3.2. Methods and Results 
3.2.1. Optimisation of the real-time PCR assay with plasma 
The first step was the comparison of two extraction protocols using the NucliSens 
easyMAG automated extractor (bioMérieux, Boxtel, Netherlands). For this purpose, 
20 replicates of the 4th World Health Organisation (WHO) International Standard for 
HCV RNA (06/102, NIBSC, Potters Bar, UK; HCV genotype 1a) in basematrix 
(SeraCare, Milford, MA, USA) were tested, each at a concentration of 100 IU/ml. 
Each 1ml replicate was mixed with 2ml Nuclisens lysis buffer (bioMérieux) 
containing 40µl Proteinase K (Qiagen, Hilden, Germany) and Phocine Distemper 
Virus (PDV) as an internal control (IC) prior to incubation. The first protocol utilised 
a single incubation at 56oC for 30 minutes. The second protocol employed a second 
incubation at 100oC for 30 minutes immediately following the first. The easyMAG 
Specific B 2.0.1 setting was used, with the elution volume set at 60µl. The real-time 
PCR conditions were those described in Chapter 2.5. The extraction protocol 
employing a single incubation step yielded a HCV RNA detection rate of 10/20 
(50%). The addition of a second incubation step improved the HCV RNA detection 
rate to 19/20 (95%). The second protocol was therefore adopted for further 
experiments. 
 
The second step was the evaluation of the sensitivity of the real-time PCR assay. For 
this purpose, 40 replicates of the WHO HCV RNA Standard in basematrix 
(SeraCare) were tested at concentrations of 10 IU/ml, 50 IU/ml, 100 IU/ml, and 110 
IU/ml. The HCV RNA detection rate (1 ml input) ranged from 12/40 (30%) at 10 




Figure 3.1. HCV RNA detection rate using serial dilutions of the WHO 
International Standard in basematrix. Each dilution underwent nucleic acid 
extraction (1ml input, two incubation steps), followed by real-time PCR. 
Numbers represent the percentage of positive tests in each series of 40 
replicates. 
 
3.2.2. Optimisation of HCV RNA detection in DPS 
Dried plasma spots (DPS) were prepared by spotting 50μl of plasma onto each of 
five 12mm discs on a Protein saver 903 card (Whatman, Maidstone, UK). DPS were 
dried at room temperature for a minimum and maximum of 12 hours and 18 hours, 
respectively, before being placed into individual sealable plastic bags with silica 
desiccant sachets. DPS were then stored at -80oC until needed. Upon being taken out 
of the freezer, DPS were left at room temperature for 30 minutes before being 






























A dilution series of DPS was prepared in duplicate with WHO HCV RNA Standard 
at concentrations ranging from 100,000 IU/ml to 100 IU/ml. Prior to testing, the DPS 
underwent elution in an appropriate medium to allow the release of HCV RNA from 
the paper. Two different elution protocols were assessed for the recovery of HCV 
RNA from DPS, adapting approaches used in previous studies (Ayele et al., 2007, 
Andreotti et al., 2010, Tuaillon et al., 2010, Bennett et al., 2012, Ross et al., 2013, 
Shepherd et al., 2013). In the first protocol, two 6mm DPS punches per sample were 
eluted in 1ml 1xPBS with 0.5% Tween for 2 hours at room temperature with gentle 
agitation on a roller-mixer. In the second protocol, two 6mm DPS punches per 
sample were eluted in 3ml Nuclisens lysis buffer (bioMérieux) for 2 hours at room 
temperature with gentle agitation on a roller mixer. Both elution media contained 
40µl Proteinase K (Qiagen) and PDV as IC. The eluted samples were then tested for 
HCV RNA by the real-time PCR assay. After elution in PBS/Tween, no HCV RNA 
was detected at any of the concentrations tested, including the highest viral load of 
100,000 IU/ml. In contrast, elution in Nuclisens lysis buffer resulted in HCV RNA 
detection at viral loads down to 1000 IU/ml. The lysis buffer protocol was therefore 
adopted for further experiments. 
 
Assay sensitivity was verified by testing DPS prepared with the WHO HCV RNA 
Standard in basematrix (Seracare) at concentrations ranging from 500 to 2500 IU/ml. 
DPS were prepared with 50μl of the appropriate dilution and two 6mm punches per 
specimen were eluted and extracted according to the method optimised above. Thirty 
replicates of each dilution were tested. The HCV RNA detection rates were 30/30 
(100%) at 2500 IU/ml, 29/30 (97%) at 2000 IU/ml, 21/30 (70%) at 1000 IU/ml, and 




Figure 3.2. HCV RNA detection rate in individual dried plasma spots prepared 
with standard in serial dilutions. Input was 50µl per disc and two 6mm punches 
from each disc were tested. Numbers represent the percentage of positive tests 
in each series of 30 replicates. 
 
Inter-assay and intra-assay variation was calculated using DPS prepared with 10,000 
IU/ml of the WHO HCV RNA Standard in basematrix (Seracare) and tested in five 
replicates in three independent experiments. The CT values showed an intra-assay 
coefficient of variation (CoV) ranging from 0.8% to 1.4% across the three 
experiments (Table 3.1), whilst the mean inter-assay CoV from three experiments 





























Table 3.1. Intra-assay variation of the real-time PCR protocol when using DPS. 











 1 2 3 4 5    
1 37.5 37.7 37.9 37.7 38.4 37.9 0.34 0.9 
2 39.3 38.6 38.2 38.0 39.0 38.6 0.54 1.4 
3 37.9 37.6 38.0 38.4 38.1 38.0 0.29 0.8 
 
Table 3.2. Inter-assay variation of the real-time PCR protocol when using DPS. 









1 2 3    
37.9 38.6 38.0 38.2 0.38 1.0 
 
3.2.3. Optimisation of pooling strategy 
Based upon the earlier finding of a lower limit of detection of 110 IU/ml with a 
single plasma specimen, it was assumed that a lower limit of detection of 550 IU/ml 
would be obtained by pooling five plasma specimens of 200µl each, which was 
considered acceptable for screening an untreated HCV positive population. In order 
to test this assumption, mock plasma pools were prepared and tested in triplicate, 
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each comprising one HCV RNA positive specimen and four negative specimens. 
HCV negative plasma was spiked with the WHO HCV RNA Standard at 
concentrations of 500 IU/ml, 550 IU/ml, 1000 IU/ml, 5000 IU/ml and 10000 IU/ml, 
and each spiked sample was combined with equal volumes of four negative plasma 
specimens to make up mock pools of 1 ml each. In triplicate testing, HCV RNA was 
detected in all pools containing a positive sample with HCV RNA concentration 
≥550 IU/ml, and in 2 of 3 pools containing the 500 IU/ml sample (Table 3.3). 
 
Table 3.3. Sensitivity of the real-time PCR assay for the detection of HCV RNA 
in pools of five specimens. NT=not tested 
Viral load of positive 
sample in pool (IU/ml) 
Detection rate in plasma 
pools (%) 
Detection rate in DPS pools 
(%) 
500 2/3 (67) NT 
550 3/3 (100) NT 
1000 3/3 (100) NT 
5000 3/3 (100) 3/3 (100) 
10000 3/3 (100) 3/3 (100) 
 
To determine the number of DPS samples that could be pooled together without a 
detrimental effect on assay sensitivity, mock DPS pools comprising one positive 
specimen and a further one to four negative specimens were prepared. The positive 
DPS specimen was prepared using HCV RNA negative plasma spiked with the 
WHO HCV RNA Standard at a concentration of 10,000 IU/ml. Two 6mm punches 
from each specimen were used per pool. Each of the pools was detected as HCV 
RNA positive, with little variation in the CT values between the pool containing two 
specimens and the pool containing five specimens. Five DPS specimens were 
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deemed to be a suitable number of samples to pool together to reduce the cost whilst 
still maintaining an appropriate level of sensitivity. 
 
To verify the assay sensitivity of pooled DPS specimens, mock pools comprising 
five samples were tested in triplicate. Pools consisted of one WHO International 
Standard at 5000 IU/ml or 10000 IU/ml and four negative specimens and were eluted 
and extracted according to the method optimised above. The pool containing one 
positive DPS prepared with 5000 IU/ml international standard and four negative 
specimens was HCV RNA positive in all three replicates (Table 3.3), providing a 
suitable sensitivity for screening a treatment-naïve population. 
3.2.4. Genotyping by sequencing optimisation 
Clinical plasma samples positive for HCV RNA genotypes 1a, 2b, 3a, and 4d were 
obtained from the Royal Liverpool Hospital, UK. DPS samples were prepared with 
50µl of plasma as described above. Two methods were tested for the extraction of 
plasma and DPS specimens prior to amplification for NS5B genotyping. One method 
was to use the two-step extraction protocol described above for the real-time PCR 
assay. The other extraction method used the Qiagen Viral RNA Mini kit (Qiagen), 
following manufacturer’s instructions. For DPS extraction with the Qiagen Viral 
RNA Mini kit, the initial incubation step with AL lysis buffer was increased to 30 
minutes. For DPS, two 6mm punches were extracted for each specimen. 
Interestingly, the NS5B region was not amplified from either plasma or DPS when 
following the extraction protocol used for the real-time PCR assay. The extracts 
from the Qiagen kit were successfully amplified for both plasma and DPS 
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Figure 3.3. Phylogenetic tree displaying the relationship between the NS5B 
sequences of test samples (highlighted red) and genotype reference sequences. 
The number shown alongside clusters represents the genotype. Bootstrap values 
≥80% are shown. 
 
The protocols for the amplification and Sanger sequencing of core and NS5B were 
those described in Chapter 2. Sequences obtained from plasma samples were aligned 
against reference sequences from the Los Alamos Database and phylogenetically 
analysed (pipeline in Chapter 2.13). 
The genotypes/subtypes determined through the NS5B (Figure 3.3) and core 
sequencing from plasma samples were the same. 
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HCV NS5B sequences obtained from DPS were compared to those recovered from 
plasma samples. The assigned genotypes and subtypes with plasma and DPS were 
identical to each other and to those provided by the reference diagnostic laboratory.  
When comparing plasma and DPS, upon alignment, the sequences showed identities 
of 99.7% to 100%. The differences observed were always mixed bases versus a 
single base e.g. C/T versus T, although these differences were rare occurring a 




The data presented in this chapter relate to the optimisation of a labour- and cost-
effective methodology for large volume HCV screening. We first focused on the 
optimisation of the in-house real-time PCR assay for HCV RNA detection. Using 
plasma, we found that the efficiency of the extraction process was markedly 
increased when a second incubation step of 100oC was added to the protocol. This 
may be due to the fact that a higher temperature relaxes the secondary structure of 
the HCV RNA target region, thereby increasing the binding capabilities of primers in 
the subsequent PCR reaction. A similar effect was previously seen when testing 
plasma for HBV DNA. Prior to easyMAG extraction, an incubation of 80oC for 10 
minutes improved detection rate compared to a 37oC incubation period for 30 
minutes (Gobbers et al., 2001). 
 
We then evaluated the performance of the real-time PCR assay with DPS. When 
using DPS or DBS, the nucleic acid must be eluted from the filter paper prior to 
extraction. Although elution in PBS and Tween has been previously used to elute 
HCV RNA from DBS, this approach resulted in no amplification from any of the 
samples tested despite a relatively high HCV RNA load. This was in contrast with 
the excellent yield of elution in the Nuclisens lysis buffer. It should be noted that 
previous studies (Ross et al., 2013, Shepherd et al., 2013) incubated DBS in PBS 
overnight before the extraction process, differing from the 2 hours tested in this 
study. This shortened incubation time may be the key determining factor in the lack 
of detection. However, we were interested in a reduced incubation time to facilitate 
use in resource-limited settings where power interruptions during the agitation step 
may be an issue. At the shortened incubation time, the PBS may not be a strong 
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enough agent to elute sufficient viral nucleic acid material from the filter paper. The 
previous studies used PBS as an eluting agent for DBS rather than the DPS used in 
this study. One possibility is also that the difference in composition between blood 
and plasma drives the difference in efficacies between the eluting agents. 
 
Real-time detection of HIV-1 RNA from DPS has been documented (Cassol et al., 
1997, Brambilla et al., 2003, Ayele et al., 2007, Rottinghaus et al., 2012). In contrast, 
there is a paucity of data available on HCV RNA testing using DPS. Whilst some 
studies have observed strong correlations between HIV viral load measurements in 
plasma and DPS (Cassol et al., 1997, Brambilla et al., 2003, Ayele et al., 2007), 
there is also evidence that suggests DPS show greater variability and underestimate 
the viral load of samples, showing a significantly lower mean HIV viral load than 
plasma samples (Rottinghaus et al., 2012). Many studies on DBS for the detection of 
HCV only used the technique for a qualitative assessment (Solmone et al., 2002, De 
Crignis et al., 2010, Bennett et al., 2012, Santos et al., 2012), as we have done in this 
study. This does not affect the assay’s performance at diagnosing an active infection. 
 
The lower limit of detection with single plasma samples was found to be 110 IU/ml 
while individual DPS specimens showed a lower limit of detection of 2500 IU/ml 
with an input of two 6mm punches. This lower sensitivity is in concordance with 
previous studies employing DBS for the detection of HCV RNA, which observed 
limits of detection of 250 IU/ml to 4830-24160 IU/ml (Bennett et al., 2012, 
Rottinghaus et al., 2012). The difference in sensitivity between plasma and DPS is 
easily explained by the much lower input into the reaction when using DPS. A DPS 
sample with a viral load of 100,000 IU/ml would contain only 5000 IU, as the input 
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into each of the DPS circles is 50µl. In addition to this, only two 6mm punches are 
used in the extraction. Assuming an even distribution of viral particles over the area 
of the dried spot, each 6mm punch would hold approximately 1250 IU, yielding a 
total input of around 2500 IU in each reaction. This lower sensitivity is in 
concordance with previous studies observing DBS, with researchers concluding the 
limited sample size obtained from DBS and less efficient nucleic acid extraction 
were the contributing factors (Bennett et al., 2012, Santos et al., 2012). An increase 
in the number of DPS input into the reaction may counteract this effect. However, it 
would also increase the number of DPS to be collected, negating the benefit that only 
a small sample volume is required for DPS. 
 
A high sensitivity of detection was maintained when five samples were pooled 
together for extraction and testing. There was a dilution effect when pooling plasma 
samples, due to a five-fold reduction in input per sample. However, DPS pools did 
not experience such a phenomenon. An explanation for this is that under the set 
conditions, the lysis buffer effectively eluted available nucleic acid from the DPS 
without saturation effects leading to a loss of sensitivity. 
 
The topic of HCV RNA stability in DBS and DPS at room temperature has been 
studied relatively little, given the importance that this plays in the role of this testing 
matrix. It should be noted that the term room temperature is non-specific and would 
vary widely from country to country. The studies which have explored this have 
found conflicting results although the lack of information regarding environmental 
conditions such as humidity and specific temperatures between the studies make it 
more difficult to draw firm conclusions. Two studies found a decrease in RNA; one 
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observed a ten-fold decrease after a period of 4 weeks (Abe and Konomi, 1998) and 
another determined a three-fold decrease after 6 days (Tuaillon et al., 2010). These 
reductions in HCV RNA would have to be taken into consideration when planning 
the testing procedure.  While it is important to ensure optimal sample preservation, 
for diagnostic purposes, any degradation may not be as detrimental in an untreated 
patient cohort given the likely high viral loads. Two further studies found no 
significant decrease in RNA levels of DBS stored at room temperature and tested 
intermittently over one year and 11 months, respectively (Solmone et al., 2002, 
Bennett et al., 2012). The DPS used in this study were stored at -80oC until required 
so the stability of the RNA should not be an issue, giving accurate results during the 
optimisation. In resource-limited settings, immediate transportation of specimens 
may not be possible. Alongside this, room temperature in SSA is likely to be 
significantly higher than the European countries in which the above studies took 
place. Consequently, in order to ensure the preservation of samples, short-term cold 
storage of samples at -20oC may be required until shipment to a centralised facility 
could be arranged. However, the effect of freeze-thaw on DPS samples should first 
be investigated further. 
 
This real-time PCR assay was developed to screen a population of HIV-infected 
individuals from Ghana. A previous study from blood donors in Ghana identified a 
median viral load of 2.5 x 105 IU/ml (range 3.3 × 103 to 9.0 × 106 IU/ml) (n=20) 
(Candotti et al., 2003). Another study states that the majority of untreated patients 
have viral loads above 1000 IU/ml (Tuaillon et al., 2010). Both of these figures 
suggest that plasma and DPS, either single specimens or pools, are suitable testing 




A previous study (Lakshmi et al., 2011) extracted DBS separately before pooling the 
extracts for the real-time PCR assay whereas our study both extracted and amplified 
pools of DPS. This strategy reduces the extraction costs, an important consideration 
for resource-limited areas. The use of pooled samples in diagnostic testing for HCV, 
as used in this study, has the potential to reduce costs by up to five-fold. A previous 
study demonstrated that $345,000 per year could be saved through the use of pooled 
DBS samples in HIV viral load testing in Malawi (Pannus et al., 2013). The exact 
saving from the tests used here would be dependent on the prevalence of HCV in the 
population undergoing screening. A cohort with a high percentage of HCV RNA 
positive samples would not reduce costs if real-time PCR was used as the initial test. 
Appropriate use of serological screening may first reduce the number of samples to 
be tested by pooled real-time PCR by eliminating antibody-negative samples. 
 
Although real-time PCR represents a sensitive and specific test for the diagnosis of 
active HCV infection, the specialised equipment required does present an obstacle in 
resource limited settings. Loop-mediated isothermal amplification (LAMP) is a 
recent development, which overcomes this obstacle (Notomi et al., 2000). It employs 
a constant temperature and a positive result can be identified by either a change in 
turbidity or a fluorescence visible to the naked eye (reviewed in Mori and Notomi, 
2009), negating the requirement for specialised equipment. These features make it a 
suitable candidate for routine clinical diagnostics in resource limited settings. 
Previous studies have explored the use of this technique for the detection of HCV 
(Wang et al., 2011, Yang et al., 2011, Kargar et al., 2012). LAMP uses multiple 
primers with amplification only occurring upon the binding of all primers to the 
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target regions, making it highly specific (Notomi et al., 2000). However, this may 
present a problem in sub-Saharan Africa where there is a large degree of variation in 
HCV subtypes (Jeannel et al., 1998, Candotti et al., 2003, Markov et al., 2009). 
Variation in one of the target regions would restrict amplification and thereby give a 
false negative result. 
 
The methods employed for detection of HCV each have their own advantages and 
disadvantages. Immunoassays targeting anti-HCV antibodies are relatively cheap 
and require little infrastructure, making them a suitable diagnostic tool for sub-
Saharan Africa. However, they rely on the presence of anti-HCV antibodies, which 
do not appear until approximately 7-8 weeks after infection (Bowen and Walker, 
2005). In some African cohorts, their specificity has also been questioned with high 
rates of false positive results (Chasela et al., 2012, Mullis et al., 2013). Such tests 
also cannot distinguish between an active and resolved infection, meaning that 
further diagnostic procedures are required following a positive antibody test in order 
to confirm infection. Rapid screening assays also target anti-HCV antibodies but can 
use a much smaller sample size i.e. finger stick blood specimens making them a 
suitable candidate for hard-to-reach populations. Similar sensitivities and 
specificities between rapid tests and immunoassays have been observed although 
HIV-positive patients were more likely to have a false result when tested with a rapid 
test (Smith et al., 2011). 
Nucleic acid amplification techniques remain the most reliable procedure for the 
diagnosis of an active HCV infection. As their target is the nucleic acid of the virus, 
they can provide a diagnosis from a very early time during infection, before 
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antibodies have appeared (Centers for Disease Control and Prevention, 2013). 
However, these tests are often expensive and require specialised equipment. 
Non-specific tests such as the measurement ALT levels provide an indication of liver 
damage although this is not necessarily due to HCV or even infection with a virus. 
However, as these tests are relatively cheap, the identification of patients with an 
elevated ALT may aid in reducing the number of patients targeted for HCV 
screening with further tests. A previous study examining patients with a single 
elevated ALT result observed an anti-HCV prevalence of 8.4% (Smith and Yartel, 
2014). However, an estimated 30%-50% of patients infected with HCV demonstrate 
persistently normal ALT levels (Alberti et al., 2002, Puoti, 2003), meaning they 
would not be identified for screening. 
Unfortunately, there does not seem to be a definitive method of diagnosis which 
meets all of the requirements for a resource-limited setting such as SSA, especially 
given the genetic variation observed in this region. However, the combination of 
more than one method alongside the careful interpretation of results may provide the 
most reliable results. 
 
NS5B sequences of 329bp in length provide sufficient distance between samples 
when phylogenetically analysed to allow the interpretation of 99.8% of strains 
(Sandres-Sauné et al., 2003). Consequently, the NS5B sequencing protocol used 
here, which produces an amplicon with a maximum length of 380bp is more than 
sufficient for subsequent phylogenetic analysis to determine genotype and subtype. 
The use of a sequencing protocol provides researchers with an electropherogram 
which can be manually inspected, if a mixed infection is suspected. Previous studies 
have successfully sequenced HIV-1 RNA recovered from DPS for the purposes of 
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genotyping and monitoring drug resistance (Dachraoui et al., 2008). Genotyping 
HCV from DBS using sequencing has been established (Solmone et al., 2002, 
Tuaillon et al., 2010) but, thus far, DPS have not been used for this purpose. 
Previous studies have demonstrated the ability to obtain a sufficient quantity of HCV 
RNA from DBS for amplification and sequencing and a strong concordance between 
the HCV genotypes obtained from the sequencing of plasma and DBS samples has 
been shown (Solmone et al., 2002, Tuaillon et al., 2010). This study has 
demonstrated that HCV RNA of sufficient quality can be recovered from DPS for 
sequencing. Thus, the method has the potential for use in determining the molecular 
epidemiology of HCV infections. 
 
Many of the commercial assays employ either fluorescent oligonucleotide probes to 
bind to specific region of the genome or reverse hybridisation technology. These 
tests are able to differentiate between genotypes but are often not able to distinguish 
a subtype level. Previous studies comparing genotyping by sequencing to 
commercial assays have found good concordance between the two methods with 
regards to the determination of genotypes. However, at the subtype level of HCV, 
discordance levels were as high as 47.9% (Nakatani et al., 2011). Another study 
found that HCV subtypes were only assigned to 47.2% of samples when using a 
commercial line probe assay compared to 95.8% when sequencing was used (Avo et 
al., 2013). Misclassification or non-assignment of subtype by commercial assay 
represents a problem in resource-limited settings such as SSA where previous work 
has shown a wide genome diversity among isolates (Ruggieri et al., 1996, Candotti 
et al., 2003, Ndjomou et al., 2003, Markov et al., 2009), displaying possible new 
subtypes. In such cases, commercial assays would fail to determine the subtypes of 
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the isolates, making the epidemiological study and identification of possible 
transmission networks impossible. Mixed infections may prove more difficult to 
genotype successfully as the more dominant of the two strains present will account 
for a higher proportion of the sequenced amplicons (Sandres-Sauné et al., 2003). 
However, commercial genotyping assays also encounter similar problems in mixed 
infections (Sandres-Sauné et al., 2003). The cost of commercial assays versus in-
house sequencing also affects the uptake in resource-limited areas. The sequencing 
of PCR products has been shown to be three times cheaper than some commercial 
genotyping assays and also has the benefit of providing a large amount of 
information to the researcher (Lam et al., 2010). 
 
In conclusion, this work identified and optimised two techniques which are 
important tools in the monitoring of HCV infection at both an individual and 
population level. The transfer of these techniques for use on DPS specimens 
represents an important step in reducing costs while still maintaining a high degree 
of sensitivity, allowing resource-limited settings to adopt the strategies in an effort to 
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4. Prevalence and molecular epidemiology of HCV infection in a 
Ghanaian HIV-positive cohort 
Abstract 
Background HIV co-infection with HCV has been poorly studied in Ghana and the 
reliability of current HCV seroprevalence estimates remains uncertain. The study 
aim was to determine HCV RNA prevalence in HIV-infected subjects receiving care 
in Kumasi, and assess the diversity of the circulating strains. 
Methods From a population of 1520 HIV-infected adults undergoing hepatitis B 
surface antigen (HBsAg) testing, all HBsAg positive subjects (n=236) and a random 
subset of HBsAg negative subject (n=172) were screened for HCV RNA using 
pooled plasma. A further 875 HBsAg negative patients were tested for HCV RNA 
using pooled dried plasma spots. HCV RNA positive samples were genotyped by 
core and NS5B sequencing. 
Results HCV RNA prevalence was 0.70% (95% confidence interval 0.24-1.16%) 
and 1.27% vs. 0.57% in HBsAg positive vs. HBsAg-negative subjects, respectively. 
Of the HCV positive subjects available for questionnaire, surgical procedures and 
blood transfusion were reported as risk factors for HCV infection. Circulating HCV 
strains were predominantly genotype 2 (subtypes 2c/r/j, 2l, 2q/l, unassigned) and a 
small minority of genotype 1 (subtype unassigned). 
Conclusions The prevalence of HCV RNA was substantially lower than previous 
estimates using serological assays. A subset of co-infected subjects carried a HCV 





HCV infection is a common co-infection in Western HIV-positive cohorts, reflecting 
shared transmission routes, predominantly injecting drug use (Kim et al., 2013). Sub-
Saharan African (SSA) countries are thought to account for 32 million of the 
estimated 150 million cases of chronic HCV worldwide (Karoney and Siika, 2013, 
World Health Organisation, 2015).  However, there have been few studies on HCV 
infection in SSA and the figures from previous studies vary depending on the testing 
methods used. As access to HCV RNA testing is limited in SSA, the majority of 
HCV prevalence studies have typically relied solely on antibody screening tests with 
few surveys employing the use of supplementary antibody testing or HCV RNA 
testing (Madhava et al., 2002, Agwale et al., 2004, Laurent et al., 2010, Mohd 
Hanafiah et al., 2013). A systematic review of 35 studies indicated a mean HCV 
seroprevalence of 7% among 9029 HIV-infected adults in SSA (Barth et al., 2010). 
However, there has been a wide variety in the results, with estimates ranging from 
1.6% to 6% in the general population (Karoney and Siika, 2013) and up to 22% 
among HIV-positive patients (Barth et al., 2010). This disparity between studies is 
likely to reflect, at least in part, the variable performance of serological assays in the 
African context (Seremba et al., 2010, Mullis et al., 2013). 
 
Ghana is a SSA country in West Africa with an estimated 250000 individuals 
infected with HIV in 2014, comprising a majority of HIV-1 and a subset of HIV-2 
infections (UNAIDS, 2014b). Recent WHO guidelines recommend HCV serology 
testing for high-risk groups, which includes HIV-infected patients (World Health 
Organisation, 2014). Despite this, testing for HCV infection is not commonly 
undertaken in Ghana. A study published in the late 90s reported that 8% of 182 HIV-
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positive subjects tested positive for HCV antibody (Brandful et al., 1999). More 
recently, HCV seroprevalence was nearly 4% among 138 HIV-positive adults that in 
2007 were receiving care in the capital city of Accra (Sagoe et al., 2012). If proven 
to be accurate, the high estimates presented in these studies would indicate that 
without appropriate intervention and management strategies, a high burden of HCV 
co-infection threatens the long-term success of HAART programmes in the region. 
Large surveys are urgently required to determine the true burden of chronic HCV 
infection in Ghana and the rest of sub-Saharan Africa, and the associated risk factors. 
 
The use of dried blood spots (DBS) for sample collection offers a modality for 
epidemiological surveys with the advantage of nucleic acid stability at room 
temperature (Solmone et al., 2002, Tuaillon et al., 2010, Bennett et al., 2012) and 
reduced biohazard risk, facilitating storage and transport to centralised molecular 
testing facilities. Whereas whole blood collection for DBS preparation is highly 
suitable for epidemiological surveys, there are circumstances where there may be 
access to plasma and dried plasma spots (DPS) may be used instead. These include 
circumstances when EDTA blood is processed locally for other tests such as HIV-1 
RNA load monitoring during antiretroviral therapy, or when local plasma 
repositories exist that would require expensive shipment on dry ice to preserve 
sample viability during transport to molecular testing facilities. 
 
One added advantage of DBS and DPS usage is that it also allows recovery of 
sufficient nucleic acid for sequencing and phylogenetics. The distribution of HCV 
genotypes and subtypes varies worldwide, with clear differences between regions. 
Western Europe and the USA have high proportions of genotypes 1 and 3 whereas in 
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Africa, genotypes 1, 2 and 4 are more commonplace (Simmonds et al., 2005). 
Previous investigations in Ghana and West Africa identified a dominance of 
genotype 2 HCV strains (Jeannel et al., 1998, Candotti et al., 2003, Markov et al., 
2009), in comparison to a high proportion of genotype 4 in Central Africa (Ndjomou 
et al., 2003). Molecular characterisation of HCV enables the identification of 
possible transmission networks, thus aiding management and prevention strategies. 
 
In order to obtain more definitive evidence on the rates of HIV/HCV co-infection in 
Ghana, the work outlined in this chapter investigated HCV RNA prevalence in a 
large HIV-positive cohort receiving care in Kumasi, the second largest city of Ghana 
using the techniques optimised in the previous chapter. Molecular analysis was used 




4.2. Materials and Methods 
4.2.1. Study population 
From a total of 1520 HIV-infected adults that attended the outpatient service of the 
Komfo Anokye Teaching Hospital in Kumasi between 2010 and 2012, all HBsAg 
positive subjects (n=236) and a random subset of HBsAg negative subjects (n=172) 
had plasma stored locally at -80oC before transport on dry ice to the United Kingdom 
for HCV testing. A further 875 DPS were prepared locally from HIV-
positive/HBsAg-negative patients using plasma collected for HIV-1 RNA testing and 
stored at -80oC until use. DPS were prepared according to the protocol detailed 
earlier (Chapter 2.3) and shipped to the UK at room temperature, before storage at -
80oC. Retrospectively, subjects with confirmed HCV infection were invited to 
complete a structured questionnaire about risk factors for acquiring HCV. The study 
conformed to the standards of the Helsinki Declaration and was approved by the 
Committee on Human Research Publications and Ethics at the Kwame Nkrumah 
University of Science and Technology of Kumasi, Ghana (reference 
CHRPE/143/10). Written consent was obtained from participants. 
4.2.2. HCV RNA detection 
Plasma samples were initially screened for HCV RNA by pooling five samples 
(200µl each) into a single 1 ml specimen, followed by individual screening of the 
samples from RNA positive pools. Basematrix (SeraCare, Milford, MA, USA) was 
added to pools containing fewer than five specimens to maintain a total volume of 
1ml. DPS specimens were initially screened for HCV RNA in pools of five 
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specimens prepared by combining two 6mm punches of each specimen. DPS from 
positive pools were then screened individually using two 6mm punches. 
Nucleic acid elution, extraction and real-time PCR were performed as detailed in 
Chapter 2. 
4.2.3. Sequencing of HCV core and NS5B regions 
Nucleic acid extraction, amplification and sequencing were performed as described 
in Chapter 2. The primers for each region targeted conserved regions of the genome, 
allowing multiple genotypes to be amplified. Sequence electropherograms were 
manually inspected for quality, before undergoing phylogenetic analysis and being 
submitted to GenBank. The GenBank accession numbers of nucleotide sequences 
analysed in the study are KJ642622 to KJ642630 (core region) and KJ642631 to 
KJ642638 (NS5B region). 
4.2.4. Phylogenetic and statistical analysis 
HCV RNA prevalence in HBsAg positive vs. negative patients was compared by 
Fisher’s exact test. Statistical analysis was performed using SPSS version 21 (IBM 
Corporation, Armonk, NY, USA). Sequences were aligned against reference 
sequences (genotypes 1-7) from the Los Alamos database for the purposes of 
genotyping. For subtyping, sequences were aligned against reference sequences from 
the appropriate genotype from throughout the world. The pipeline for phylogenetic 
analyses is described in Chapter 2.13. Assessment of sequence identity by pairwise 
alignment was performed using the EMBOSS Needle Nucleotide Alignment tool 
(http://www.ebi.ac.uk/Tools/psa/emboss_needle/nucleotide.html). The sequences 




4.3.1. Prevalence of HCV RNA in the plasma samples 
From 1520 HIV-infected adults undergoing HBsAg testing, 236 consecutive HBsAg 
positive subjects and 172 HBsAg negative subjects were tested for HCV RNA using 
plasma samples. Overall, 270/408 (66.2%) subjects were females and the median 
(interquartile range, IQR) age was 40 (35-47) years. 
HCV RNA was detected in 4/82 plasma pools, with each pool comprising five 
samples. Testing of the individual samples of positive pools detected one positive 
sample in each pool, yielding a HCV RNA prevalence of 0.98% (95% confidence 
interval, CI, 0.02-1.94%). 
4.3.2. Prevalence of HCV RNA in DPS samples 
Of the 1047 HBsAg negative subjects, 875 were tested for HCV RNA using DPS. 
HCV RNA was detected in 5/175 DPS pools, with each pool comprising five 
samples. Testing of the individual samples from the positive pools detected one 
HCV RNA positive sample in each pool, yielding a prevalence of 0.57% (95% CI, 
0.07-1.07%). 
The overall prevalence of HCV RNA in the entire cohort studied was 0.70% (95% 
CI, 0.24-1.16%). Overall, HCV RNA prevalence was 3/236 (1.27%; 0.0-2.7%) and 
6/1047 (0.57%; 0.11-1.03%) in HBsAg-positive vs. HBsAg-negative patients, 
respectively (p=0.22). The difference in prevalence between plasma samples and 





4.3.3. Molecular characterisation of HCV 
The nine HCV RNA positive samples – four from plasma and five from DPS – 
underwent population sequencing of the HCV core and NS5B genes to determine the 
HCV genotypes present. Sequences from both genes were obtained from all four 
plasma samples and four of the five DPS specimens. However, one DPS sample did 




Figure 4.1. Phylogenetic relationship between HCV core sequences. Ghanaian 
sequences (in red) were aligned to reference sequences from the Los Alamos 
database. The seven major HCV genotypes (1-7) are indicated along the 




Eight of the Ghanaian strains (89%) clustered with genotype (Gt) 2 reference 
sequences with a bootstrap value of 83.2% over 1,000 replicates for the core region 
(Figure 4.1). The remaining one strain (11%) clustered with Gt1 reference sequences 
with a bootstrap value of 81.1% over 1,000 replicates for the core gene. The results 
were concordant in NS5B sequences (Figure 4.2), with bootstrap values of 80.8% 
and 99.5% for Gt1 and Gt2 strains, respectively. 
 
 
Figure 4.2. Phylogenetic relationship between HCV NS5B sequences. Ghanaian 
sequences (in red) were aligned to reference sequences from the Los Alamos 
database. The seven major HCV genotypes (1-7) are indicated along the 








Figure 4.3. Phylogenetic relationship between HCV genotype 1 core sequences. 
The genotype 1 Kumasi sample (in red) was aligned against genotype 1 
sequences from throughout the world obtained from the Los Alamos database. 
HCV genotype 1 subtypes are indicated along the branches. Nodes/clusters 
without a subtype label have an unassigned subtype. Bootstrap values ≥80% are 
indicated by an asterisk. 
 
The Ghanaian Gt1 strain was distinct from Gt1 sequences from elsewhere in the 
world and did not cluster with any previously defined subtype with either the core 
(42.7% bootstrap value) (Figure 4.3) or NS5B sequence (38.3% bootstrap value) 
(Figure 4.4). There were two related African Gt1 sequences in the Los Alamos 
database, one from Nigeria (core; accession number U31232) and one from 
Equatorial Guinea (NS5B; accession number AJ851228), with sequence homologies 
of 92% and 86.1%, respectively (bootstrap values of 42.7% and 38.3%). A 
previously defined Gt1 strain from Kumasi, Ghana (Candotti et al., 2003) also 
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clustered with this strain in the core (bootstrap value 26.7%) analysis and shared 




Figure 4.4. Phylogenetic relationship between HCV genotype 1 NS5B sequences. 
The genotype 1 Kumasi sample (in red) was aligned against genotype 1 
sequences from throughout the world obtained from the Los Alamos database. 
HCV genotype 1 subtypes are indicated along the branches. Nodes/clusters 
without a subtype label have an unassigned subtype. Bootstrap values ≥80% are 






Figure 4.5. Phylogenetic relationship between HCV genotype 2 core sequences. 
The genotype 2 Kumasi samples (in red) were aligned against genotype 2 
sequences from throughout the world obtained from the Los Alamos database. 
HCV genotype 2 subtypes are indicated along the branches. Nodes/clusters 
without a subtype label have an unassigned subtype. Bootstrap values ≥80% are 
indicated by an asterisk. 
 
Upon further analysis against Gt2 sequences from throughout the world, the 
Ghanaian Gt2 strains displayed great diversity (Figures 4.5 and 4.6). Three of the 
strains (GH03, GH07 and GH08) clustered with subtype 2l (bootstrap values of 
100% and 99.9% for core and NS5B respectively). The three strains core sequences 
shared an average sequence homology of 95.1% whilst the NS5B sequences 
averaged 89.2% sequence identity. A previously detected strain (core accession 
number AY236365; NS5B accession number AY236381) from a blood donor in 
Kumasi (Candotti et al., 2003) also clustered closely with these three strains in both 
core (100% bootstrap value) and NS5B (49.1% bootstrap value) analyses. GH03, 
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GH07 and GH08 showed sequence homologies of 91.6%/83.7%, 93%/85.1% and 
91.8%/84% with the core/NS5B sequences of the aforementioned Ghanaian strain 
from a blood donor. 
The other five Gt2 strains had less defined subtype assignment with poor bootstrap 
support. Two Ghanaian strains (GH04 and GH05) clustered together in both analyses 
sharing sequence homology of 92.7% and 88.5% in the core and NS5B genes, 
respectively. Unsubtyped strains previously identified in Kumasi blood donors 
(accession numbers AY236374, AY236375, AY236380, AY236386) clustered with 
these two Ghanaian sequences in the NS5B analysis (7.9% bootstrap value), whereas 
the two strains clustered on their own in the analysis of the core region (17.1% 
bootstrap value). 
 
GH06 did not cluster with any known subtype (100% bootstrap value) in the core 
analysis. Two of the strains showed discordant results between core and NS5B 
analyses. The GH02 NS5B sequence clustered most closely with subtype 2j 
(bootstrap value of 20.6%), whereas the core sequence formed a cluster with two 
strains of subtypes 2c and 2r (5.9% bootstrap value). The second strain (GH09) 
clustered most closely with subtype 2q (39.7% bootstrap value) in the core analysis 
whilst the NS5B sequence clustered most closely with subtype 2l and an unassigned 





Figure 4.6. Phylogenetic relationship between HCV genotype 2 NS5B sequences. 
The genotype 2 Kumasi samples (in red) were aligned against genotype 2 
sequences from throughout the world obtained from the Los Alamos database. 
HCV genotype 2 subtypes are indicated along the branches. Nodes/clusters 
without a subtype label have an unassigned subtype. Bootstrap values ≥80% are 
indicated by an asterisk. 
4.3.4. HCV RNA positive subjects 
Four of the HCV positive subjects with an active infection completed a questionnaire 
to determine risk factors associated with HCV infection in this population. The 
remaining five HCV positive subjects could not be contacted despite repeat attempts. 
The HCV positive individuals with demographic data available comprised two males 
and four females aged 25-46 years (Table 4.1). Using a structured questionnaire, the 
reported risk factors for HCV infection were surgical procedures and blood 
transfusion and these had occurred ≥12 months prior to HCV testing. No patient 
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reported any history of jaundice, intravenous or illicit drug use, needle stick injury, 
therapeutic or cosmetic cuts, or body tattooing.  
 
Table 4.1. Demographic and clinical characteristics of the subjects from the 
Kumasi HIV cohort that tested HCV RNA positive 
ID Gender Age HBsAg status CD4 
count 
ALT HCV 
Genotype Core Subtype NS5B Subtype 
GH01 F 46 Negative ND ND 1 Unassigned Unassigned 
GH02 F 32 Positive 110 168 2 2c/2r 2j 
GH03 M 43 Positive 441 50 2 2l 2l 
GH04 M 41 Positive 385 44 2 Unassigned Unassigned 
GH05 NA NA Negative ND ND 2 Unassigned Unassigned 
GH06 NA NA Negative ND ND 2 Unassigned NA 
GH07 F 25 Negative 602 ND 2 2l 2l 
GH08 F 26 Negative 207 ND 2 2l 2l 
GH09 NA NA Negative ND ND 2 2q 2l 




This study is the first to employ HCV RNA testing to determine HCV prevalence in 
HIV-positive patients in Ghana. It is also the first to use DPS from a sub-Saharan 
African, resource-limited setting for HCV RNA screening and molecular 
characterisation. It was found that around 0.7% of subjects were positive for HCV 
RNA, thus indicating an active infection. These findings are consistent with the 
previously reported HCV RNA prevalence of 0.6-0.9% among blood donors in 
Ghana (Ampofo et al., 2002, Candotti et al., 2003). 
 
Previous work within our group has shown variable performance between three 
widely used commercial assays on a subset of the samples tested in this study (King 
et al., 2015). The seroprevalence rate of 6.7% found in HIV-infected patients in West 
Africa from a meta-analysis (Rao et al., 2015) is almost ten-fold higher than the 
prevalence found in this study. However, the previous work from our group and the 
prevalence determined by real-time PCR call into question the reliability of this 
estimate alongside others from Ghana (Brandful et al., 1999, Nkrumah et al., 2011, 
Kubio et al., 2012, Sagoe et al., 2012). Results of two previous studies from Uganda 
and Malawi are in agreement with these findings (Chasela et al., 2012, Mullis et al., 
2013). Among 500 HIV-positive subjects in Uganda, anti-HCV prevalence by the 
Ortho assay was 7.5%. However, none of the anti-HCV reactive samples had 
detectable HCV RNA (Mullis et al., 2013). Among 2041 HIV-positive pregnant 
women in Malawi, HCV antibody prevalence by a chemiluminescence immunoassay 




Nucleic acid amplification technology (NAT) has proved useful in determining an 
accurate assessment of the prevalence of HCV in various populations in a range of 
SSA countries (Ampofo et al., 2002, Candotti et al., 2003, Agwale et al., 2004, 
Laurent et al., 2010, Abreha et al., 2011, Zeba et al., 2011, Chasela et al., 2012) and 
represents a gold-standard test for the screening of active HCV infections. 
Unfortunately, it is often cost prohibitive for standard screening in resource-limited 
settings. In Ghana, HCV RNA testing is currently available in large research 
facilities and private laboratories, although the recommended introduction of routine 
HIV-1 RNA monitoring may in the future expand access to molecular assays in the 
region. Ghana is described as a lower middle income country with a gross national 
income per capita of US$1,600 (World Bank, 2014). Thus, measures to reduce the 
cost of diagnostic methods are necessary. This was achieved in two ways in this 
study, i) through the use of pooled samples; and ii) using DPS for screening. 
 
Sample pooling strategies have been shown before to be effective for surveying low 
prevalence populations. Many developed countries utilise pool screening systems to 
screen blood donations for the presence of HIV, HBV and HCV (Gentili et al., 2001, 
Ohnuma et al., 2001, Stolz et al., 2003). Although effective at detecting the presence 
of blood-borne viruses, the sensitivity of the assay is reduced when samples are 
pooled. After extensive optimisation detailed in Chapter 3, our pooling approach 
proved to be effective for HCV RNA screening, reducing cost and labour, and 
confirming the previous observation that pooled testing is a realistic strategy for 
identifying HCV carriers in low-prevalence settings (Brant et al., 2008, Keys et al., 
2014). In the case of plasma samples, pooling reduced the sensitivity of the assay by 
five-fold, which could result in the misdiagnosis of patients with a low HCV RNA 
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load. However, a previous study indicated that among 20 Kumasi blood donors 
infected with HCV Gt1 or Gt2, HCV RNA levels were a median 2.5 × 105 IU/ml and 
ranged from 3.3 × 103 to 9.0 × 106 IU/ml (Candotti et al., 2003), which is still above 
the lower limit of detection (550 IU/ml with pooled plasma samples) of our assay. 
Also, the cohort in this study had never been tested for HCV and was therefore naïve 
to all anti-HCV therapy, reducing the probability of a false negative misdiagnosis.  
 
DBS have been used in limited-resource settings in South Africa to detect HIV RNA 
and DNA in infants, helping to expand access to these important diagnostic tests 
(Sherman et al., 2005). Furthermore, a study in Malawi used pooled DBS to monitor 
the HIV viral load of patients being treated with ART, a strategy that would reduce 
the cost of HIV virological monitoring by $345,000 per year if implemented (Pannus 
et al., 2013). In South Africa, use of pooled DPS has been shown to be successful in 
reducing the cost of monitoring HIV whilst still maintaining a high level of accuracy 
during testing (van Zyl et al., 2011).  
DBS have been successfully used to screen a cohort of injecting drug users for both 
anti-HCV antibody and HCV RNA (Hope et al., 2011) although DPS have not been 
previously employed to study the prevalence of HCV. Although DPS still incur the 
cost of processing blood to plasma, like DBS, they do not require the cold storage for 
shipment, which, in resource-limited settings, would be beneficial if samples needed 
to be shipped to a central testing facility. This has been a proven approach in Haiti, 
where DBS from infants have been shipped overseas to the Netherlands for 
diagnostic testing of HIV (Ivers et al., 2008). 
Employing DPS for screening does reduce the sensitivity of the assay. In the case of 
our assay, 2500 IU/ml was the lower limit of detection when using single DPS 
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specimens as the testing medium. As with pooling plasma samples, there is a risk of 
missing an active infection when utilising DPS. However, as mentioned above, the 
median viral load of samples from Ghana was much higher than the aforementioned 
limit of detection. 
There was a difference in the prevalence of infection tested by plasma and DPS, 
although this was not significant. It is likely that the difference is due to the patient 
characteristics, as the plasma samples also contained HBsAg-positive patients, which 
had approximately double the prevalence of HCV infection compared to HBsAg-
negative patients. Although there was a loss in sensitivity when using DPS for 
screening, the number of patients with a low enough viral load to be missed would 
be very few to none and not enough to substantially impact upon the prevalence. 
As shown in this study, the combination of these two strategies could be easily 
adapted to allow routine testing of HCV whilst reducing costs. 
 
It should be noted however that HCV prevalence was nearly double among HBsAg-
positive subjects relative to those who tested HBsAg negative, although the 
difference did not reach statistical significance. This trend has also been examined in 
a cohort of blood donors from Kumasi (Layden et al., 2015), possibly reflecting 
shared transmission routes of the two viruses. There are an estimated 250,000 
patients infected with HIV in Ghana (UNAIDS, 2014b), of whom 16.7% are co-
infected with HBV (Geretti et al., 2010). Thus, the data here suggest an estimated 
530 subjects with triple HIV/HBV/HCV co-infection and 1,750 subjects with 
HIV/HCV co-infection are living in Ghana. The triple infection prevalence of 1.27% 
found in this study is higher than many of the reported rates from other African 
countries, which are commonly under 1% (Cunha et al., 2007, Harania et al., 2008, 
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Patel et al., 2011). Larger studies are required to confirm an association between 
HBV and HCV co-infection in this population. 
 
Taken together with previous results (Ampofo et al., 2002, Candotti et al., 2003), our 
findings do not suggest a marked excess risk of HCV infection in HIV-positive 
subjects in the region. The conclusion is in line with the observation that the reported 
risk factors for HCV infection were healthcare-related, with several of the identified 
strains showing clustering with strains previously detected in Kumasi blood donors 
(Candotti et al., 2003). Despite this agreement, certain limitations should be 
considered before classifying HCV as low prevalence in SSA. Previous studies have 
observed fluctuating HCV RNA levels during the early stages of infection 
(McGovern et al., 2009, Loomba et al., 2011). Consequently, it is possible that a 
patient with an acute infection may be misdiagnosed as non-infected if tested during 
a trough in HCV RNA levels. A pooled testing strategy with a higher limit of 
detection such as the one used in this study may increase the chance of this 
occurring. Secondly, HCV variants in Africa have showed a wide degree of variation 
in both the present study and previous studies, with many of the observed subtypes 
seemingly unique to this region (Ruggieri et al., 1996, Jeannel et al., 1998, Candotti 
et al., 2003, Markov et al., 2009). Although the primers used here in the real-time 
PCR target a conserved region of the genome, there is a concern that the African 
subtypes may not be detected by these. Designing primers based on African strains 
may increase the prevalence of HCV observed in this population. 
 
Molecular characterization of the HCV positive specimens revealed that the majority 
of HCV-positive samples were Gt2 (89%), whilst a small proportion were Gt1 
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(11%). Overall, there was high molecular diversity among the strains and only three 
readily clustered with a well-defined subtype (2l). This was observed in the analysis 
of both of the sequenced genes. These three subtype 2l strains also clustered closely 
together and with another previously identified strain from a blood donor from the 
same region in Ghana. This could indicate a possible transmission network, 
especially as two of the risk factors identified were healthcare-related i.e. blood 
transfusion and surgery. The diversity is similar to findings from Ghanaian blood 
donors (Candotti et al., 2003) and other West African countries (Ruggieri et al., 
1996, Jeannel et al., 1998, Markov et al., 2009). The proposed long-term endemicity 
and evolution of HCV genotypes 1 and 2 in West Africa provides an explanation for 
this diversity (Jeannel et al., 1998, Markov et al., 2009). A recent study placed the 
origin of Gt2 in Ghana, with subsequent spread to other West and North African 
countries (Purdy et al., 2015). Similar patterns to this can be seen in Gt6 found in 
Southeast Asia, which is thought to be its origin (Pybus et al., 2001). 
 
Upon further analysis, the Gt1 sample did not cluster with any known subtype. 
However, the bootstrap value for this was under the 80% threshold in both core and 
NS5B analyses so it would be difficult to conclude that it is a new subtype without 
further sequence analysis. Possible new subtypes of HCV Gt1 have been previously 
characterised from SSA countries (Candotti et al., 2003, Bracho et al., 2006). 
According to nomenclature guidelines, further characterisation of this sample would 
need to be carried out, alongside further evidence from independently infected 
individuals, before the designation of a new subtype (Simmonds et al., 2005). 
However, the determination of another subtype may not be necessary if there is no 
clear benefit to clinical or epidemiological studies (Bracho et al., 2006). The low 
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prevalence of Gt1 found in this population may indicate that it is not endemic to the 
region and therefore of limited clinical value to classify new subtypes. Regions such 
as Ghana seem to contain such a high molecular diversity within genotypes that the 
number of subtypes would become unwieldy if new classifications of subtypes 
continued. The Gt1 strain may represent a variant that originated in Cameroon and 
spread to West Africa (Ndjomou et al., 2003, Bracho et al., 2006), although full 
genome sequencing is required to provide a more detailed molecular 
characterisation. 
 
The choice and duration of HCV treatment is dependent on a number of viral factors, 
including the genotype, subtype, mutational profile and HCV viral load (European 
Association for the Study of the Liver, 2015). Some of the newly licensed DAAs are 
pan-genotypic (Lawitz et al., 2013, Rodriguez-Torres, 2013, Vince et al., 2014). 
However, other DAAs are only effective against certain genotypes or show greater 
efficacy against certain subtypes of the same genotype. For example, simeprevir is 
more effective against Gt1b than Gt1a (Jacobson et al., 2014). Consequently, the 
distribution of genotypes is not only important from an evolutionary perspective but 
also for the healthcare system. The lack of subtype assignment to the Gt1 strain may 
pose subsequent problems in the selection of the most appropriate treatment. 
Treatment of HCV infection in Africa is extremely limited and thus the response of 
widely diverse strains is unknown. Although Gt2 has historically been shown to 
respond well to treatment with peg-interferon and ribavirin (Dalgard et al., 2004, 
Mangia et al., 2005), African-American populations have a high proportion of the 
TT allele at the IL28B site, which negatively affects treatment response to interferon 
(Ge et al., 2009). New DAAs have shown high SVR rates against this genotype 
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(Lawitz et al., 2013), offering hope that chronic HCV infections in this region of the 
world may be easily treated as long as such drugs become available at an affordable 
level. 
 
There are limitations to this study. The number of patients identified with current 
infections was small, leaving limited scope for a detailed analyses of factors 
associated with HCV infection alongside molecular characterisation. Large-scale 
studies are necessary in order to define the epidemiological characteristics of 
HIV/HCV co-infection in Ghana and SSA. The additional time and cost involved in 
processing whole blood to plasma restricts the use of DPS for screening purposes to 
populations that already have stored plasma samples, such as HIV-positive patients. 
Nevertheless, this still represents an important demographic as, unlike Western 
cohorts, HIV-positive patients in SSA countries are not routinely screened for HCV 
co-infections. For the purposes of screening a new cohort or the general population 
for HCV RNA, DBS would represent a more suitable and practical approach unless 
the extra time and expense to obtain plasma could be justified. In a previously 
reported approach, plasma which has been separated by gravity without the aid of 
machines has been used for the detection of HIV (Mwebaza et al., 2013). This 
strategy could form the preliminary step to preparing DPS with little associated cost 
and the use of already existent infrastructure. However, further tests would be 
required to ensure the techniques give comparable results when using DPS prepared 
from both centrifuged and non-centrifuged plasma. Taking these factors into 
account, the data presented here still provide novel information with implications for 




In summary, the use of a pooling strategy to screen both plasma and DPS for HCV 
RNA enabled a large cohort of HIV-infected individuals from Ghana to be tested in a 
shorter timescale and at a reduced cost than individual screening of each sample, 
thus providing laboratories with a useful diagnosis procedure in resource-limited 
settings. DPS testing also allows the recovery of RNA for sequencing, allowing the 
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5. Determining the prevalence of the HCV NS3 Q80K polymorphism in a 
UK population 
Abstract 
Background The Q80K polymorphism in the hepatitis C virus (HCV) NS3 gene 
reduces susceptibility to simeprevir and has potential effects on other novel protease 
inhibitors. The aims of this chapter were to i) determine the prevalence of Q80K in 
treatment-naïve patients infected with HCV genotype 1a in the North-West (NW) 
and South-East (SE) of England, ii) investigate the occurrence of Q80K as a minority 
variant (>1%), and iii) characterise the phylogeny of NS3 sequences from the United 
Kingdom (UK).  
Methods Plasma samples from genotype 1a infected subjects, naïve to all anti-HCV 
therapy, underwent Sanger sequencing and deep sequencing (Illumina MiSeq, 1% 
interpretative cut-off) of the NS3 gene. Sequences underwent phylogenetic analysis 
to determine their distribution within the two genotype 1a clades. 
Results Q80K occurred in 34/200 subjects (17.0%, 95% confidence interval 11.8%-
22.2%), including 9/32 (28.1%) in the NW and 25/168 (14.9%) in the SE (p=0.076), 
with no difference by HCV RNA load and HIV status. The frequency of the 
polymorphism in the patients’ samples was >40% in all cases. Phylogenetic analysis 
identified the two recognised HCV genotype 1a lineages with UK sequences being 
interspersed with sequences from both Europe and USA. 
Conclusions Q80K occurs at high prevalence among treatment-naïve genotype 1a 
HCV patients in England, and conventional sequencing provides sufficient 
sensitivity to detect the polymorphism for pre-treatment screening. UK sequences 
are highly interspersed with sequences from elsewhere in Europe and USA, and their 




The NS3/4A protease is an essential enzyme for the replication of HCV and 
represents a target for several direct acting antivirals (DAAs) (Schneider and 
Sarrazin, 2014). In genotype (Gt) 1 infection, traditional therapy of pegylated-
interferon and ribavirin (P/R) had a limited success rate of around 50% after 48 
weeks of therapy (Fried et al., 2002). Sustained virological response (SVR) rates 
increased to approximately 70% following introduction of first generation NS3 
protease inhibitors (PIs) boceprevir and telaprevir for use as third agents with P/R 
(Jacobson et al., 2011, Poordad et al., 2011). Although first generation PIs proved 
effective, tolerability was problematic due to anaemia with boceprevir and skin 
rashes with telaprevir (7-11% treatment discontinuation). The introduction of the PI 
simeprevir further increased SVR rates to 80% in Gt1, treatment-naïve patients 
whilst decreasing treatment discontinuation rates due to adverse events to 3% 
(Jacobson et al., 2014). 
 
Naturally occurring mutations in NS3 that reduce the susceptibility of HCV to PIs 
have previously been observed in treatment-naïve patients (Kuntzen et al., 2008, 
Cento et al., 2012). One notable polymorphism, glutamine to lysine at position 80 
(Q80K) in NS3, increases the resistance to the newly licensed PI simeprevir by 
approximately 8-fold in vitro (Lenz et al., 2010). Whilst other resistance associated 
mutations (RAMs) seem to occur at relatively low frequencies in the population, 
Q80K is more common and has been observed at a natural prevalence of up to 48% 
in Gt1a patients from the USA (Lenz et al., 2015). The overall prevalence in Europe 
is 20% although this differs by country (Paolucci et al., 2012, Vicenti et al., 2012, 
Palanisamy et al., 2013, Sarrazin et al., 2015b). Phase III trials of treatment with 
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simeprevir plus P/R observed a lower SVR in patients harbouring Q80K than in 
those without the mutation (Forns et al., 2014, Jacobson et al., 2014, Manns et al., 
2014). In a randomised trial of P/R plus simeprevir or placebo for treatment-naïve 
patients, the SVR measured 12 weeks after treatment completion (SVR12) was 
similar between placebo and simeprevir recipients when the Q80K polymorphism 
was present at baseline (Jacobson et al., 2014). Consequently, current guidelines 
indicate that Gt1a patients should be tested for Q80K before starting therapy with 
simeprevir and if the polymorphism is present, for an alternative therapy to be 
considered (European Association for the Study of the Liver, 2015). 
 
Previous studies have produced prevalence estimates for Q80K using population 
(Sanger) sequencing. This technique is limited to detecting variants that are present 
at ≥10-20% of the total viral strains in a sample. The existence of HCV as a 
quasispecies results in the circulation of many different variants during infection. 
Consequently, drug resistant variants will be present but often at too low a frequency 
to be detected by population sequencing. The development of next generation 
sequencing (NGS) technologies now offers improved sensitivity, enabling the 
detection of low frequency HCV variants, an approach defined as “deep 
sequencing”. Relatively few studies have used this technique to study low-frequency 
HCV RAMs in treatment-naïve individuals (Fonseca-Coronado et al., 2012, 
Bartolini et al., 2013, Dierynck et al., 2014, Jabara et al., 2014, Margeridon-Thermet 
et al., 2014) and none have specifically focussed on Q80K. The high prevalence and 
impact of the polymorphism warrants further investigation to determine its presence 




The prevalence of the Q80K polymorphism has been well described in the United 
States and Europe (Cento et al., 2012, Berger et al., 2014, Lenz et al., 2015, Sarrazin 
et al., 2015b) but there is limited data available on the prevalence in the UK, 
especially using NGS. This study aimed to gain a better understanding of the natural 
prevalence of the Q80K mutation in a UK population from two regions of England. 
A second aim was to utilise deep sequencing to investigate the rate at which Q80K 
exists as a low frequency variant and therefore determine whether traditional 
population sequencing provides a sufficient level of sensitivity to screen patients 
prior to the commencement of simeprevir therapy. Finally, we aimed to determine 





5.2.1. Patient population 
The study was performed retrospectively using stored plasma samples from adults 
that attended for care at the Royal Liverpool University Hospital in Liverpool 
(North-West region) and at King’s College Hospital, Chelsea & Westminster 
Hospital, and Charing Cross Hospital in London (South-East region) between 2006 
and 2013. Eligible patients were infected with Gt1a HCV and naïve to all anti-HCV 
therapy, including pegylated-interferon and ribavirin, at the time of sampling. HIV 
status and HCV RNA load were retrieved from the clinics’ databases. Ethics 
permission was granted by the South Berkshire Regional Ethics Committee to 
conduct the study after removing personal identifiable information from the samples. 
5.2.2. Population sequencing 
HCV RNA was extracted from 100μl plasma using the Nuclisens easyMAG system 
(bioMérieux, Boxtel, Netherlands) in a 60μl elution, further detailed in Chapter 
2.7.1. A partial NS3 region (727bp) was amplified by nested PCR as detailed in 
Chapter 2.7.2. PCR products were purified and sequenced using the Applied 
Biosystems 3730 DNA Analyser as outlined in Chapter 2.8-2.12. The cycle 
sequencing reaction and Sanger sequencing of 63 samples was carried out by Thanos 
Papadimitropoulos. 
5.2.3. Next generation sequencing 
Samples were extracted, amplified and purified as detailed in Chapter 2.15-2.20 in 
preparation for next generation sequencing. Amplicons were prepared using the 
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Nextera XT Sample Preparation kit and the Illumina MiSeq platform was used to 
deep sequence the products (Chapter 2.21). A 727bp region of a plasmid control 
encompassing the full length NS3 gene was amplified and sequenced in four 
replicates to determine the error rate of the assay. 
5.2.4. Sequence analysis 
Consensus sequences from population sequencing were assembled using SeqScape 
(v2.7) and tested for Q80K using geno2pheno 
(http://hcv.geno2pheno.org/index.php). NGS reads underwent initial preliminary 
processing at The Centre for Genomics Research, University of Liverpool. 
BAMStats (http://sourceforge.net/projects/bamstats/files/) was used to calculate the 
read statistics. The VirVarSeq pipeline (Verbist et al., 2015) was used for the 
analysis of the deep sequencing reads, full details of which are in Chapter 2.22. 
Descriptive statistics were used to analyse the frequency of mutants in each patient’s 
sample (as the proportion of deep sequencing reads showing the mutation). The 
plasmid control yielded an average of 174,799 reads, with a mean coverage of 
46,268 reads per nucleotide. The average error rate, calculated by counting false 
positive reads at the codon level over NS3 amino acids 1-181, was 0.6% (SD 
±0.2%). A threshold of 1% was used as a cut-off for minority variants. 
5.2.5. Phylogenetic analysis 
Gt1a HCV sequences from the USA and Europe were retrieved from the Los Alamos 
HCV Database. Multiple sequences from the same patient i.e. from clones or 
timepoints during therapy, were discarded along with sequences from non-human 
hosts. The resulting sequences were aligned against the sequences obtained from this 
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study using Clustal W. Where available, the consensus sequence from deep 
sequencing reads was used. The alignment was trimmed to nucleotide positions 
3420-4014 (amino acids 1-198 of NS3). Sequences with strings of N >20bp in length 
were discarded. The resulting alignment was phylogenetically analysed using the 
PHYLIP v3.69 package (Felsenstein, 1989) as described in Chapter 2.13. Regional 
clusters were identified as clusters containing ≥3 sequences unique to either the NW 
or SE region and supported by a bootstrap value of ≥80%. Inter-regional clusters 
contained sequences from both the NW and SE regions. 
5.2.6. Statistical analysis 
Fisher’s exact test was used to compare the proportion of subjects with Q80K by 
geographic location and HIV status. The Mann-Whitney U test was used to compare 
the HCV RNA load and CD4 counts (in HIV co-infected only) of patients with and 
without Q80K. The analysis was performed using SPSS version 21 (IBM 




5.3.1. Patient population 
Overall, 200 adults (median age 43 years, interquartile range, IQR, 39-50) infected 
with Gt1a HCV were studied, including 32/200 (16%) in the North-West (NW) and 
168/200 (84%) in the South-East (SE). At the time of testing, HCV RNA load was 
median (IQR) 6.3 (5.8-6.7) log10 IU/ml. Subjects were naïve to all anti-HCV therapy. 
A total of 61/200 (30.5%) subjects, all from the SE, were co-infected with HIV. A 
summary of the patient population is detailed in Table 5.1. 
Of the 200 patient samples, 22 were population sequenced only, 63 were deep 
sequenced only and 115 samples underwent both population and deep sequencing. 
 





Number 32 168 200 
Median age (IQR) 41 (38-44) 44 (39-51) 43 (39-50) 
Average HCV VL (log10 
IU/ml), median (IQR) 
5.9 (5.5-6.6) 6.3 (5.9-6.8) 
6.3 (5.8-6.7) 
HIV co-infection 0 61 (36.3%) 61 (30.5%) 
Q80K detecteda 9 (28.1%) 25 (14.9%) 34 (17.0%) 




5.3.2. Overall Q80K prevalence 
Overall, the Q80K polymorphism was identified in 34/200 (17%, 95% confidence 
interval, CI 11.8%-22.2%) samples (Table 5.2). The prevalence of Q80K in the 
North-West was nearly double of that in the South East region, with 9/32 (28.1%) 
and 25/168 (14.9%) patients harbouring the polymorphism, respectively (p=0.076). 
When comparing results by HIV status in the SE, Q80K prevalence was 18/107 
(16.8%) in HCV mono-infected subjects and 7/61 (11.5%) in HIV/HCV co-infected 
subjects (p=0.379). In HIV/HCV co-infected subjects, there was no significant 
difference (p=0.80) in the CD4 count of samples with and without the 
polymorphism, with medians (IQR) of 519 (199-701) vs. 474 (318-646) cells/mm3, 
respectively. The median HCV RNA load was 6.4 (IQR 5.6-6.7) vs. 6.2 (IQR 5.8-
6.7) log10 IU/ml in samples with vs. samples without Q80K, respectively (p=0.63). 
 
Table 5.2. Prevalence of the Q80K polymorphism in each region by Sanger and 
deep sequencing 
Region Number with Q80K Mutant frequency (%) 






Sanger and Illumina 
(n=115) 
   Sanger Illumina  
North West 2 0 7 7 All ≥99.8% 
South East 4 8 13 13 41.1%, 45.8%, 
Remaining ≥98.9% 




5.3.3. Q80K prevalence by population sequencing 
Of the 137 samples that were population sequenced, the Q80K polymorphism was 
found in 26, yielding a prevalence of 19.0% (95% CI 12.4%-25.6%) samples. Two 
samples positive for Q80K displayed a mixed first base of codon 80; one had a 
dominant C and the other had an equal distribution of C and A at this position, as 
determined by manual inspection of the electropherogram peaks. One sample (0.7%) 
had the Q80L mutation. 
5.3.4. Q80K prevalence by next generation sequencing 
A subset of 178 samples underwent deep sequencing using the Illumina MiSeq. An 
average of 58,585 reads per sample was obtained (median; 53,413, IQR; 40,740-
70,255) with an average coverage of 16,107 per nucleotide. The Q80K 
polymorphism was observed in 28/178 (15.7%, 95% CI 10.4%-21.0%) samples 
(Table 5.2). Of the samples deep sequenced, 115 had also undergone population 
sequencing; 20 of which showed the Q80K polymorphism. All samples showing the 
polymorphism by population sequencing showed Q80K by deep sequencing, at 
frequencies ≥98% in 18/20 cases. Of the two samples showing a Q/K mixed 
population by population sequencing, one displayed a Q:K ratio of 54.2:45.8 and the 
other showed Q:K:L at a ratio of 56.8:41.1:2.1, by deep sequencing. 
NGS revealed a mixed population of Q/L at a ratio of 11.8:88.2 in the sample 
showing Q80L by population sequencing. 
None of the samples that had Q at position 80 by population sequencing showed the 
polymorphism by deep sequencing, when an interpretative cut-off of 1% was 
applied. Introducing a lower interpretative cut-off increased the prevalence of Q80K; 
a further 2.0% (3/150) and 10.0% (15/150) of samples displayed the polymorphism 
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at cut-off values of ≥0.5% x <1%, and ≥0.2% x <0.5%, respectively. However, these 
cut-offs fell within the estimated error rate of the assay (0.6%, SD ±0.2%). 
A further six samples showed low levels of other resistance mutations at position 80 
comprising L (5.6%, 5.1% and 1.4%) and R (1.7% [n=2] and 1.1%). 
5.3.5. Phylogeny of NS3 sequences 
In order to determine the distribution of sequences containing the Q80K 
polymorphism within the two distinct clades of Gt1a, a phylogenetic analysis was 
performed. The analysis also allowed the assessment of the relatedness of the Q80K 
sequences present in the UK to other sequences from the USA and Europe. The NS3 
sequences obtained from sequencing of UK samples (n=200) were phylogenetically 
analysed against Gt1a reference sequences (Figure 5.1). There was no difference in 
the proportion of the samples clustering in clade 1 between the two regions (NW; 
17/32, 53.1% vs. SE; 74/168, 44.0%, p=0.44). Of the 34 sequences with the Q80K 
polymorphism present (either dominant or as a mixture), 32 (94.1%) clustered within 
clade 1 of Gt1a. The remaining two sequences clustered in the other Gt1a clade. 
These two sequences were the samples which showed a mixed population of both Q 
and K at position 80. An additional 54 samples without the Q80K polymorphism at 
any level >0.2% clustered within clade 1. Of 18 samples showing Q80K at levels 
≤1%, 13 (72.2%) aligned with clade 2; the lineage of Gt1a not associated with the 
Q80K polymorphism. The UK sequences did not form a distinct cluster, but were 
interspersed with sequences from the USA and Europe, suggesting that they arose 
from multiple introductions. Six regional clusters were identified in the UK 
sequences - all comprising sequences from the SE - the largest of which contained 20 
sequences from co-infected subjects from the SE, representing a possible 
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transmission network. One inter-regional cluster was identified, comprising two 
sequences from the SE and one from the NW. The sequences in this inter-regional 
cluster all contained the Q80K polymorphism. Of the remaining 29 samples with 
Q80K in clade 1, 11 (37.9%) were present in regional or inter-regional clusters, 
although these did not reach the 80% bootstrap threshold. 
 
 
Figure 5.1. Phylogenetic relationship between genotype 1a NS3 sequences. 
Sequences were aligned against genotype 1a NS3 reference sequences from the 
USA and Europe. Sequences from the USA are highlighted red, Europe are 






This study expands upon the knowledge of Q80K in a UK population of patients 
with chronic HCV infection and offers novel insights into the impact deep 
sequencing can have on the detection. In this study, we determined that Q80K was 
present in a large proportion of the HCV infected treatment-naïve UK population, 
particularly in the North West. In the UK, data from Phase II/III clinical trials of 
telaprevir and simeprevir showed 23% of Gt1a patients had Q80K (Sarrazin et al., 
2015b) whilst a small study of HIV/HCV co-infected patients with acute HCV 
infection observed a prevalence of 16% with the polymorphism (Leggewie et al., 
2013). The highest prevalence in Europe (45%) was seen in a Berlin cohort 
comprising Gt1a, HCV mono-infected and HIV/HCV co-infected patients (n=42) 
(Ehret et al., 2014), although many of the previous estimates from other European 
countries remain under 20% (Trevino et al., 2011, Vallet et al., 2011, Paolucci et al., 
2012, Vicenti et al., 2012, Palanisamy et al., 2013) (Table 5.3). The lowest 
prevalence previously identified was 5.7% from a cohort of PI-naïve, Gt1a infections 
(n=53) in Sweden (Palanisamy et al., 2013). An Italian study determined a 
prevalence of 16.4% in Gt1a patients (Vicenti et al., 2012) and a similar prevalence 
of 16% was observed in a Spanish cohort of HIV/HCV co-infected patients with Gt1 
infection (Trevino et al., 2011). The prevalence of this polymorphism in North 
America was observed at 48.1% in Gt1a patients (Lenz et al., 2015); approximately 
three times the value of many estimates from Europe included the one observed in 
this study. These data, along with the observations from this study, indicate that the 














Austria 109 18 (16.5%) 94 1 (1.1%) (Sarrazin et al., 2015b) 
Belgium 61 11 (18%) 147 1 (0.7%) (Sarrazin et al., 2015b) 
Bulgaria 14 0 35 0 (Sarrazin et al., 2015b) 
France 275 38 (13.8%) 244 3 (1.2%) (Sarrazin et al., 2015b) 
France 46 3 (6.5%) 35 2 (5.7%) (Vallet et al., 2011) 
France 447 25 (5.6%) 203 6 (3.0%) (Hajji et al., 2015) 
Germany 42 19 (45.2%) - - (Ehret et al., 2014) 
Germany 241 70 (29%) 345 2 (0.6%) (Sarrazin et al., 2015b) 
Italy 31 3 (9.7%) 39 0 (Paolucci et al., 2012) 
Italy 60 12 (20%) 150 1 (0.7%) (Sarrazin et al., 2015b) 
Italy 67 11 (16.4%) 42 0 (Vicenti et al., 2012) 
Italy 103 23 (22.3%) 80 0 (Ruggiero et al., 2015) 
Netherlands 26 3 (11.5%) 14 0 (Sarrazin et al., 2015b) 
Norway 21 1 (4.8%) 5 0 (Sarrazin et al., 2015b) 
Poland 20 15 (75%) 444 2 (0.5%) (Sarrazin et al., 2015b) 
Portugal 37 3 (8.1%) 9 0 (Sarrazin et al., 2015b) 
Romania - - 92 1 (1.1%) (Sarrazin et al., 2015b) 
Russia 6 4 (66.7%) 177 0 (Sarrazin et al., 2015b) 
Spain 82 7 (8.5%) 181 0 (Sarrazin et al., 2015b) 
Spain 43 8 (18.6%) 20 1 (5%) (Trevino et al., 2011) 
Sweden 53 3 (5.7%) - - (Palanisamy et al., 2013) 
Sweden 46 7 (15.2%) 13 0 (Sarrazin et al., 2015b) 
UK 38 6 (15.8%) - - (Leggewie et al., 2013) 





In this study, the difference in prevalence of the polymorphism between the two 
regions of the UK approached significance and, as described above, prevalence rates 
also differ markedly between European countries. Multiple studies have identified 
two distinct clades within Gt1a (Pickett et al., 2011, Vicenti et al., 2012, De Luca et 
al., 2015, McCloskey et al., 2015), and the Q80K polymorphism is associated with 
one of these clades (McCloskey et al., 2015). The circulation of these two clades 
may provide some explanation as to the differences in Q80K prevalence observed 
between European countries and regions within countries (Sarrazin et al., 2015b). 
However, in this study, we did not observe a difference in the proportion of samples 
clustering in the Q80K-associated clade between the NW and SE regions. This is 
despite the fact that the prevalence of the polymorphism in the NW was nearly 
double that of the SE. Our observations suggest that the distribution of clades may 
not be the determining factor in the prevalence of Q80K although larger studies 
should be performed to assess the distribution of the two clades within the UK and 
Europe in order to confirm this. 
The results from our study are in concordance with these previous results, with all of 
the sequences containing a dominant (>98%) Q80K polymorphism aligning in clade 
1. Interestingly, the two samples showing mixed amino acids (Q/K) were the only 
two sequences that clustered in the other Gt1a clade. One possible explanation for 
this may be that the Q80K mutation in these two strains is a de novo mutation, in 
contrast to the majority of circulating Q80K strains which are likely to have 
descended from a common ancestor. 
 
The Q80K polymorphism is believed to have originated in the United States in a 
period from the 1940s to 1950s (McCloskey et al., 2015). Given the estimated date 
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of origin, this substitution would not have arisen through the pressure of drug 
selection but appears to be a naturally occurring polymorphism with an increased 
resistance to drugs (McCloskey et al., 2015). One of the possible hypotheses to 
explain the high prevalence of Q80K is that the variant is transmissible (McCloskey 
et al., 2015). If this hypothesis is correct, then it is likely that the spread of the 
polymorphism did not occur until much later than it arose, when international travel 
and transmission events became more common. If the polymorphism is 
transmissible, then it may be considered that a proportion of the circulating strains in 
the UK have either descended from transmission events from the USA or involved 
migrants from the USA in the UK. Our phylogenetic analysis showed that the UK 
sequences carrying Q80K were interspersed with sequences from both the USA and 
Europe and did not cluster with strains from one particular country. This suggests 
that there have been multiple introductions of Q80K into the UK. One inter-regional 
cluster, containing 3 sequences with the polymorphism, was identified. Other 
clusters containing Q80K sequences were identified but were less well supported by 
bootstrap values. These data indicate that Q80K has spread through transmission 
events within the UK although a large scale phylogenetic study with more UK 
sequences is required to confirm this hypothesis. 
Another hypothesis is that the mutation frequently arises de novo during infection 
(McCloskey et al., 2015) although this seems less likely due to the large difference in 
the prevalence of the polymorphism between countries that has been observed. The 
emergence of de novo mutations may be influenced by pressure from the immune 
system. The epitope which includes the Q80 site is restricted by HLA A24 (Ward et 
al., 2002). However, a study of acute HCV infections found no association between 
this HLA type and substitutions at position 80 although only a small number of 
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patients were studied (Applegate et al., 2015).  If the polymorphism did emerge de 
novo during infections, the prevalence would be expected to be less diverse between 
different parts of the world.  
 
Currently, it is recommended that patients with a Gt1a infection undergo resistance 
testing for Q80K using traditional Sanger sequencing prior to the commencement of 
therapy with simeprevir (European Association for the Study of the Liver, 2015). 
The data from NGS showed that all Q80K mutants existed at high frequencies 
(>40%) allowing their detection by population sequencing. This finding is consistent 
with the observation that, in vitro, variants harbouring the polymorphism have a 
replication capacity similar to that of wild-type virus (Lenz et al., 2010), which 
would allow transmissibility and persistence at high frequency within the viral 
quasispecies despite the absence of drug selective pressure (McCloskey et al., 2015). 
There was no increase in prevalence of Q80K in the cohort below the detection 
threshold of population sequencing and above 1%, which was the threshold set for 
analysis. This value was above the assay average error rate of 0.6% and is a 
recommended cut-off to distinguish between true mutations and those caused by 
PCR and sequencing errors (Gianella et al., 2011). The application of lower 
thresholds resulted in an increased proportion of samples with Q80K. These data are 
in concordance with a previous study which found that of 21 patients harbouring the 
Q80K polymorphism, it occurred at levels >99% in 17, with only four carrying the 
mutation at levels lower than 1% (Jabara et al., 2014). A similar finding was 
observed in an Italian cohort, where 5 (18%) patients carried Q80K at levels ≥20% 
but the polymorphism existed as a minority variant (0.49-0.91% frequency) in only 3 
(11%) patients (Bartolini et al., 2013). A large study of 185 patients from throughout 
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the world identified only two additional patients carrying the Q80K mutation (1% 
and 14% frequency) through the use of NGS when compared to population 
sequencing (Dierynck et al., 2014). The majority of the ultra-low frequency (≤1%) 
Q80K substitutions observed in the present study aligned with clade 2 of Gt1a, 
which is not associated with the polymorphism. This suggests that they were not 
biologically meaningful substitutions and were errors introduced by the assay or 
were de novo mutations present at the time of sampling with no significance. 
 
Q80K reduces susceptibility to simeprevir by approximately 8 fold in vitro (Lenz et 
al., 2010) and the presence of the polymorphism reduces SVR rates of treatment with 
simeprevir plus P/R in both treatment-naïve (from 85% to 52%) and treatment-
experienced patients (from 79% to 47%) (Forns et al., 2014, Jacobson et al., 2014). 
A recent phase III trial employing simeprevir plus sofosbuvir for the treatment of 
Gt1-infected patients with cirrhosis reported higher SVR rates in patients without 
Q80K versus those with the mutation (92% vs. 74%, respectively) (Lawitz et al., 
2015b). This is an alarming observation, which may further reduce treatment options 
for patients harbouring Q80K. The polymorphism also confers a low-level (3-fold) 
decrease in susceptibility to paritaprevir in vitro (Pilot-Matias et al., 2015). The 
mutations Q80L and Q80R were found at low levels (≥1%) in patient samples. These 
mutations confer a 2- and 7-fold change in susceptibility to simeprevir in vitro, 
respectively (Lenz et al., 2010). Q80R has also been observed in a small number of 
patients experiencing failure of simeprevir therapy, when it occurred alongside major 




It is unclear whether the presence of the Q80K polymorphism at an ultra-low 
frequency would impact upon treatment response. A previous study using deep 
sequencing to track the changes in RAMs in Gt1b infected patients (n=18) 
undergoing simeprevir therapy found that ultra-low frequency variants (0.2%-0.3%) 
of Q80L and Q80R persisted at low background levels with no increase in frequency 
in two patients whilst another patient displayed an increase of Q80L from 1.0% at 
baseline to 76.0% during treatment (Akuta et al., 2014b). Failure of treatment due to 
simeprevir-resistant mutants could not be predicted at baseline and was mostly due 
to the emergence of de novo variants (Akuta et al., 2014b). More studies into the 
dynamics of low-level variants during treatment are required to confirm this 
observation although, if found to be true, the use of deep sequencing for routine 
diagnostic testing of minority variant Q80K strains is not necessary as they are 
unlikely to impact on treatment. 
 
In conclusion, we have demonstrated that populations from two regions in the UK, 
including those with HIV co-infection, have a high prevalence of Q80K, adding 
valuable data to previous estimates from Europe. The use of deep sequencing only 
increased the prevalence of the polymorphism over that detected by Sanger 
sequencing when frequencies under 1% were included and these are likely to be 
technical artefacts. The UK sequences did not form a distinct cluster, instead 









The impact of HIV co-infection on the 
prevalence of baseline HCV drug resistance 




6. The impact of HIV co-infection on the prevalence of baseline HCV 
drug resistance associated mutations  
Abstract 
Background Co-infection with HIV is known to accelerate disease progression and 
increase the viral load of HCV. Despite this, the effect of co-infection of resistance 
associated mutations (RAMs) has been poorly studied. This study aimed to 
determine the impact of HIV co-infection on the prevalence of RAMs at both high 
and low frequencies. 
Methods Samples from HCV mono-infected (n=177) and HIV/HCV co-infected 
patients (n=188) were collected from sites throughout the UK and Europe. Next 
generation sequencing was used to determine the prevalence of RAMs in two genes 
(NS3 and NS5A), using an interpretative cut-off value of ≥1%. 
Results Overall, RAMs were relatively common in both the NS3 and NS5A gene, 
with prevalences of 58.4% and 26.8%, respectively. There was no difference in the 
prevalence of high frequency RAMs between mono- and co-infected patients in 
either NS3 (46.9% vs. 55.3%, p=0.12) or NS5A (17.5% vs. 10.6%, p=0.07). The 
same was true of low frequency RAMs in NS3 (14.7% vs. 9.6%, p=0.15) and NS5A 
(16.4% vs. 14.4%, p=0.66). 
Conclusion Generally, there was no difference in the prevalence of RAMs between 
mono-infected and co-infected patients. Consequently, the presence of HIV co-






The HCV NS3 gene plays a vital role in the replication of the virus by encoding the 
viral protease, which cleaves the HCV polyprotein into the individual components, 
thus allowing the production of infectious virions (Lindenbach and Rice, 2005). The 
role of the HCV NS5A protein has not yet been fully elucidated. Although the 
protein does not have enzymatic activity, it is thought to play a key role in both the 
synthesis of viral RNA and the assembly or secretion of infectious virions (Scheel 
and Rice, 2013). It is known that NS5A can down-regulate the translation of viral 
RNA, through interactions between amino acids and RNA (Hoffman et al., 2015a, 
Hoffman et al., 2015b), and is also responsible for binding to host Cyclophilin A 
(CypA), which is involved in the subcellular distribution of NS5A (Dujardin et al., 
2015). 
 
In recent years, direct acting antivirals (DAAs) have been developed which 
specifically target HCV proteins including NS3 and NS5A. Protease inhibitors (PIs) 
such as telaprevir (now discontinued), boceprevir (soon to be discontinued), 
simeprevir and paritaprevir compete with the polyprotein substrate of the NS3 
protease’s active site, blocking the binding and subsequent cleavage of the 
polyprotein (Raney et al., 2010). NS5A inhibitors such as daclatasvir, ledipasvir and 
ombitasvir display extremely high potency (Guedj et al., 2013). The exact 
mechanism of action of NS5A inhibitors is still unclear although daclatasvir has 
been shown to block hyperphosphorylation of the NS5A protein, which is essential 




Clinical trials exploring the efficacy of PIs and NS5A inhibitors with either 
pegylated-interferon and ribavirin (P/R) or in interferon-free combination regimens 
have observed far greater SVR rates than the previous standard of care combination 
of peg-IFN and RBV (Afdhal et al., 2014b, Forns et al., 2015, Lawitz et al., 2015a). 
The combination of ledipasvir (NS5A inhibitor) and sofosbuvir (NS5B polymerase 
inhibitor), for instance, has lead to SVR rates >90% in both treatment-naïve and 
treatment experienced patients (Afdhal et al., 2014a, Afdhal et al., 2014b). 
 
Combination therapy with multiple DAAs offers an effective treatment regimen, 
although instances of treatment failure have been identified and, in such cases, 
variants harbouring resistance mutations to one or all of the antivirals used during 
therapy have been observed at the time of treatment failure (Black et al., 2015, 
Krishnan et al., 2015c). Through the assessment of the prevalence of variants 
carrying resistance to more than one DAA before the initiation of therapy, the 
influence of the selective pressure exerted by antiviral therapy can be determined. 
 
HCV not only displays great diversity between genotypes and subtypes at the 
population level, but also within an individual infection. The HCV RNA-dependent 
RNA polymerase is extremely error prone and lacks proofreading capacity, 
generating an error rate of approximately 1.2x10-4 to 2.5x10-5 mutations per 
nucleotide per genome replication in vivo (Cuevas et al., 2009, Ribeiro et al., 2012). 
When combined with its high replication rate of 1012 virions per day, every possible 
resistance-associated mutation (RAM) could, in theory, arise multiple times per day 
in an infected host (Rong et al., 2010). As a result, HCV exists in a host as a 
quasispecies – a mixture of related but genetically diverse variants (Martell et al., 
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1992). The replicative fitness of a proportion of the spontaneously generated variants 
will be impaired by the mutation to such a degree that they either die out or persist at 
a low frequency in the quasispecies (Tong et al., 2006, Lenz et al., 2010). In the 
event of the introduction of a selective pressure such as antiviral therapy, such low-
frequency variants acquire a replication advantage, providing the potential to emerge 
as the dominant strains in the quasispecies (Halfon and Sarrazin, 2012). The same 
process has been described for HIV and hepatitis B virus. However, in the case of 
HCV, variants often still retain a sufficient replicative capacity to allow them to exist 
as the dominant strain as single or even double mutants, prior to the introduction of 
selective pressure.  
 
Many of the studies examining the presence of drug resistance associated mutations 
(RAMs) in treatment-naïve HCV-positive individuals have utilised population 
(Sanger) sequencing technology, allowing the detection of variants present at a 
frequency of ≥10-20%. In some studies, naturally occurring drug-resistant variants 
carrying mutations in the NS3 gene have been found by Sanger sequencing to occur 
at prevalences ranging up to 19% in treatment-naïve patients with HCV genotype 
(Gt) 1 (Vicenti et al., 2012). A growing number of studies have also examined the 
NS5A gene and its associated RAMs, and commonly detected mutations in baseline 
samples from antiviral-naïve patients (Plaza et al., 2012, Suzuki et al., 2012, 
Paolucci et al., 2013, McCormick et al., 2015). Naturally occurring RAMs in this 
gene have been observed at prevalences up to 53% in Gt1b patients (Paolucci et al., 
2013), while Gt1a patients generally harbour a lower prevalence of mutations (Plaza 




The relatively high detection threshold of Sanger sequencing means that there is the 
potential for drug resistant variants present at low frequencies in a patient’s sample 
to go undetected. Other methods such as clonal sequencing can detect lower 
frequencies but are costly and labour intensive (Halfon and Locarnini, 2011). 
Recently, next generation sequencing (NGS) has enabled the identification of 
variants at levels undetectable by traditional population sequencing techniques, with 
costs per Mb of data as low as US$0.5 (Loman et al., 2012). This represents a 
relatively affordable technique for the sensitive detection of resistant variants, 
without the increase in labour associated with other methods, although still requiring 
complex bioinformatics for analysis and interpretation. 
 
Co-infection with HIV is relatively common, and from a global perspective an 
estimated 4% of HCV infected patients carrying both viruses (Fernandez-Montero 
and Soriano, 2012). HIV is known to promote HCV replication and accelerate the 
progression of liver fibrosis (Lin et al., 2013). There have been few studies 
comparing the quasispecies complexity and presence of RAMs between HCV mono-
infections and HIV/HCV co-infections and those studies that have performed 
comparisons have found conflicting results (Shuhart et al., 2006, Xu et al., 2012, 
Bartolini et al., 2013, Jabara et al., 2014). Depressed immune function may reduce 
immunological selective pressure and the diversity of the HCV quasispecies in HIV 
co-infected patients. Conversely, the increased replication of HCV observed during 
co-infection with HIV (Eyster et al., 1994, Beld et al., 1998) may be postulated to 
increase the likelihood of mutants emerging, increasing the diversity of circulating 
variants and therefore the risk of a co-infected patient harbouring baseline RAMs to 
DAAs. If this concern was realised, it would add further complications to the 
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treatment of HCV in co-infections and may increase the need for baseline screening 
of patients for resistance substitutions. Reassuringly, to date treatment responses to 
DAA-based therapy have shown to be as high as those seen in HIV-negative 
individuals, with SVR rates exceeding 90% in many studies (Antonini et al., 2015, 
Wyles et al., 2015). 
 
This study aimed to assess the influence of HIV co-infection on the detection of 
RAMs in the NS3 and NS5A genes of HCV in a large cohort of chronically infected 
individuals, naïve to all forms of anti-HCV therapy, and to relate the findings to the 
subjects’ CD4 cell counts. An NGS assay was developed and tested to allow the 
determination of low-frequency variants, thus increasing the sensitivity of 





6.2.1. Preliminary testing of the NGS assay 
To determine the sensitivity of detection of low-frequency resistant variants, mock 
specimens were constructed using two NS3 DNA plasmids. The plasmid encoded a 
2897bp region, encompassing the full length NS3 gene, in a pCR 2.1 vector (Life 
Technologies, Carlsbad, CA, USA). One plasmid was classified as a ‘wild-type’ 
sequence. The other encoded an identical sequence with the addition of 5 RAMs: 
V36A, T54S, V55A, R155K, and A156S. The plasmids were obtained from Andrea 
Rosi at the University of Siena, Italy. The constructed specimens comprised mixtures 
of the wild-type plasmid with the RAM-containing plasmid at frequencies of 1%, 
2%, 5% and 10%. The plasmids were mixed at the appropriate proportions prior to 
amplification using the nested PCR protocol and the NGS protocol detailed in 
Chapter 2. The error rate of the assay was determined by testing four replicates of the 
wild-type plasmid and counting false positive reads (mutations relative to the input 
wild-type sequence) at the codon level over NS3 amino acids 1-181. 
6.2.2. Study population 
The study was performed retrospectively using stored plasma samples from the 
Royal Liverpool Hospital in Liverpool, and King’s College Hospital, Chelsea & 
Westminster Hospital, and Charing Cross Hospital in London (UK); Hospital Carlos 
III in Madrid (Spain) and the University Hospital in Siena (Italy). Specimens were 
collected from treatment-naïve adults with HCV Gt1 infection with or without HIV 
co-infection who were naïve for all forms of anti-HCV therapy and attended for care 
between 2006 and 2013. Overall, 367 samples were tested; 178 HCV mono-infected 
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and 189 HIV/HCV co-infected.  Of the HIV-positive patients, 24/189 (12.7%) were 
ART-naïve. A sub-set of 107 mono-infected samples were matched 1:1 with 107 co-
infected samples by HCV genotype (1a or 1b) and HCV RNA load (±0.1 log10 
IU/ml). 
6.2.3. Next generation sequencing 
Full details of the NGS protocol are given in Chapter 2. Briefly, samples underwent 
nucleic acid extraction using the QIASymphony automated extraction platform 
(Qiagen, Hilden, Germany), and subjected to reverse transcription into cDNA before 
amplification using nested PCR. The amplicons comprised a 727bp region of NS3 
and a 1474bp (Gt1a) or 1378bp (Gt1b) region of NS5A. The NS3 amplicon encoded 
the region from aa180 of NS2 to aa204 of NS3 and did not include the helicase 
domain. The Gt1a NS5A amplicons encoded the entire NS5A gene (aa218 of NS4B 
to aa447 of NS5A); the Gt1b amplicons omitted the final 30 amino acids of the 
NS5A gene (aa218 of NS4B to aa416 of NS5A). The two amplicons for each sample 
were pooled together in equimolar amounts before undergoing library preparation 
using the Nextera XT sample preparation kit (Illumina, San Diego, CA, USA). 
Normalised libraries were sequenced at the Centre for Genomic Research, University 
of Liverpool, UK on an Illumina MiSeq instrument. The NS3 wild-type plasmid (see 
above) was included in each run, which allowed for the checking of cross-
contamination in the downstream analysis. 
6.2.4. NGS data analysis 
Reads trimmed of the adaptor sequences underwent preliminary filtering of poor 
quality reads at the Centre for Genomics Research. The variant-calling pipeline 
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VirVarSeq (Verbist et al., 2015) was used to analyse the samples at the codon level. 
VirVarSeq utilises the quality of the sequencing run to filter poor quality individual 
bases from the reads thereby reducing the false positive rates. Further steps of the 
pipeline employed by VirVarSeq are detailed in chapter 2. BAMStats 
(http://sourceforge.net/projects/bamstats/files/) was used to calculate the read 
statistics.  
 
Nineteen amino acid positions of the NS3 protease gene and nine amino acid 
positions in domain I of the NS5A gene were analysed for the presence of 
substitutions known to cause resistance to DAAs. The positions and RAMs analysed 
are listed in Tables 6.1 and 6.2. Mutations listed on geno2pheno 
(http://hcv.geno2pheno.org/index.php) as ‘resistant’ or ‘possibly resistant’ 
(according to version updated March 2015) were included alongside other mutations 
which have been observed to cause resistance in vitro and/or in vivo in Gt1 infections 
based on published studies. For the purposes of this study, a major RAM was 
defined as any mutation listed as ‘resistant’ on geno2pheno whilst ‘possibly 
resistant’ mutations were considered minor RAMs. RAMs were defined as high-





Table 6.1. Table of resistance associated mutations in NS3. Mutations were 
obtained from geno2pheno and other sources, indicated accordingly. 






36 V A/G/L/M  
41 Q  R 
43 F I/L/S/V  
54 T A/C/G/S  
55 V A I1 
80 Q K G2/H/L2/R 
107 V  I1 
109 R  K2 
117 R  H 
122 S R  
132 Ia/Vb  V3a 
138 S  T 
155 R G/I/K/M/Q/T  
156 A F/G/N/S/T/V  
158 V  I1 
168 D A/E/H/I/N/Q/T/V/Y G 
170 V/I A/T  
174 Na/Sb F Sa 
175 La/Mb  Lb 
 
1 (Barnard et al., 2013) 
2 (Lenz et al., 2010) 
3 (Kieffer et al., 2012) 
a Genotype 1a only 




Table 6.2. Table of resistance associated mutations in NS5A. Mutations were 
obtained from geno2pheno and other sources, indicated accordingly. 






24 K  Ga1/Na1/Ra1 
28 Ma/Lb Aa/T Ab/Ga1/Mb2/Va 
30 Qa/Rb Da/E/H/Ka/Ra Ga1/La1/Ta1 
31 L I/M/Va Fb/Gb3/Vb/Wb3 
32 P L  
38 S  Fa1 
58 Ha/Pb D Pa4/Sb 
92 A Kb Ta1 
93 Y Ca/H/N/S/Ta Fa1 
 
1 (dvory-Sobol et al., 2014) 
2 (Fridell et al., 2010) 
3 (Walker et al., 2014) 
4 (Fridell et al., 2011b) 
a Genotype 1a only 
b Genotype 1b only 
 
The Shannon entropy of each specimen was calculated to assess the complexity of 
the quasispecies. This value represents the number of variants and the evenness of 
their distribution; an increase in the number of variants or unevenness results in a 




The formula used to calculate the Shannon entropy is: 




where pi is the probability of the amino acid at that position in the sequence. The 
Shannon entropy of each specimen was calculated using the output of VirVarSeq. 
The entropy of the NS3 protease region (amino acid 1-181) and NS5A Domains I 
and II (amino acids 1-342) were calculated for each patient using a custom script 
written by Sam Haldenby of the CGR, University of Liverpool. 
6.2.5. Statistical analysis 
Descriptive statistics were used to analyse the prevalence of mutants in the study 
population (as the proportion of subjects showing the mutation) and the frequency of 
mutants in each patient’s sample (as the proportion of deep sequencing reads 
showing the mutation). Fisher’s exact test was used to examine differences between 
groups. The Mann-Whitney U test was used to assess differences in the CD4 cells 
counts and HCV viral load of subjects with vs. those without detectable RAMs. 
Spearman’s rank correlation coefficient was used to assess the association between 
the Shannon entropy and the CD4 cell count or HCV viral load. A p-value of ≤0.05 
was considered significant. Statistical analysis was performed using SPSS version 21 




6.3.1. Preliminary testing of the NGS assay 
To test the sensitivity of the NGS assay for low-frequency variants, mock specimens 
consisting of mixtures of two wild-type and RAM-containing NS3 plasmids were 
tested, where the input of the RAMs-containing plasmid ranged from 1% to 10%. 
The plasmids were sequenced with an average of 233,331 reads (median 224,041; 
interquartile range, IQR 212,148-243,831). In each of the assays, the lowest input of 
the RAMs-containing plasmid was detected consistently. The estimated frequency of 
each RAM in the tested samples was approximately double the input (Table 6.3).  
 
The NS3 wild-type plasmid was used to determine the assay error rate. The average 
error rate was 0.6% (SD ±0.2%) at the amino acid level. As a result, a cut-off value 
of 1% was chosen for analysis, which is also consistent with previous studies 
(Gianella et al., 2011, Dierynck et al., 2014). 
 
The sequences obtained through Sanger sequencing of 115 samples (Chapter 5) were 
compared against the NGS reads to determine the frequency at which traditional 
sequencing fails to detect the variant. All RAMs present at a frequency ≥20% in the 
deep sequencing reads were also detected in the Sanger sequences. Of the 115 
samples, two had a RAM at a frequency >10% and <20%. Both RAMs could also be 
identified in the Sanger sequences. Of the 10 RAMs present at a frequency <10% 
(range 1%-8.7%), none were detected in the Sanger sequences. Consequently, the 




Table 6.3. The identification of low frequency variants in mock specimens comprising mixtures of wild type and resistant HCV NS3 
plasmids 
 Proportion of RAM-containing plasmid 

























V36A 3.4 1.7 2.6 4.1 4.5 4.3 11.0 10.8 10.9 20.8 16.5 18.7 
T54S 2.9 1.5 2.2 3.7 4.2 4.0 10.4 9.9 10.2 19.5 15.6 17.6 
V55A 3.7 1.8 2.8 4.4 5.2 4.8 11.9 11.8 11.9 22.3 18.4 20.4 
R155K 2.9 1.5 2.2 3.7 3.9 3.8 8.8 9.7 9.3 18.7 15.1 16.9 
A156S 3.2 1.5 2.4 3.9 4.3 4.1 9.1 10.3 9.7 19.7 15.9 17.8 
Each mock specimen was constructed according to the column heading i.e. 1% drug resistance contained the plasmid encoding drug resistance 




6.3.2. Study population 
Of the 178 HCV mono-infected samples, 118 (66%) were Gt1a and 60 (34%) Gt1b. 
Of the 189 HIV/HCV co-infected samples, 156 (83%) were Gt1a and 33 (17%) were 
Gt1b. The average (median; IQR) HCV RNA load in mono-infected and co-infected 
samples was 6.1 (6.2; 5.7-6.5) and 6.4 (6.5; 6.1-6.8) log10 IU/ml, respectively. The 
average (median; IQR) CD4 count of HIV-positive individuals was 524 (468; 313-
656) cells/mm3. The subset of samples that were matched for genotype and HCV 
RNA load comprised 80 Gt1a and 27 Gt1b patients from the mono-infected and co-
infected cohorts. Further details are summarised in Table 6.4. 
 
Table 6.4. Characteristics of the matched subset of the study population 













HCV Viral Load (log10 IU/ml), 
median [IQR] 
6.30 [5.94-6.60] 6.33 [5.94-6.60] 
CD4 count (cells/mm3), median 
[IQR] 
NA 455 [276-668] 




6.3.3. Next generation sequencing 
Overall, 365 clinical samples yielded NGS results, with an average of 233,912 reads 
(median 228,482; IQR 179,019-277,616). One Gt1b sample from a HIV/HCV co-
infected subject failed to amplify during the library preparation step. One HCV 
mono-infected sample did not align to either Gt1a or Gt1b reference sequences 
during the analysis and was excluded from further analysis. 
6.3.4. Prevalence of RAMs in NS3 
Nineteen positions in the NS3 gene known to cause a decrease in susceptibility to 
either linear and/or macrocyclic PIs were analysed (Table 6.1). RAMs occurring at 
any frequency ≥1% within the Illumina reads were identified at 14/19 recognised 
resistance sites, and involved NS3 codons 36, 54, 55, 80, 107, 109, 117, 132, 155, 
158, 168, 170, 174, and 175. No RAMs were found at positions 41, 43, 122, 138, and 
156. Gt1a strains displayed a significantly higher prevalence of RAMs (193/274, 
70.4%) compared to Gt1b infections (20/91, 22.0%) (p=0.0001). The difference was 
driven mainly by the high prevalence of Q80K and N174S in Gt1a strains. Whereas 
Gt1a displayed a significantly higher prevalence of Q80K than Gt1b strains 
(p=0.0001), the RAM R117H was observed in a higher proportion of Gt1b patients 
than Gt1a patients (p=0.026) (Table 6.5). 
 
In Gt1a, overall 37/274 (13.5%) subjects showed dual mutants, 10/274 (3.6%) 
subjects displayed triple mutants, and 2/274 (0.7%) displayed quadruple mutants 
(Table 6.6). In Gt1b, 3/91 (3.3%) patients harboured double mutants. No triple or 




When analysing prevalence of RAMs by HIV co-infection status, in Gt1a infections 
71.2% (84/118) of mono-infected patients vs. 69.9% (109/156) of co-infected 
patients displayed ≥1 RAM (p=0.89); in Gt1b infections, prevalence of ≥1 RAM was 
18.6% (11/59) vs. 28.1% (9/32), respectively (p=0.30). Major RAMs were identified 
in 28.0% (33/118) mono- and 28.2% (44/156) co-infected subjects with Gt1a 
infection. In Gt1b infections, 6.8% (4/59) and 9.4% (3/32) of mono- and co-infected 
patients, respectively, harboured a major RAM. 
 
Multiple major RAMs were identified in 2.7% (10/365); 4/118 Gt1a mono-infected, 
1/59 Gt1b mono-infected and 5/156 Gt1a co-infected patients. All of these patients 
harboured two major NS3 RAMs except one Gt1a mono-infected patient who 




Table 6.5. Difference in NS3 RAM prevalence between Gt1a and Gt1b infected 
patients. Subtype-specific RAMs are not included 
RAM Prevalence in Gt1a 
(n=274) 
n (%) 





V36A - 1 (1.1) 0.25 
V36L 4 (1.5) - 0.58 
V36M 6 (2.2) - 0.34 
T54S 7 (2.6) 2 (2.2) 1.00 
V55A 9 (3.3) 1 (1.1) 0.46 
V55I 6 (2.2) - 0.34 
Q80H - 1 (1.1) 0.25 
Q80K 44 (16.1) - 0.0001* 
Q80L 9 (3.3) 1 (1.1) 0.46 
Q80R 3 (1.1) 1 (1.1) 1.00 
V107I 2 (0.7) 3 (3.3) 0.10 
R109K 1 (0.4) - 1.00 
R117H 3 (1.1) 5 (5.5) 0.026* 
R155K 1 (0.4) - 1.00 
V158I - 1 (1.1) 0.25 
D168E 3 (1.1) 2 (2.2) 0.60 
I/V170A 1 (0.4) 1 (1.1) 0.44 
I/V170T 3 (1.1) - 0.58 
N174F - 2 (2.2) 0.06 
* indicates a significant difference (P-value <0.05) between the two subtypes 
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Table 6.6. Prevalence of multiple mutations in the NS3 and NS5A genes 
Mutations HCV Mono-infected HIV/HCV Co-infected 








NS3     
Double 18 (15.3) 2 (3.4) 19 (12.2) 1 (3.1) 
Major 3 (2.5) 1 (1.7) 5 (3.2) - 
Triple 6 (5.1) - 4 (2.6) - 
Major - - - - 
Quadruple 1 (0.8) - 1 (0.6) - 
Major 1 (0.8) - - - 
NS5A     
Double 8 (6.8) 3 (5.1) 5 (3.2) - 
Major 1 (0.8) 1 (1.7) 2 (1.3) - 
Triple 2 (1.7) - 2 (1.3) - 
Major - - - - 
Quadruple - - - - 
Major - - - - 
6.3.5. Prevalence of high-frequency RAMs in NS3 
Overall, high-frequency RAMs were found at 11/19 sites analysed, comprising 36, 
54, 55, 80, 107, 117, 132, 155, 168, 170, and 174. Of 177 HCV mono-infected 
patients, 83 (46.9%) harboured ≥1 RAM at a high frequency compared to 104/188 
(55.3%) co-infected patients (p=0.12). There was no difference in the prevalence of 
RAMs when comparing mono-infected and co-infected patients by HCV Gt1 
subtypes. HCV Gt1a strains showed RAMs in 76/118 (64.4%) mono-infected 
subjects vs. 100/156 (64.1%) co-infected patients (p=1.00) (Figure 6.1); HCV Gt1b 
strains showed prevalences of 7/59 (11.9%) vs. 4/32 (12.5%) respectively (p=1.00) 





Figure 6.1. The prevalence of Gt1a infected patients harbouring resistance 
mutations in the NS3 gene at high frequency (≥10%) and low frequency (≥1% x 
<10%). 
 
Figure 6.2. The prevalence of Gt1b infected patients harbouring resistance 






















































The subtype-specific substitution N174S was the most common mutation observed 
in Gt1a samples from both mono- and co-infected subjects, with a prevalence of 
45.8% (54/118) and 45.5% (71/156), respectively. The polymorphism Q80K was the 
second most prevalent substitution observed in the cohort, with a prevalence of 
19.7% (54/274) in Gt1a and 0% (0/91) in Gt1b samples (p=0.0001). Within HCV 
Gt1a strains, 21/118 (17.8%) HCV mono-infected patients harboured the Q80K 
polymorphism whilst 33/156 (21.2%) HIV/HCV co-infected patients harboured this 
substitution (p=0.54). Excluding the substitutions N174S and Q80K, high frequency 
RAMs were identified in 22/177 (12.4%) mono-infected subjects; 15/118 (12.7%) 
for HCV Gt1a and 7/59 (11.9%) for HCV Gt1b. Of 188 co-infected samples, 20 
(10.6%) harboured a RAM; 16/156 (10.3%) Gt1a and 4/32 (12.5%) Gt1b. Again, 
there was no difference in the prevalence of high-frequency RAMs between mono- 
and co-infected subjects with either Gt1a infection (15/118, 12.7% vs. 16/156, 
10.3%; p=0.57) or Gt1b infection (7/59, 11.9% vs. 4/32, 12.5%; p=1.00). 
 
In Gt1a infections, major RAMs were identified in 27.1% (32/118) and 27.6% 
(43/156) mono- and co-infected patients, respectively (p=1.00). A lower proportion 
of Gt1b patients harboured major RAMs; 3.4% (2/59) mono-infected and 6.3% 
(2/32) co-infected subjects (p=0.61). Patients harbouring dual major RAMs at high 
frequencies were rare, with only 2.5% (3/118) and 1.9% (3/156) of Gt1a mono- and 
co-infected patients showing such resistance profile. No Gt1b patients were 
identified as having multiple major RAMs. 
 
In Gt1a patients, 15/118 (12.7%) and 19/156 (12.2%) of mono-infected and co-
infected patients harboured dual mutants whilst 2/118 (1.7%) and 2/156 (1.3%) 
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patients were identified with triple mutants, respectively. One co-infected Gt1b 
patient was found to harbour two high frequency RAMs in the NS3 gene. 
 
Patients with Gt1a infections displayed a significantly higher prevalence of high-
frequency RAMs (176/274, 64.2%) compared to Gt1b (11/91, 12.1%) (p=0.0001). 
However, excluding the N174S and the Q80K polymorphism, which did not occur in 
Gt1b infections, there was no significant difference between Gt1a and Gt1b in the 
prevalence of other RAMs (31/274, 11.3% vs. 11/91, 12.1%; p=0.85). 
 
Upon comparing the HCV RNA load of patients with and those without a high 
frequency RAM, no difference was found (median [IQR], 6.33 [5.94-6.70] vs. 6.27 
[5.84-6.65] log10 IU/ml, respectively) (p=0.39). 
 
Among HIV/HCV co-infected subjects, prevalence of RAMs was 11/24 (45.8%) in 
ART-naïve subjects ([T54S (n=1), Q80K (n=3) and N174S (n=10)]. There was no 
difference between the prevalence of RAMs in ART-naïve vs. ART-experienced 
patients, when Q80K and N174S were either included (11/24, 45.8% vs. 93/164, 
56.7%; p=0.38) or excluded (1/24, 4.2% vs. 19/164, 11.6%; p=0.48). When RAM 
prevalence was analysed by CD4 cell counts, there was no difference between those 
patients harbouring a RAM vs. those without (p=0.92). The median (IQR) CD4 
count was 464 (301-661) vs. 469 (313-658) cells/mm3 in patients with vs. patients 
without RAMs, respectively. 
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6.3.6. Prevalence of low-frequency RAMs in NS3  
Of the 19 NS3 positions analysed, 12 showed ≥1 low-frequency RAM, occurring at 
positions 36, 54, 80, 107, 109, 117, 132, 158, 168, 170, 174, and 175. No low-
frequency RAMs were observed at positions 41, 43, 55, 122, 138, 155, and 156. 
Among the HCV mono-infected patients, 26/177 (14.7%) harboured ≥1 low-
frequency RAM compared to 18/188 (9.6%) HIV/HCV co-infected patients 
(p=0.15). The detected RAMs are detailed in Figures 6.1 and 6.2. Tables detailing 
the frequencies of RAMs observed can be found in the Appendix. When analysing 
the prevalence of low-frequency RAMs by HIV co-infection status and HCV Gt1a 
subtype, HCV mono-infected patients had a significantly higher prevalence of low- 
frequency RAMs than HIV/HCV co-infected patients: 17.8% (21/118) vs. 8.3% 
(13/156), respectively (p=0.026). This difference was still significant upon the 
exclusion of N174S (14/118, 11.9% vs. 7/156, 4.5%) (p=0.037). Within HCV Gt1b, 
the prevalence of low-frequency RAMs was approximately double in HIV/HCV co-
infected patients (5/32, 15.6%) compared to HCV mono-infected patients (5/59, 
8.5%) although the difference was not significant (p=0.31). As was the case for high 
frequency RAMs, the substitution N174S was also the most commonly observed 
low-frequency RAM present in 5.9% (7/118) mono- and 5.1% (8/156) co-infected 
Gt1a individuals. 
 
Major RAMs were not as prevalent at low frequency as they were at high frequency 
in Gt1a infections; with only 2.5% (3/118) and 1.9% (3/156) of mono- and co-
infected patients harbouring a major RAM, respectively (p=1.00). No difference was 
observed between the prevalence of low-frequency major RAMs in mono and co-
infected subjects (2/59, 3.4% vs. 1/32, 3.1%, p=1.00). Two patients were identified 
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as harbouring dual major RAMs at low frequency; one (0.8%) Gt1a mono-infected 
patient and one (1.7%) Gt1b mono-infected patient. 
 
Dual low frequency mutants were identified in 1/118 (0.8%) mono-infected and 
2/156 (1.3%) co-infected Gt1a patients and 1/59 (1.7%) Gt1b mono-infected patient. 
Of the 44 patients harbouring ≥1 low-frequency RAM, 18 (36.7%) showed also ≥1 
high-frequency RAM. 
 
Upon comparing HCV Gt1 subtypes, 34/274 (12.4%) of Gt1a samples and 10/91 
(11.0%) Gt1b samples harboured ≥1 low-frequency RAM (p=0.85). 
 
There was no difference in the HCV viral load between patients showing a low-
frequency RAM and those not displaying a RAM (median [IQR], 6.29 [6.03-6.71] 
vs. 6.31 [5.90-6.68] log10 IU/ml, respectively) (p=0.60). 
 
Four (16.7%) ART-naïve subjects harboured at least one RAM at a low abundance; 
Q80L (n=1), I132V (n=1), N174S (n=2) and M175L (n=1). This was no different to 
the prevalence of 14/164 (8.5%) observed in ART-experienced patients (p=0.26). 
The prevalence of low-frequency RAMs did not differ by CD4 cell count, with 
medians (IQR) of 397 (273-556) vs. 486 (314-664) cells/mm3 in individuals with vs. 
without RAMs, respectively (p=0.25). 
6.3.7. Detection of NS3 RAMs below the interpretative cut-off of 1% 
The utilisation of a lower interpretative cut-off resulted in 22/177 mono-infected and 
15/188 co-infected samples harbouring a RAM at a level between 0.5% and 1%. In 
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Gt1a individuals, there was no significant difference between mono- (18/118, 
15.3%) and co-infected (14/156, 9.0%) individuals (p=0.13). This was also true of 
Gt1b individuals; 8.5% (5/59) mono-infected vs. 3.1% (1/32) co-infected (p=0.42). 
Further analysis with a lower interpretative cut-off of 0.1% revealed 62.1% of mono-
infected subjects displayed a RAM compared to 69.1% of co-infected individuals. 
As before, there were no significant differences between mono- and co-infected 
patients with Gt1a infection (67.8% vs. 71.8%, p=0.51) or with Gt1b infection 
(50.8% vs. 56.3%, p=0.67). 
6.3.8. Prevalence of RAMs in NS5A  
Nine sites known to harbour RAMs to NS5A inhibitors were analysed (Table 6.2). 
Overall, RAMs occurring at any frequency were observed at 7/9 sites analysed, 
comprising 24, 28, 30, 31, 32, 58, and 93. No RAMs were found at positions 38 and 
92 at any level. The prevalence of RAMs did not differ between HCV mono-infected 
and HIV/HCV co-infected patients with either HCV Gt1a infections (33/118, 28.0% 
vs. 35/156, 22.4%, p=0.32) or Gt1b infections (21/59, 35.6% vs. 9/32, 28.1%, 
p=0.50). Although HCV Gt1b strains displayed a higher prevalence of RAMs than 
Gt1a infections; 30/91 (33.0%) vs. 68/274 (24.8%), respectively, the difference was 
not significant (p=0.14). Overall, in Gt1a infections, double mutants were identified 
in 14/274 (5.1%) patients and triple mutants in 4/274 (1.5%) patients (Table 6.6). 
Quadruple mutants were not identified in any Gt1a infection. In Gt1b infections, 
3/91 (3.3%) patients showed double mutants. Triple or quadruple mutants were not 




Table 6.7. Difference in NS5A RAM prevalence between Gt1a and Gt1b 
infected patients. Subtype-specific RAMs are not included. 
RAM Prevalence in Gt1a 
(n=274) 
n (%) 





M/L28T 4 (1.5) - 0.58 
Q/R30H 6 (2.2) - 0.34 
L31I - 1 (1.1) 0.25 
L31M 6 (2.2) 4 (4.4) 0.27 
L31V 1 (0.4) - 1.00 
P32L - 1 (1.1) 0.25 
Y93H 2 (0.7) 14 (15.4) 0.0001* 
* indicates a significant difference (P-value <0.05) between subtypes 
 
Only one RAM showed a difference in prevalence between the two subtypes (Table 
6.7). There was a significantly higher prevalence of Y93H in Gt1b strains compared 
to Gt1a strains (p=0.0001). 
In Gt1a infections, major RAMs were identified in 11.9% (14/118) mono-infected 
and 8.3% (13/156) co-infected patients. Gt1b infections showed prevalences of 
23.7% (14/59) and 15.6% (5/32) in mono- and co-infection, respectively. Multiple 
major RAMs were rare, with only 1.1% (4/365) of patients harbouring them; 1/118 
Gt1a mono-infected, 1/59 Gt1b mono-infected and 2/156 Gt1a co-infected. 
6.3.9. Prevalence of high-frequency RAMs in NS5A 
Overall, high-frequency RAMs were found at 6/9 sites, comprising codons 24, 28, 
30, 31, 58 and 93. Of 177 mono-infected patients, 31 (17.5%) harboured at least 1 
high frequency RAM whilst 20/188 (10.6%) co-infected patients were identified as 
having ≥1 RAM (p=0.07). Of the Gt1a patients, 18/118 (15.3%) mono-infected 
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patients harboured ≥1 RAM at a high frequency whilst prevalence was 13/156 
(8.3%) in co-infected patients (p=0.085) (Figure 6.3). In Gt1b infected patients, the 
prevalence of high frequency RAMs was 22.0% (13/59) vs. 21.9% (7/32) in mono- 
and co-infected patients, respectively (p=1.00) (Figure 6.4). Tables detailing the 
frequencies of RAMs identified can be found in the Appendix. 
 
 
Figure 6.3. The prevalence of Gt1a infected patients harbouring resistance 
































Figure 6.4. The prevalence of Gt1b infected patients harbouring resistance 
mutations in the NS5A gene at high frequency (≥10%) and low frequency (≥1% 
x <10%). 
 
The most common substitution was M28V in Gt1a patients, observed in 10/118 
(8.5%) mono-infected and 4/156 (2.6%) co-infected patients. In Gt1b patients, Y93H 
was the most common substitution seen in 6/59 (10.2%) and 1/32 (3.1%) mono- and 
co-infected patients, respectively. 
 
Major RAMs were observed in 5.9% (7/118) and 2.6% (4/156) mono- and co-
infected patients infected with Gt1a (p=0.22). In Gt1b infections, 11.9% (7/59) 
mono-infected and 12.5% (4/32) co-infected patients showed a major RAM at high 
frequency (p=1.00). No patients were identified as having multiple major RAMs at 
high frequency. 
 
Gt1b patients showed significantly higher prevalence of high frequency RAMs 


























mutation was not observed at high frequencies in any Gt1a patients in comparison to 
7/91 (7.7%) Gt1b patients. 
 
The HCV viral load did not differ between patients harbouring a high frequency 
RAM (median [IQR], 6.37 [5.90-6.75] log10 IU/ml) and those not showing a high 
frequency RAM (median [IQR], 6.30 [5.92-6.68] log10 IU/ml) (p=0.65). 
 
Among HIV/HCV co-infected subjects, no ART-naïve patient harboured a high 
frequency RAM in the NS5A gene. There was no difference in RAM prevalence 
between ART-naïve vs. ART-experienced patients (0/24, 0% vs. 20/164, 12.2%; 
p=0.081). No difference was found between the CD4 count of HIV-positive patients 
with and without a high frequency RAM (median [IQR], 561 [271-718] vs. 455 
[312-652] cells/mm3) (p=0.60). 
 
In Gt1a infected patients, dual RAMs were identified in 4/118 (3.4%) mono-infected 
and 1/156 (0.6%) co-infected patients. Of Gt1b infected patients, only one mono-
infected patient harboured two mutants. One patient was identified with three high 
frequency RAMs; one Gt1a mono-infected patient. 
6.3.10. Prevalence of low frequency RAMs in NS5A 
Low frequency RAMs were observed at 7/9 positions analysed; 24, 28, 30, 31, 32, 
58, and 93. Of 177 mono-infected patients, 29 (16.4%) harboured ≥1 low frequency 
RAM compared to 27/188 (14.4%) co-infected patients (p=0.66). When analysing 
prevalence of low-frequency RAMs by HIV status and HCV subtype, there was no 
difference between HCV mono-infected and HIV/HCV co-infected patients. In Gt1a 
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infections, 20/118 (16.9%) mono-infected patients showed ≥1 RAM compared to 
25/156 (16.0%) HIV/HCV co-infected subjects (p=0.87) (Figure 6.3). In Gt1b 
infections, 9/59 (15.3%) mono-infected patients vs. 2/32 (6.3%) co-infected patients 
harboured ≥1 low frequency RAM (p=0.32) (Figure 6.4). Tables detailing the 
frequencies of RAMs identified can be found in the Appendix. 
 
Major RAMs present at a low frequency were identified in 6.8% (8/118) and 5.1% 
(8/156) of mono- and co-infected patients, respectively, with Gt1a infection. In Gt1b, 
despite mono-infected subjects displaying a higher prevalence of major RAMs than 
co-infected subjects (8/59, 13.6% vs. 1/32, 3.1%), this difference was not significant 
(p=0.15). 
Two patients were identified with dual major RAMs at low frequencies; both were 
Gt1a co-infected subjects. There was no difference in prevalence of low frequency 
RAMs between Gt1a and Gt1b infected subjects (45/274, 16.4% vs. 11/91, 12.1%, 
respectively) (p=0.40). 
 
No difference in HCV RNA load was observed between patients with vs. those 
without a low frequency RAM (median [IQR], 6.36 [6.02-6.71] vs. 6.27 [5.90-6.68] 
log10 IU/ml, respectively) (p=0.23). 
 
The proportion of ART-naïve patients displaying a low frequency RAM (2/24, 8.3%) 
was not different to that of ART-experienced patients (25/164, 15.2%) (p=0.54). 





Among HIV-positive patients, there was no difference in the CD4 count of patients 
harbouring a low frequency RAM to those who did not harbour one (median [IQR], 
419 [281-550] vs. 474 [312-670] cells/mm3) (p=0.24). 
 
In Gt1a patients, 1/118 (0.8%) and 1/156 (0.6%) were identified as having two low 
frequency RAMs. One (1.7%) Gt1b mono-infected patient harboured two RAMs. 
Two patients, both Gt1a co-infected, were identified with three RAMs present at low 
frequency. Of the 54 patients harbouring a low frequency substitution in NS5A, 9 
(16.7%) also carried ≥1 high frequency mutation. 
6.3.11. Detection of NS5A RAMs below the interpretative cut-off of 1% 
RAMs occurring at a frequency of ≥0.5% and <1% were found in 13.0% and 13.8% 
of mono- and co-infected subjects, respectively. In Gt1a individuals, there was no 
significant difference between mono- (18/118, 15.3%) and co-infected (24/156, 
15.4%) individuals (p=1.00). This was also true of Gt1b individuals, with a 
prevalence of 11.9% (5/59) in mono-infected and 6.3% (2/32) in co-infected patients 
(p=1.00). Mutations at even lower levels of ≥0.1% and <0.5% were present in 34.5% 
in mono-infected subjects and 64.9% in co-infected individuals. In Gt1a, a 
significantly higher proportion of co-infected patients harboured a mutation 
compared to mono-infected subjects; (116/156, 74.4% vs. 50/118, 42.4%, 
respectively) (p=0.0001). No significant difference was found in the prevalence of 
such low-level resistance mutations between mono-infected (11/59, 18.6%) and co-
infected patients (6/32, 18.8%) in Gt1b infections (p=1.00). 
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6.3.12. Prevalence of dual-class NS3/NS5A resistance   
The occurrence of high-frequency RAMs in both NS3 and NS5A was uncommon: 
7.9% (14/177) mono-infected and 5.3% (10/188) co-infected patients harboured such 
dual-class substitutions. Low-frequency RAMs or a combination of high- and low-
frequency RAMs occurring in both genes were present in 10.7% (19/177) mono-
infected and 11.7% (22/188) co-infected patients. Of the 57 patients harbouring 
multiple RAMs, N174S was the only NS3 RAM present in 28 (49.1%) of them. 
6.3.13. Quasispecies complexity of NS3 
Overall, co-infected patients showed a trend towards a higher complexity than mono-
infected patients in the NS3 protease region (median [IQR], 3.10 [2.54-4.34] vs. 2.82 
[2.27-4.17], respectively, p=0.05). 
In Gt1a infections, mono-infected patients showed a median (IQR) complexity of 
2.83 (2.26-4.13) compared to 3.01 (2.46-4.34) of co-infected patients (p=0.11). In 
Gt1b infections, the median (IQR) complexity was 2.80 (2.38-4.34) and 3.44 (2.76-
4.55) in mono- and co-infected patients, respectively (p=0.16). Among HIV-positive 
subjects, the entropy value showed no association with the CD4 count (Spearman’s 
rank=-0.02, p=0.79). There was a weak, positive correlation between the entropy 
values and the HCV viral load (Spearman’s rank=0.26, p=0.0001). 
6.3.14. Quasispecies complexity of NS5A 
Overall, there was no difference in quasispecies complexity between mono-infected 
and co-infected subjects (median [IQR] 7.67 [5.77-11.02] vs. 8.43 [6.20-11.46], 
respectively, p=0.27). As was the case with NS3 complexity, co-infected patients 
showed a non-significant increase in NS5A complexity compared to mono-infected 
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patients when split by subtype. In Gt1a infections, mono-infected subjects showed a 
median (IQR) complexity of 7.41 (5.62-10.12) against 8.30 (6.13-11.15) of co-
infected subjects (p=0.15). In Gt1b infections, the median (IQR) complexity was 
8.57 (5.98-12.53) vs. 9.78 (6.81-12.88) for mono-infected vs. co-infected patients, 
respectively (p=0.60). Shannon entropy values showed a very weak, positive 
correlation with CD4 count (Spearman’s rank=0.08, p=0.27). There was a weak, 
positive correlation between the entropy and the HCV viral load (Spearman’s 
rank=0.25, p=0.0001) 
6.3.15. Prevalence of RAMs and quasispecies complexity in the matched 
subgroup of patients 
A subgroup of samples was matched according to the HCV Gt1 subtype and the 
HCV RNA load to enable a direct comparison to be made between HCV mono-
infected and HIV/HCV co-infected patients. 
In this subset, there was no difference in the prevalence of high-frequency NS3 
RAMs between mono-infected and co-infected subjects in Gt1a (51/80, 63.8% vs. 
53/80, 66.3% p=0.87) or Gt1b (5/27, 18.5% vs. 3/27, 11.1%, p=0.70). However, the 
prevalence of low- frequency RAMs was significantly higher in mono-infected 
patients than co-infected patients in Gt1a (16/80, 20% vs. 3/80, 3.8%, respectively, 
p=0.0025). Again, this significance was still present upon the exclusion of N174S 
(11/80, 13.8% vs. 3/80, 3.8%, p=0.047). In Gt1b strains, there was no difference in 





Upon comparing high frequency RAMs in the NS5A gene of Gt1a infected patients, 
mono-infected subjects showed approximately double the prevalence compared to 
co-infected subjects (14/80, 17.5% vs. 6/80, 7.5%) although this difference did not 
reach statistical significance (p=0.092). Among Gt1b infections, there was no 
difference between mono-infected (6/27, 22.2%) and co-infected (7/27, 25.9%) 
patients (p=1.00). When analysing prevalence of low-frequency RAMs, there was no 
difference between HCV mono-infected and HIV/HCV co-infected patients in either 
subtype. In Gt1a infections, 14/80 (17.5%) mono-infected patients showed ≥1 RAM 
compared to 16/80 (20.0%) HIV/HCV co-infected subjects (p=0.84). In Gt1b 
infections, mono-infected patients displayed double the prevalence of low-frequency 
RAMs compared to co-infected patients (5/27, 18.5% vs. 2/27, 7.4%) although the 
difference was not significant (p=0.42). 
 
In the matched subset of patients, there was no difference in NS3 quasispecies 
complexity between mono- and co-infected subjects (median [IQR] 3.05 [2.43-4.31] 
vs. 2.93 [2.50-4.39], respectively, p=0.84). Difference in NS3 complexity in mono-
infected patients vs. co-infected patients did not reach statistical significance for 
either Gt1a (median [IQR] 3.08 [2.34-4.31] vs. 2.80 [2.25-4.39]) (p=0.68) or Gt1b 
(median [IQR] 2.84 [2.48-4.41]) vs. 3.42 [2.74-4.67] (p=0.32). Similarly, NS5A 
complexity in co-infected patients (median [IQR] 8.08 [6.06-11.41]) was not 
different from that of mono-infected patients (8.58 [5.95-12.38]), (p=0.65). In Gt1a 
strains, the median (IQR) complexity was 8.57 (5.93-10.94) vs. 7.66 (5.96-11.00) in 
mono-infected vs. co-infected patients (p=0.52). The median (IQR) in Gt1b strains 
was 9.83 (6.08-14.05) vs. 9.58 (6.77-13.10) in mono-infected vs. co-infected 




In this large cross-sectional cohort study of HCV mono-infected and HIV/HCV co-
infected patients, we determined the prevalence of recognised HCV RAMs in HCV 
treatment-naïve patients using an NGS approach. This is the largest study to date to 
use NGS technology to determine the impact of HIV on the natural prevalence of 
HCV RAMs in two key genes. Overall, RAMs were relatively common in both NS3 
and NS5A, occurring in 58.4% and 26.8% of patients, respectively. Multiple NS3 
RAMs were seen in 14.2% while multiple NS5A RAMs were observed in 5.8%. 
Major RAMs were seen in approximately half of patients harbouring ≥1 RAM. It 
was observed that, generally, there was no significant difference in the prevalence of 
high or low frequency RAMs between HIV/HCV co-infected patients and HCV 
mono-infected patients. Viral load and CD4 count did not differ between those 
patients with and those patients without a RAM. 
 
During the preliminary testing of the NGS protocol, the frequency of the RAMs in 
the RAM-containing plasmid was estimated at double the input. This may reflect 
preferential amplification, which is known to account for a skew in the frequency 
measurement of HIV variants, typically by 2- to 15-fold (Jabara et al., 2011). 
However, the wild-type and RAMs-containing plasmids did not differ in nucleotides 
within the primer binding region, which is believed to account for the skew during 
PCR (Kanagawa, 2003). One alternative explanation lies with the 
underquantification of the plasmids prior to NGS, which may have lead to an 
increase in the input of the RAMs-containing plasmid. It is nevertheless important to 
emphasise that the assay was still able to detect variants present at low frequencies. 
The average error rate of the assay was determined as 0.6% at the codon level. This 
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is consistent with the recommended threshold of 1% used in previous studies 
examining HIV variants (Gianella et al., 2011). A threshold of 1% provides a useful 
cut-off for two main reasons: i) levels below this fall into the error rate of the assay 
and, as such, variants may be artefacts and ii) true variants at ultra-low levels <1% 
may have no biological significance in the treatment of HCV (Akuta et al., 2014a, 
Akuta et al., 2014b, Murakami et al., 2014). 
 
The VirVarSeq pipeline used for the analysis of the deep sequencing reads in this 
study has previously been validated for the detection of minority variants present at 
frequencies as low as 0.5% in a population (Verbist et al., 2015). The pipeline also 
includes the production of a consensus sequence of the sample in question, to which 
sequencing reads can be subsequently mapped (Verbist et al., 2015). This procedure 
increases the coverage in samples which differ from the reference sequence, thus 
greatly reducing the likelihood of false negative results. These features make this 
pipeline a suitable tool for the analysis of the deep sequencing reads in the present 
study. Furthermore, the reporting of variants at a codon level makes VirVarSeq 
suitable for a high-throughput clinical setting, where the immediate detection of drug 
resistance would be important. 
 
NS3 RAMs were relatively common in both mono- and co-infected patients, with 
58.4% of patients showing ≥1 RAM at a frequency ≥1%. One of the most common 
RAMs observed in NS3 was Q80K, which, as discussed in the previous chapter, 
confers an ~8 fold change (FC) in resistance to simeprevir in vitro and also reduces 
responses to simeprevir treatment (Lenz et al., 2010, Forns et al., 2014, Jacobson et 
al., 2014, Manns et al., 2014). The N174S substitution was highly prevalent in HCV 
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Gt1a strains, occurring in 51.1% of patients. This finding is consistent with previous 
studies (Vallet et al., 2011, Paolucci et al., 2012). N174S is a minor RAM and 
believed to play an accessory role in drug resistance. It has been observed as an 
emerging mutation at the time of treatment failure in a small minority of patients 
failing treatment with simeprevir plus P/R, but only in combination with a mutation 
at positions 80, 155 and/or 168 (Lenz et al., 2015). 
 
Major RAMs were observed at a prevalence of 23.0% in our cohort. The mutation 
R155K, conferring a 30- and 37-FC in resistance to simeprevir (Lenz et al., 2010) 
and paritaprevir (Pilot-Matias et al., 2015), respectively, was only observed in one 
patient at a high frequency. The RAM D168E was identified in five patients; three of 
which harboured it at high frequency. This mutation decreases susceptibility to 
simeprevir and paritaprevir by 40- and 14-FC in vitro (Lenz et al., 2010, Pilot-Matias 
et al., 2015). Both of these RAMs have been observed at treatment failure with 
paritaprevir, ombitasvir and dasabuvir combination therapy (Krishnan et al., 2015c). 
RAMs at positions 36(A/L/M), 54(S) and 55(A/I) were more commonly seen 
mutations in patients, with 7.7% of patients harbouring at least one of these RAMs. 
Decreases in susceptibility to simeprevir and paritaprevir are no higher than 3-fold in 
vitro in any of these mutations (Lenz et al., 2010, Pilot-Matias et al., 2015). Several 
mutations at position 156 are known to confer high levels of resistance to current PIs 
in vitro, although none were observed in this study. 
 
Upon excluding the Q80K and N174S polymorphisms, the overall prevalence of 
high-frequency NS3 RAMs (11.5%) lies somewhere between the range of 
prevalences seen in other studies using traditional population sequencing (Bartels et 
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al., 2008, Kuntzen et al., 2008, Paolucci et al., 2012, Vicenti et al., 2012, Palanisamy 
et al., 2013). One reason for the higher prevalence seen here than in some of the 
other studies (Bartels et al., 2008, Kuntzen et al., 2008, Paolucci et al., 2012) is 
probably due to a larger number of sites associated with resistance being studied 
relative to these earlier studies. The study population is also likely to account for 
differences. In a recent study, the prevalences of NS5A RAMs were seen to differ 
between populations from different countries (Svarovskaia et al., 2015). 
 
RAMs were found at seven of the nine key sites associated with resistance in domain 
I of NS5A, with positions 38 and 92 showing no mutations at frequencies ≥1%. 
Overall, 26.8% of patients harboured a RAM in the NS5A gene. The M28V 
mutation was the most common substitution observed at both high and low 
frequencies. This RAM only occurs in Gt1a strains, and confers low-level (1.3FC) 
resistance to daclatasvir and a 58-fold reduced susceptibility to ombitasvir in vitro 
(Fridell et al., 2011b, Krishnan et al., 2015a). M28V has been observed as a variant 
present at the point of virological failure in a study of paritaprevir, ombitasvir and 
dasabuvir, either as the sole RAM or in combination with RAMs in other genes 
(Krishnan et al., 2015c). Y93H confers resistance to daclatasvir, ledipasvir and 
ombitasvir – all three NS5A inhibitors currently licensed for clinical use. The 
mutation causes a more dramatic reduction in susceptibility to the inhibitors in Gt1a 
strains, ranging from 1,677-FC to 41,383-FC compared to Gt1b, where the highest 
FC is 77 (Fridell et al., 2011b, Wong et al., 2013, Krishnan et al., 2015a). Y93H has 
also been observed in cases of virological failure in both Gt1a and Gt1b patients 
upon treatment with daclatasvir with P/R or in combination with asunaprevir (Suzuki 
et al., 2013, Hezode et al., 2015, Kosaka et al., 2015). Another Gt1a-specific RAM, 
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Q30R, was seen at a prevalence of 3.3%. This confers a high-level of resistance to all 
three NS5A inhibitors (range 632-FC to 1227-FC in susceptibility) (Fridell et al., 
2011b, Wong et al., 2013, Krishnan et al., 2015a) and has also been observed in 
cases of virological failure during treatment with paritaprevir, ombitasvir and 
dasabuvir (Krishnan et al., 2015c). The Gt1a-specific K24R mutation, which confers 
low-level resistance to ledipasvir in vitro and has also been identified in treatment 
failures, was also relatively common being observed in 5.8% of Gt1a patients 
(dvory-Sobol et al., 2014, dvory-Sobol et al., 2015). 
 
Previous studies using deep sequencing to study low-frequency RAMs in HCV 
infection have shown a large degree of variation in prevalences observed. However, 
the comparison of results is confounded by two factors; i) the difference in RAMs 
examined and ii) the differences in cut-off values used for the identification of 
minority variants. Through the examination of more sites associated with resistance, 
the likelihood of a patient harbouring a RAM increases. Our study examines nearly 
double the number of sites than that of a previous study (Dierynck et al., 2014) and 
thus contributes to the difference in prevalence observed. However, the additional 
RAMs observed confer only minor resistance to PIs. If only the same substitutions 
were examined, the overall prevalence of low frequency NS3 RAMs in our study 
would decrease from 13.4% to 4.9%; a value much closer to the prevalence of 3.8% 
observed in the aforementioned study (Dierynck et al., 2014). The field of resistance 
to DAAs is evolving rapidly as more drugs are licensed and more studies, both in 
vitro and in vivo, are performed to identify sites associated with resistance. This adds 




Jabara et al., (2014) observed that 98% of 40 patients carried at least 1 low-
frequency RAM using an interpretative cut-off value of 0.08% whilst another study 
observed a low-frequency RAM (<20%) prevalence of 33% (n=28) when using a 
cut-off value of 0.35% (Bartolini et al., 2013). However, in a larger study of baseline 
samples (n=185) using a cut-off value of 1%, it was found that only 3.8% of patients 
harboured a low-frequency RAM, not detected by Sanger sequencing (Dierynck et 
al., 2014). Our observation of 13.4% of patients harbouring a low-frequency NS3 
RAM, using a 1% cut-off value, lies somewhere between two of the studies. All of 
the samples in our study were from patients naïve to all forms of anti-HCV therapy, 
meaning that none of the variants observed are expected to be a result of selection by 
previous treatment. Previous studies indicated that the majority of low-frequency 
RAMs observed existed at frequencies of below 1%. This is in concordance with our 
study, where applying lower interpretative cut-off values of 0.5% and 0.1% 
increased the proportion of samples showing ≥1 RAM. It should be noted that the 
ultra-low frequency (<1%) variants observed fell within the error rate of the assay, 
which makes the significance of such mutations doubtful. These variants are likely to 
be technical artefacts as a result of misincorporation during reverse transcription, 
PCR stages or a false call by the sequencing platform. NS5A variants present at a 
frequency between 0.1% and 0.5% were present in a significantly higher proportion 
of co-infected subjects than mono-infected patients. If the variants were truly 
artefacts, then one would expect a similar proportion in each of the two groups. 
Immunosuppression and a reduced ability to clear the virus in these co-infected 
patients may contribute to this difference. Nevertheless, substitutions at such low 
levels are not expected to impact on the treatment outcome (Akuta et al., 2014a, 
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Akuta et al., 2014b, Murakami et al., 2014) meaning that this association with co-
infected patients should not affect the risk of virological failure. 
 
Our study observed a significant difference between the presence of high frequency 
NS3 RAMs in Gt1a and Gt1b infections although this was due to the Gt1a-specific 
N174S mutation and the Q80K substitution. Whilst there was still a modest increase 
in the presence of high-frequency RAMs in Gt1a when these polymorphisms were 
excluded, the significance was lost. There was also no significant difference between 
subtypes upon the comparison of low frequency RAMs. This observation is in 
concordance with a previous study, which also used NGS to determine the 
differences in RAM frequencies between the two subtypes of Gt1 (Margeridon-
Thermet et al., 2014). Apart from Q80K, the only other NS3 mutation with a 
significant difference in prevalence between the two subtypes was R117H. This was 
seen in more Gt1b patients than Gt1a (5.5% vs. 1.1%, respectively). This is a minor 
RAM, seen at long-term follow-up in a very limited number of patients (n=2) treated 
with telaprevir (Susser et al., 2012). 
 
In comparison to the NS3 protease, the prevalence of patients with a high frequency 
RAM in NS5A was significantly higher in Gt1b patients than in Gt1a patients. This 
is in concordance with previous studies which observed the same association in 
smaller cohorts using population sequencing (Plaza et al., 2012, Paolucci et al., 
2013). One of these studies observed a prevalence of 12.5% in Gt1a patients (n=32) 
compared to 53.3% of Gt1b patients (n=30) harbouring a RAM (Paolucci et al., 
2013). In this study, only one NS5A resistance mutation had a significantly different 
prevalence between the two subtypes. Y93H was detected in a significantly higher 
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proportion of Gt1b samples compared to Gt1a samples (15.4% vs. 0.7%), an 
association which has previously been observed (Plaza et al., 2012, Paolucci et al., 
2013). 
 
Despite this apparent increase in the prevalence of NS5A RAMs, clinical trials have 
observed a higher SVR rate in Gt1b patients over Gt1a patients, when treated with 
NS5A inhibitor daclatasvir and P/R (Hezode et al., 2015). One possible explanation 
is that the mutations only confer a low-level resistance to inhibitors whilst having a 
reduced replicative capacity and as such can be overcome by the dose of DAA 
administered. Plaza et al., (2012) previously described no mutations being found in 
Gt1a samples from both their cohort and the Los Alamos database (n=189). This is a 
stark contrast to our study which found 11.3% of Gt1a patients harboured a RAM at 
levels ≥10%. This difference between subtypes was lost when observing the 
presence of low-frequency RAMs, with 16.4% and 12.1% of Gt1a and Gt1b patients, 
respectively, harbouring a low-frequency mutation(s). The differences between 
subtypes are likely due to a combination of factors, one such being the genetic 
barrier to resistance, which is used to describe the challenge of a virus acquiring 
specific mutations (Gotte, 2012). The lower the genetic barrier, the easier it is for a 
mutation to arise and different subtypes can display different genetic barriers at the 
same position. This is displayed at position 155 of the NS3 gene. In Gt1a, a single 
transition event (AGG to AAG) is required to substitute arginine for lysine. In 
comparison, a higher genetic barrier is present in Gt1b at the same position, where 
both a transition and a transversion (CGG to AAG) are required for the amino acid 
substitution. In this study, the V36M mutation in NS3 was observed at a higher 
prevalence in Gt1a than Gt1b (2.2% vs. 0%), although not significant. The genetic 
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barrier is lower in Gt1a requiring one transition compared to one transition and one 
transversion for Gt1b strains (Bartels et al., 2013). The NS5A mutation Q30H was 
also observed at varying proportions in each subtype (Gt1a, 2.2% vs. Gt1b, 0%). 
This pattern also follows the genetic barrier with one transversion required in Gt1a 
but one transition and one transversion necessary for the same mutation in Gt1b 
(Bartels et al., 2013). Such genetic barriers also play an important role in 
combination therapy. Through increasing the potency and number of DAAs used in 
treatment, the number of mutation events to confer resistance to the regimen is also 
raised (Gotte, 2012). 
 
Treating co-infected individuals is more problematic due to possible drug-drug 
interactions between DAAs and ART. Therefore, the fewer resistance mutations are 
present, the wider the choice of possible drugs to use. There have been surprisingly 
few studies using NGS to examine the effect HIV co-infection has upon the presence 
of RAMs compared to mono-infected  patients (Bartolini et al., 2013, Jabara et al., 
2014), given the high rate of co-infection in some cohorts (Garten et al., 2004). Both 
of the aforementioned studies found no difference in the presence of NS3 RAMs 
between mono-infected and co-infected patients, although both studied only a 
limited number of patients (28 and 40, respectively). The co-infected patients were 
on ART in both studies with similar median CD4 counts of approximately 
500cells/mm3, a value similar to our study. The cut-off values used were lower than 
that used in this study, at 0.35% and 0.08%. 
 
When analysed by HCV Gt1 subtype, mono- and co-infected subjects showed a 
similar prevalence of high-frequency RAMs in the NS3 gene. Upon analysing the 
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presence of low-frequency NS3 RAMs in Gt1a patients, mono-infected patients 
displayed a significantly higher prevalence compared to co-infected subjects. The 
only instance of co-infected subjects displaying a higher prevalence of RAMs than 
mono-infected patients was the determination of low frequency NS3 RAMs in Gt1b 
infected patients; where the prevalence was approximately double that of mono-
infected patients although this did not reach statistical significance. The latter two 
observations are in contrast to the findings of the two previous studies, which found 
no difference in NS3 RAM frequency between mono- and co-infected subjects using 
ultra deep pyrosequencing (Bartolini et al., 2013, Jabara et al., 2014). Regardless of 
the subtype, there was either no difference or mono-infected patients displayed a 
higher prevalence of RAMs in NS5A than co-infected patients, although in these 
cases, the difference did not reach statistical significance. 
 
In the subset of patients matched by HCV RNA load, the differences between mono-
infected and co-infected patients reflected those already seen in the whole cohort. 
The only difference was in low frequency NS3 RAMs in Gt1b infected subjects. 
Whereas co-infected patients displayed double the prevalence compared to mono-
infected patients when studying the whole cohort, there was no difference between 
the two groups in the matched subset. These observations that HIV/HCV co-infected 
patients are generally not at an increased risk of harbouring a drug resistant variant at 
either high or low frequency suggests that drug resistance should not present a 
greater challenge to treat co-infected individuals. 
In this chapter, multiple hypotheses were tested on the same set of data, with a p-
value ≤0.05 considered as significant and the null hypothesis being rejected. 
However, as more hypotheses are tested on the same set of data, the chance of 
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observing a significant result, and therefore a Type I error, increases (Bland and 
Altman, 1995). The Bonferroni correction method can be employed to counteract 
this problem, which, using the number of hypotheses being tested, lowers the p-value 
at which a result would be considered significant [Bland & Altman, 1995]. 
 
In this study, we determined the Shannon entropy of patients; a measure of 
complexity indicating the number of variants and evenness of their distribution in a 
population. In the whole cohort, it was observed that co-infected patients had a 
higher complexity than mono-infected patients, although this difference rarely 
reached statistical significance. This may partly be due to the HCV RNA load of the 
samples. The viral load had a weak, positive correlation with the entropy values and 
HIV-positive individuals had slightly elevated viral loads over mono-infected 
patients. The combination of these two factors is likely to play a role in the 
difference between mono- and co-infected patients. The correlation between viral 
load and quasispecies complexity may, at least in part, be technical. As the viral load 
increases, so does the likelihood of sampling a variant, contributing to a higher 
complexity. We attempted to reduce the influence of the HCV RNA load on the 
technical aspects of testing by matching a subset of sample by the HCV RNA load. 
In this group, the opposite was found, with co-infected patients generally displaying 
lower complexity than mono-infected patients. This is in concordance with a 
previous study employing deep sequencing to examine quasispecies complexity in 
the NS3 gene (Jabara et al., 2014). 
 
Other studies examining different regions of the genome have also found a decreased 
complexity among co-infected patients, although most of these studies have used 
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small cohorts (Shuhart et al., 2006, Lopez-Labrador et al., 2007). Shuhart et al., 
(2006) studied the E2-HVR region of the HCV genome, finding that HIV-positive, 
ART-naïve subjects displayed a significantly lower quasispecies complexity than 
both HIV-positive patients receiving ART and HIV-negative individuals. The CD4 
count also impacted upon the quasispecies, with an increase in the complexity upon 
the doubling of the CD4 count (Shuhart et al., 2006), suggesting that the immune 
system does play a role in driving evolution and diversity in the quasispecies. Upon 
comparison of HIV-negative and HIV-positive subjects receiving ART, no 
difference in the complexity of quasispecies was observed (Shuhart et al., 2006). 
Another study of the HVR-1 region also observed a non-significant decrease in 
quasispecies complexity in co-infected patients compared to mono-infections 
(Lopez-Labrador et al., 2007). In contrast, another study found an increased 
complexity in the core gene in HIV/HCV co-infected patients with low (<350 
cells/µl) CD4 count compared to HCV mono-infected patients and co-infected 
patients with normal (>400 cells/µl) CD4 count (Xu et al., 2012). 
 
The conflicting results between studies may be a consequence of the different genes 
examined and the pressure that each is subjected to from the immune system. The 
HVR region is subject to strong selection pressures and thus has a high mutation rate 
which aids its escape from the immune system (Kato et al., 1994, van Doorn et al., 
1995). Therefore, in an environment with a diminished pressure such as an 
immunocompromised patient, it may be expected that co-infected individuals exhibit 




A decrease in RAM prevalence and quasispecies complexity in co-infections may be 
because the patient’s immune system is a selective force behind the emergence of 
mutations. Hence, during HIV infection, a compromised immune system would not 
present as much of a challenge to the virus, decreasing the number of different 
circulating variants. On the other hand, it is known that co-infection with HIV 
increases HCV replication (and HCV RNA load) compared to mono-infections 
(Neukam et al., 2012). This increase in viral load may increase the likelihood of a 
drug resistant variant or other mutation arising and existing as a minority variant or, 
if replicative fitness is high enough, the dominant variant. This can be seen in the 
difference in the prevalence of NS3 low frequency RAMs between the whole cohort 
and matched subset of Gt1b patients. In the matched subset, the elimination of the 
elevated viral load in the HIV-positive cohort lead to a reduction in RAMs to a 
prevalence equal to that of mono-infected patients. The diminished capability of the 
immune system in HIV infection may also contribute to an increase in RAMs and 
complexity through its reduced capacity to clear minority variants. 
 
In both NS3 and NS5A, although ART-experienced patients tended to display higher 
RAM prevalences than ART-naïve patients, the differences never reached 
significance, although this is probably due to the small number (n=24) of ART-naïve 
patients tested. Further studies are required to confirm this association. If the 
difference between the two groups is true, then it may be a consequence of the 
impact of ART on the function of the immune system through restoration of CD4 
cells, which may produce an evolutionary pressure on HCV. Some sites associated 
with resistance such as Q80 and R155 in NS3 are known to exist in epitopes exposed 
to the immune system and restricted by certain HLA types (Ward et al., 2002, Lauer 
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et al., 2004). This may provide sufficient pressure for resistant variants to dominate 
in the quasispecies, as the wild-type virus diminishes. One piece of contrasting 
evidence to this hypothesis is that we did not observe any difference between the 
CD4 cell counts of patients with and without RAMs at high or low frequency in 
either gene. In addition, there was only a very weak association between the CD4 
count and Shannon entropy value. If CD4 cells were involved in selective pressure at 
these sites of resistance or in the overall complexity, then one would expect a higher 
CD4 count in the patients harbouring a RAM and a positive correlation between the 
CD4 count and the complexity. A previous case report of a co-infected patient found 
a dominant R155K in the NS3 gene of a co-infected patient (Kim et al., 2009). 
Following the re-initiation of ART the virus eventually reverted to the wild-type 
variant. This does not support the hypothesis that the immune system drives 
selection for drug resistance, as the reconstitution of the immune system eventually 
lead to the wild-type virus becoming dominant. This may be because an improved 
immune function actually aids in the clearance of resistant variants with an impaired 
replicative capacity. Of course, this reversion may also be a natural fluctuation in the 
levels of variants. 
 
The impact of low frequency HCV variants on the outcome of treatment is largely 
unknown and has only been studied in small numbers of patients with pre-existing 
RAMs at baseline (Fevery et al., 2015). While it has been observed that the presence 
of PI-resistant variants at baseline may have negatively affected the response to 
therapy (Lenz et al., 2012), there is also evidence to suggest that low level pre-
existing drug resistant variants are not selected for upon the initiation of treatment 
(Fevery et al., 2015). In one study, all four patients identified with minority (<20%) 
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RAMs at baseline achieved SVR when treated with simeprevir plus sofosbuvir 
(Fevery et al., 2015). Another study identified minority variants present at baseline 
which became dominant variants at the time of treatment failure in two patients who 
failed PI triple therapy (Larrat et al., 2015). In a trial of ledipasvir and sofosbuvir 
therapy, only one of the eight patients who did not achieve SVR harboured only one 
NS5A minority variant at baseline (Sarrazin et al., 2015a). Minority NS5A variants 
present at baseline during treatment with grazoprevir and elbasvir were consistent 
with the variants detected at the time of treatment failure in patients who did not 
achieve SVR (Black et al., 2015). 
It is important to note that there were only a small number of patients with pre-
existing RAMs at baseline in these studies, making it difficult to draw firm 
conclusions without the addition of more data. 
 
NGS may still be useful in clinic. The use of NGS at early stages of treatment may 
aid clinicians in the detection of resistant variants starting to outgrow the wild-type 
and help to dictate the treatment options before the establishment of such variants. 
NGS also enables the quantification of variants which may aid in the determination 
of the impact of variants, guiding therapeutic decisions in the future. The threshold 
of variants which have an influence on therapy needs to be determined. Although the 
cost of NGS has reduced dramatically in recent years, the use of deep sequencing for 
the detection of low frequency variants in clinic remains limited. The initial outlay 
for a sequencing platform alongside the large amount of generated data which needs 
to be analysed present challenges which need to be overcome. If pre-existing 
mutations do not affect the outcome of treatment, as suggested above, then the 
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introduction of NGS into the clinical setting to screen baseline samples would be 
costly in return for very few benefits. 
 
Regimens of multiple DAAs, each targeting a different region of the HCV genome 
have been explored to treat chronic HCV infections in both treatment-naïve patients 
and null responders to previous therapy and are now in clinical use (Afdhal et al., 
2014a, Afdhal et al., 2014b, Feld et al., 2014). As more DAAs are licensed for 
clinical use, such combination therapies are likely to become more commonplace. 
Consequently, variants conferring resistance to multiple inhibitors may be of clinical 
significance. Although no currently licensed combination therapies comprise only a 
PI and NS5A inhibitor, one does combine a PI (paritaprevir), NS5A inhibitor 
(ombitasvir) and polymerase inhibitor (dasabuvir). In this study, we identified 6.6% 
of patients harbouring a high-frequency RAM in both the NS3 and NS5A gene. In 
29.2% (7/24) of these patients, the combination of mutations detected conferred 
resistance to both the PI (paritaprevir) and NS5A inhibitor (ombitasvir). Variants 
conferring resistance in both genes at low frequencies or a mixture of high and low 
frequencies occurred in 11.2% of patients. However, due to the sequencing protocol, 
it is not possible to determine whether the RAMs are circulating in the same or 
different variants. If multiple variants are responsible for the RAMs, then a 
combination of inhibitors may still be effective as a variant carrying a resistance 
mutation in NS3 will be susceptible to an NS5A inhibitor and vice versa. Resistance 
has been observed in clinical trials of combination therapies utilising DAAs targeting 
multiple HCV regions, leading to virological failure in some patients (Krishnan et 
al., 2015c, Lenz et al., 2015). However, using chimeric mice, another study observed 
no resistance or viral breakthrough when higher concentrations of PI and NS5A 
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inhibitor were combined (Shi et al., 2013). The use of optimum concentrations of 
DAAs may aid in the prevention of viral breakthrough, even when resistance 
mutations are present in more than one gene. 
 
In conclusion, this study provides a large amount of data on the prevalence of high- 
and low-frequency resistant variants in HCV infected patients naïve to all anti-HCV 
therapy. Our results, from the largest comparison of HCV mono-infected and 
HIV/HCV co-infected patients using NGS to date, suggest that the prevalence of 
both low- and high-frequency RAMs is similar in mono- and co-infected patients 
before the initiation of therapy. Consequently, the presence of an HIV co-infection 
should not affect treatment using DAAs. We have reduced the number of variables 
as much as possible by eliminating confounding factors such as co-infection with 
HBV, restricting the genotypes tested and, for a subset of samples, matching samples 
by viral load. Through doing so, we are able to draw a firmer conclusion of the 












7. General Discussion 
 
The overall aim of this thesis was to investigate HCV genetic variation, both in terms 
of molecular epidemiology at the population level and the occurrence of resistance 
mutations that may impact of the effectiveness of direct-acting antiviral agents 
(DAAs) in individuals, and the influence of HIV co-infection on the findings. The 
study populations included patients from Ghana and the UK. 
 
There is a scarcity of data concerning the epidemiology of HCV infection in sub-
Saharan Africa and available studies have often reported unconfirmed data. The 
investigation therefore aimed first of all to determine the prevalence of HCV 
infection in patients receiving routine HIV care in Ghana, and through this assess the 
appropriate modalities for HCV screening in such settings, which could contain cost 
whilst remaining sensitive and specific.  
The results are noteworthy on several accounts. Previous work from our research 
group demonstrated that gold-standard HCV antibody screening tests overestimate 
the true prevalence of HCV infection in this population likely due to false positivity, 
and that a number of strategies could be employed to improve specificity (King et 
al., 2015). Despite screening a large number of subjects for HCV RNA, the 
prevalence of HCV infection in the Ghana cohort was lower than 1% overall, and 
well below previous estimates based on standard HCV antibody screening assays.  
Indeed, HCV prevalence among the HIV co-infected patients was no higher than that 
previously reported for blood donors in the same region (Candotti et al., 2003). The 
prevention of transmission should complement the effort to diagnose and treat active 
HCV infections. In order to do this, and also in order to optimise the design of 
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targeted screening protocols, large surveys are required to identify the major risk 
factors of acquiring HCV in resource-limited settings. Blood transfusion and surgical 
procedures were identified as the risk factors from the limited number of HCV-
positive patients determined in our study. Other studies suggest that risk factors for 
HCV infection in the general population of Ghana include a history of medical 
interventions (e.g., transfusions) and traditional practices (e.g., scarification), 
particularly in the northern regions of Ghana (Layden et al., 2015). Measures such as 
the proper sterilisation of surgical instruments and the appropriate screening of blood 
donations are increasingly adopted in Ghana and will greatly reduce the spread of 
HCV and prevent new infections. Screening of blood donations for infectious 
diseases has previously been multiplexed, allowing the simultaneous detection of 
HIV, HBV and HCV (Ohnuma et al., 2001). This process would also be 
advantageous in regions such as Ghana where HIV and HBV are relatively common.  
 
Larger studies should seek to investigate risk factors for HCV infection in the 
HIV/HCV co-infected population, and to confirm whether co-infection with HBV is 
indeed associated with higher prevalence of HCV, as our prevalence data seemed to 
suggest. This is important, as co-existence of HCV and HBV infection would put 
patients with HIV at a very high risk of liver disease in a setting where both 
ascertainment and management options for viral hepatitis are very limited at present 
(Lemoine et al., 2015).  
 
There were other important observations made in the Ghana cohort. In order to gain 
an accurate representation of the burden of HCV infection, there is a necessity for 
the utilisation of techniques that allow detection of HCV RNA. Unfortunately, the 
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restricted access to the necessary infrastructure and high cost limit availability in low 
income countries. Studies are required to investigate the applicability of immune 
assays for HCV antigen detection. Alternatively, the use of centralised testing 
facilities along with specimen pooling techniques demonstrated in this study could 
be used to address these problems. From a practical perspective, the study 
demonstrated the feasibility of performing large molecular epidemiology studies 
using dried plasma spots (DPS). This is helpful where molecular testing may only be 
available in centralised facilities: the use of DPS circumvents the requirement for 
stringent storage and transport conditions, without affecting the ability to detect 
HCV RNA in untreated patients, and the ability to recover virus suitable for 
sequencing.   
 
Among the HCV positive subjects from the Ghana cohort, viral genetic diversity was 
assessed by sequencing two genetic regions. This enabled the identification of a 
possible new HCV strain that clustered within the HCV genotype (Gt) 1 group but 
appeared to be distinct from known Gt1 subtypes, thus furthering knowledge of the 
molecular epidemiology of HCV infection in West Africa.  Full genome sequencing 
is required to confirm the structure of the unusual HCV Gt1 strain identified in this 
study, and in another study previously performed among blood donors in the same 
region of Ghana (Candotti et al., 2003). These data are important because they 
provide an insight into the patterns of HCV spread at the population level. They also 
provide a basis for raising the question of whether treatment strategies optimised for 
HCV strains circulating in Europe or North America will be equally effective against 




The efficacy of treatment on the HCV strains found in Africa is currently unknown. 
Observations from our study and previous studies (Ruggieri et al., 1996, Candotti et 
al., 2003, Ndjomou et al., 2003) have shown a high diversity in the circulating 
strains, with a proportion being seemingly unique to those regions. This may impact 
upon treatment response rates. Several new DAAs are proposed to be pan-genotypic 
(Rodriguez-Torres, 2013, Sulkowski et al., 2014, Vince et al., 2014), whilst several 
retain at least partially genotype-specific activity. 
Access to DAAs and other forms of HCV treatment is very limited in Ghana, as is 
the rest of sub-Saharan Africa. In order for DAA treatment to become accessible in 
such regions, it is necessary for pharmaceutical companies to either; i) allow the 
production of generic versions of their therapies for use in developing countries or ii) 
reduce the cost of their antiviral drugs to an affordable level for low-middle income 
countries (LMICs). The cost of sofosbuvir is adjusted based on the GDP of the 
country meaning that a 12-week course of the drug would cost approximately 
US$1000 in a LMIC compared to US$84,000 in the USA (Hill and Cooke, 2014). 
Despite this reduction, the price point of sofosbuvir is still unattainable for much of 
the population in LMICs. 
Whilst interferon and ribavirin offer a cheaper alternative to DAAs, this approach 
may not be more cost effective than the use of new treatment options. African-
American populations have a higher proportion of the unfavourable TT allele at the 
IL28B site, which negatively affects the response to interferon treatment (Ge et al., 
2009). While good responses may be anticipated for the prevalence HCV Gt2 strains, 
interferon and ribavirin treatment are less efficacious against Gt1 infections 
compared to other genotypes (McHutchison et al., 1998), which are found in many 




As the yield of HCV infections was low in Ghana, further studies were completed 
with the UK cohort alone. In the UK HCV-positive cohort, the investigation aimed 
to characterise the diagnostic yield of deep sequencing compared with Sanger 
sequencing for the identification of naturally occurring HCV drug resistance. This 
provided information immediately relevant for clinical care, while also giving 
insights into the relative fitness of circulating HCV strains. 
 
We analysed the occurrence of a common polymorphism – Q80K – in the NS3 gene 
of HCV Gt1a strains circulating in two regions of England. Determining the 
presence of Q80K is recommended prior to the use of the NS3 protease inhibitor 
simeprevir and testing is widely available through the use of conventional (Sanger) 
sequencing. We compared results obtained with Sanger sequencing with those 
obtained by the use of deep sequencing, with the aim of determining whether the 
mutant would occur as a low frequency variant in subjects showing wild-type virus 
by Sanger sequencing. Deep sequencing can achieve a sensitivity of 1% or lower for 
low-frequency variants, which compares with a sensitivity of 10-20% for Sanger 
sequencing. Thus, the first use of next generation sequencing in this thesis was for 
the purpose of determining whether the use of this technique could benefit the clinic 
in the detection of one specific polymorphism, Q80K in NS3. Our findings indicated 
that deep sequencing offers no specific benefit over traditional Sanger sequencing 
for the detection of Q80K, as the polymorphism existed in all samples tested at 
frequencies ≥40%. Therefore, current estimates of prevalence of this polymorphism 




The Q80K polymorphism is thought to have first arisen in the USA in the 1940s 
(McCloskey et al., 2015) with subsequent migration events allowing it to establish in 
other regions of the world. The phylogenetic analysis performed in this thesis 
determined that the UK HCV Gt1a sequences containing the polymorphism were 
interspersed with sequences from both USA and Europe. There appeared to have 
been multiple introductions of the polymorphism in this country, but the spread of 
this polymorphism was also due to transmission events within this country. 
Unfortunately, the lack of publically available UK sequences from other published 
studies (Leggewie et al., 2013, Sarrazin et al., 2015b, Shepherd et al., 2015) does not 
allow any comparison between our cohort and others. Larger phylogenetic analyses 
of UK sequences would enable transmission networks to be identified and provide 
further insight into the patterns of HCV spread. Meantime, the results were 
interesting for several reasons. We were able to demonstrate that a 1% cut-off should 
be applied to the interpretation of HCV deep sequencing data produced with the 
Illumina platform. The assay error rate as determined with a molecular clone was 
below this cut-off and any detection of Q80K variants below 1% yielded sequences 
that did not cluster within the Q80K lineage, further indicating that detection was 
most likely spurious. Given that one previous UK-based study has reported on Q80K 
detection below the 1%, our proposed cut-off should be used to re-analyse these 
previously published data (Leggewie et al., 2013). Thus, the limited data on this 
polymorphism in the UK allowed this study to greatly expand on the knowledge, 
whilst also adding the impact of utilising deep sequencing for detection of this 
substitution. From a more general perspective, the observation that Q80K variants 
occurred always as dominant strains and did not influence the HCV RNA load 
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measured in the sample provides support to the notion that these strains are highly fit 
and transmissible. 
 
The third part of the investigation employed a deep sequencing approach to resolve 
the impact of HIV co-infection on the spontaneous occurrence of HCV drug 
resistance mutations, providing an opportunity to obtain a more definitive conclusion 
than the ones garnered from the few previous small-scale studies. This was the 
largest cohort to date to explore this effect using deep sequencing technology 
(Bartolini et al., 2013, Jabara et al., 2014). Generally, there were no differences in 
the prevalence of recognised drug resistance-associated mutations (RAMs) in NS3 
and NS5A when comparing HCV mono-infected and HIV/HCV co-infected patients. 
These data suggest that it is likely that the two antagonistic mechanisms – an 
increase in HCV replication that may favour virus genetic evolution and escape, and 
the impaired selective pressure from the immune system – are in equilibrium. From a 
clinical perspective, this apparent lack of difference in RAM prevalence should mean 
co-infected individuals are not at risk of further complications for the treatment of 
HCV, and is in line with the excellent responses to DAA-based therapy observed in 
HIV/HCV co-infected patients (Antonini et al., 2015, Wyles et al., 2015). 
Upon comparing the quasispecies complexity, co-infected patients displayed a higher 
complexity than mono-infected patients, although this rarely reached significance. 
This trend was reversed when the subset of samples matched by viral load were 
analysed, indicating the role that the viral load played in quasispecies complexity. It 
is difficult to ascertain whether the observed association between viral load and 
complexity is genuine or technical. 
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Although selective pressure from the immune system has been hypothesised to 
impact upon the evolution of HCV, we did not observe any association between the 
CD4 count and quasispecies complexity. There was also no difference in CD4 count 
between those with vs. those without a RAM. These observations cast doubt over the 
importance of the role that CD4 cells play in providing a selective pressure. 
However, other components of the immune system may still play a role in this 
mechanism, providing sufficient pressure to elicit a response. 
 
Unlike Q80K, both NS3 and NS5A RAMs were relatively commonly detected at low 
frequencies (≥1% x <10%) in both HCV mono-infected and HIV/HCV co-infected 
patients naïve to all forms of anti-HCV therapy, and were detected at overall 
prevalences of 12.1% and 15.3%, respectively. In NS3 and NS5A, 7.1% and 12.9% 
of patients, respectively, harboured mutation(s) only at low frequency, providing an 
insight into the extent to which deep sequencing can increase prevalence rates. 
 
Whether minority NS3 and NS5A RAMs affect responses to combination DAA 
therapy remains controversial as an effect has not been easily observed in clinical 
studies to date (Black et al., 2015, Fevery et al., 2015, Sarrazin et al., 2015a). The 
impact of low-frequency mutations present at baseline on the outcome of therapy 
needs to be further studied in larger cohorts, including patients with various clinical 
and virological characteristics i.e. previous non-responders, HIV/HCV co-infected 
patients, a range of genotypes. Meanwhile, testing of baseline samples may be 
indicated in patients who fail to respond to DAA therapy, in order to determine the 
effect of drug selective pressure in relation to pre-existing RAMs. This will also help 
the interpretation of the persistence of resistant variants after the cessation of 
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therapy. Recent studies have observed the persistence of resistance in NS3, NS5A 
and NS5B to varying degrees. One study found that 94.4% of patients still harboured 
a RAM in NS5A, detectable by deep sequencing, 96 weeks post-treatment, although 
the frequencies had declined over this period (dvory-Sobol et al., 2015). Persistence 
to this degree may restrict subsequent treatment options, especially if resistance is 
present in more than one of the genes targeted by the drugs. The codon position of 
the RAM was also found to impact upon its persistence, most likely due to the 
replicative fitness of each variant. In patients harbouring RAMs at the end of 
treatment, the R155K variant was found in 25% of patients at week 48 post-
treatment in contrast to only 2% of patients harbouring D168V at the same time 
point (Krishnan et al., 2015b). 
 
The data clearly indicate that deep sequencing can increase the detection of HCV 
RAMs in a sample. The technique is increasingly available, but not as yet part of 
routine diagnostics in most settings. There was a modest increase in the workload 
associated with the next generation sequencing protocol used in this thesis, compared 
to Sanger sequencing. These were mostly associated with quality control measures to 
ensure the input for the sequencing platform was of a high enough standard 
alongside the pooling of amplicons. The preliminary processing of reads, including 
the trimming of adapter sequences and quality filtering is an addition not necessary 
for Sanger sequencing. Although these additional procedures increase time and 
labour costs, the integration of deep sequencing into clinic should not present any 
major obstacles to overcome. As the technology is updated, it is likely that costs will 
be reduced further adding more incentive for implementation in clinics. The 
amplification of whole genome or a large fragment comprising the regions NS3 
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through NS5B would reduce the overall number of PCRs as well as the subsequent 
quality control measures, thereby reducing not only the workload but also the cost. 
 
Next generation sequencing technologies can offer the clinic an enormous amount of 
data, although this data presents a need for an easily implemented, straightforward 
bioinformatics pipeline to ensure accuracy and quality control. VirVarSeq, the 
pipeline used in this study, presents a viable option. For routine clinical use, a 
consensus approach between national centres for both laboratory and analytical 
procedures would provide easily comparable results for patients. 
 
The use of deep sequencing in clinic extends beyond the detection of minority 
variants. The ability to quantify the variants allows clinicians to assess changes in the 
dynamics of the quasispecies and identify the emergence of drug resistant variants as 
they occur during therapy. This may provide a capacity for the early cessation of 
treatment, in cases where the emergence of drug resistant variants alongside the viral 
load kinetics indicates that a sustained virological response may not be achieved. In 
doing so, the financial costs of the antiviral drugs alongside the associated laboratory 
tests necessary during treatment would be eliminated. Taking the aforementioned 
points into consideration, it would be appropriate to evaluate the cost-effectiveness 
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Table 9.1. Presence of high frequency (≥10%) drug resistance NS3 mutations 
identified using next generation sequencing in genotype 1a samples 
NS3 amino 
acid position 




% Frequencies (n) Resistance 
associated 
mutation 
% Frequencies (n) 
36 L 
M 




99.9 (1), 100 (1) 
99.3 (1), 99.8 (1) 
54 S 99.8 (1), 99.9 (2) S 99.8 (1), 99.9 (2) 
55 A 
I 
96.7 (1), 99.8 (2), 99.9 
(2), 100 (1) 
91.7 (1), 99.6 (1), 99.8 
(1), 100 (1) 
A 
I 
51.5 (1), 99.9 (1), 100 (1) 




41.1 (1), 45.8 (1), 99 (1), 
99.7 (1), 99.8 (2), 99.9 





40.2 (1), 72.3 (1), 98.3 (1), 99.6 
(1), 99.7 (2), 99.8 (6), 99.9 
(15), 100 (6) 
99.6 (1), 100 (1) 
117   H 99.6 (1), 99.9 (1) 
132 V 11.7 (1)   
155   K 97.5 (1) 
168 E 99.9 (1) E 99.8 (1), 99.9 (1) 
170 A 36.1 (1)   
174 S 12.0 (1), 21.4 (1), 27.8 
(1), 28.1 (1), 40.9 (1), 
50.3 (1), 73.1 (1), 88 (1), 
90.4 (1), 93.4 (1), 94.6 
(1), 97.1 (1), 97.6 (1), 
98.5 (1), 98.9 (1), 99 (2), 
99.3 (2), 99.4 (1), 99.5 
(5), 99.7 (2), 99.8 (3), 
99.9 (14), 100 (10) 
S 10.5 (1), 12.0 (1), 20 (1), 22.8 
(1), 25.9 (1), 27.2 (1), 56 (1), 
74.6 (1), 98.3 (1), 98.9 (1), 99 
(1), 99.2 (3), 99.4 (4), 99.5 (6), 
99.6 (4), 99.7 (9), 99.8 (17), 





Table 9.2. Presence of high frequency (≥10%) drug resistance NS3 mutations 









% Frequencies (n) Resistance 
associated 
mutation 
% Frequencies (n) 
54   S 13.7 (1) 
55   A 99.9 (1) 




107 I 100 (1) I 14.2 (1) 
117 H 98.8 (1), 99.7 (1), 
99.8 (1), 99.9 (1) 
  
168 E 76.1 (1)   
170 A 36.1 (1)   





Table 9.3. Presence of low frequency (>1%) drug resistance NS3 mutations in 














% Frequencies (n) 
36 M 1.1 (1), 2.8(1) M 1 (1) 
54   S 1.4 (1) 
80 L 
R 
1.4 (1), 2.1 (1), 
5.1 (1) 
1.1 (1), 1.7 (2) 
L 1 (1), 3.1 (1), 5.6(1) 
107 I 1.7 (1), 2 (1)   
109 K 1.2 (1)   
117 H 3.4 (1)   
132 V 1.6 (1) V 2.2 (1), 2.8 (1) 
170 T 1.1 (1), 2.1 (1) T 6.5(1) 
174 S 1 (1), 1.3 (1), 1.6 
(2), 1.8 (1), 2.1 
(1), 5 (1) 
S 1.1 (1), 1.5 (1), 2.2 
(1), 2.7 (1), 2.9 (1), 






Table 9.4. Presence of low frequency (>1%) drug resistance NS3 mutations in 














% Frequencies (n) 
36 A 8.5 (1)   
54 S 7.6 (1)   
80   H 1.2 (1) 
107   I 1.9 (1) 
117   H 1.6 (1) 
158 I 9 (1)   
168 E 1.1 (1)   
174   F 5.3 (1) 





Table 9.5. High frequency (≥10%) drug resistance mutations  present in the 














% Frequencies (n) 




14.1 (1), 20.8 (1), 
62.5 (1), 71.7 (1), 
93.3 (1), 97.6 (1), 





26.1 (1), 34.7 (1), 






14.4 (1), 47.0 (1), 
52.0 (1), 99.4 (1)  





M 99.3 (1), 99.6 (1), 
99.8 (1) 
58 P 10.0 (1), 75.2 (1), 
99.7 (1), 99.8 (1) 
P 30.4 (1), 36.7 (1), 
54.6 (1), 99.8 (1), 
99.9 (1) 





Table 9.6. High frequency (≥10%) drug resistance mutations present in the 














% Frequencies (n) 
28 M 15.2 (1), 99.4 (1) M 99.8 (1) 
31 I 100 (1)  
M 
 
70.0 (1), 99.7 (1), 
99.9 (1) 
58 S 96.6 (1), 96.8 (1), 
99.6 (1), 99.8 (1), 
99.9 (1) 
S 10.6 (1), 24.4 (1) 
93 H 10.5 (1), 12.3 (1), 
27.3 (1), 27.6 (1), 
73.9 (1), 88.0 (1) 





Table 9.7. Low frequency (>1%) drug resistance mutations present in the NS5A 














% Frequencies (n) 
24 R 1.0 (3), 1.1 (1), 
1.7 (1), 4.0 (1), 
8.1 (1) 
R 1.0 (1), 1.8 (2), 3.1 
(1), 4.7 (1), 4.9 (1) 
28 T 
V 
1.0 (1), 1.5 (1) 
1.0 (1), 1.3 (1), 
1.7 (1), 3.1 (1), 




1.0 (1), 1.3 (1), 1.6 
(1), 2.0 (1), 2.9 (1), 









1.1 (1), 1.5 (1), 3.3 
(1), 6.6 (1) 
1.2 (1), 1.7 (1) 
31 M 1.5 (1), 9.2 (1) M 9.3 (1) 
58   P 1.1 (1), 1.2 (1), 3.3 
(1), 7.8 (1), 8.2 (1) 
93   C 
H 
1.2 (1) 





Table 9.8. Low frequency (>1%) drug resistance mutations present in the NS5A 














% Frequencies (n) 





F 1.9 (1) 
32 L 6.4 (1)   
93 H 1.3 (1), 1.5 (1), 
3.4 (1), 5.4 (1), 
6.0 (1), 7.1 (1) 
H 1.7 (1) 
 
 
